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ABSTRACT 
 This dissertation is a critical examination of the relationship between sleep problems and/or 
disorders, particularly Obstructive Sleep Apnea (OSA) and Alzheimer Disease (AD). First, I conducted an 
exhaustive systematic review of existing literature, and identified gaps in research that led to specific 
research aims. For the first aim, I conducted the first ever-published meta-analysis examining sleep, 
cognitive decline and AD, providing an aggregate effect of sleep on AD. Second, focusing on OSA, I 
conducted a study examining OSA’s effect on longitudinal changes on AD biomarkers in cognitive 
normal, MCI and AD subjects, using data from the Alzheimer Disease Neuroimaging Initiative (ADNI). 
Lastly, I conducted a review, integrating over 3 decades of research examining OSA and cognition; OSA 
and subsequent cognitive decline; and OSA and AD; with particular focus in appreciating the 
heterogeneity of OSA and its outcomes in distinct age groups. 
 Results and implications from my research indicate that ample evidence exists linking sleep 
impairments and circadian regulating mechanisms directly to clinical symptoms in AD. Sleep problems 
and/or disorders increases your risk of cognitive decline and AD. OSA is associated with increased AD 
biomarker burden over time, and effects longitudinal changes in these biomarkers, such that OSA subjects 
progress faster than non-OSA subjects do. OSA may be age-dependent in older adults (60 – 70 years old) 
and the elderly (70 years and above) and is associated with neurodegenerative diseases particularly, 
cognitive decline and AD. Intermittent hypoxia and sleep fragmentation are two main processes by which 
OSA induces neurodegenerative changes. Therefore, clinical interventions aimed at OSA, such as 
treatment with CPAP or dental appliances, in cognitive normal and MCI patients, could possibly slow the 
progression of cognitive impairment to AD.
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SECTION 1 
SYSTEMATIC REVIEW: SLEEP AND ALZHEIMER’S DISEASE 
Note to the Reader:  
Portions of this section have been previously published in SLEEP journal, 2017, Jan 1; 40(1). doi: 
10.1093/sleep/zsw032 and have been reproduced with permission from Oxford University Press. 
ABSTRACT 
Background/Objective: Alzheimer’s disease (AD) is a neurodegenerative disorder with expected 
incidence of approximately a million people each year, and a total estimated prevalence of 11 to 16 
million people by 2050 in the United States. Mounting evidence implicates sleep as one of the risk factors 
for AD with an association between sleep disruption, cognitive ability, and neurodegenerative disease. 
We systematically reviewed all available studies examining any association and/or relationship and/or 
biologic plausibility between sleep and its related problems/disorders and Alzheimer’s disease, cognitive 
decline or dementia and evaluated the evidence for a causal association.  
Methods: Original published literature assessing any association of sleep and its related 
problems/disorders with AD, cognitive decline or dementia was identified by searching four bibliographic 
databases, namely PubMed, Embase, Web of Science, and Cochrane library (i.e., the Cochrane Central 
Register of Controlled Trials). Searches on all databases were from the onset of the archives until and 
including November, 2014. The terms Alzheimer, Mild Cognitive Impairment, Sleep, Sleep Disorders 
and Circadian Rhythm were identified as MeSH terms. Other MeSH search headings related to sleep and 
various study types including cross-sectional, case control, cohort (retrospective and prospective), 
Randomized Clinical Trials (RCTs) were also identified. Articles identified from the search were first 
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screened using titles and abstracts of the publications and eligible articles for this review had to meet 
certain inclusion and exclusion criteria.  
Results: Seventy-two publications that met the selection and final inclusion criteria were identified by the 
literature search: 18 studies and 12 studies used a cross-sectional analysis and case-control design 
respectively, to examine the association of sleep alterations/disturbances, circadian rhythm abnormalities, 
and/or sleep disorders with  AD, cognitive decline and/or dementia; 22 studies were prospective studies 
examining the relationship between sleep and cognitive outcomes; 4 RCTs examined cognitive effects of 
treating sleep and its related problems/disorders in AD; and 16 experimental studies examined the 
associations between sleep and AD pathology and/or AD biomarkers. Altogether, there is substantial 
evidence providing support that sleep is associated with cognitive decline and/or AD/AD pathology. 
Prospective studies provide support that sleep problems precede the onset of cognitive impairment, 
including AD and dementia, and experimental studies provide the most compelling evidence of the 
plausibility of causal associations between sleep deprivation and AD pathology and/or AD biomarkers. 
Conclusion: There is growing experimental and epidemiological evidence for a reciprocal interaction 
between cognitive decline and sleep alteration. Ample evidence exists linking sleep impairments and 
circadian regulating mechanisms directly to clinical symptoms in AD. However, long-term longitudinal 
studies are needed to determine the relationship of chronic sleep deprivation, circadian rhythm/sleep-
wake abnormalities, sleep-disordered breathing and sleep disorders with cognitive decline. 
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INTRODUCTION 
Alzheimer’s disease (AD) is a neurodegenerative disorder with an incidence in the United States 
expected by 2050 to be of a million new cases yearly, and a  corresponding prevalence of 11 to 16 million 
people.1 In 2013, approximately 5.2 million Americans had Alzheimer’s Disease (AD), including an 
estimated 5 million age 65 and older.2  AD and other dementias cause significant morbidity and mortality 
to those afflicted, with an enormous socio-economic impact: an estimated US$604 billion worldwide, 
constituting about 1% of the aggregated global gross domestic product.3  Preventive and/or therapeutic 
measures targeted at delaying or curing AD are therefore imperative.4  Advancing age is the most 
significant risk factor for AD with most individuals with AD diagnosed at age 65 or older. Various risk 
factors for AD including family history,5-7 Apolipoprotein E epsilon4 allele (APOE-ε4 gene),8,9 
smoking,10-12 diabetes,13-15 obesity in midlife,16-20 high cholesterol in midlife,17,21 hypertension in 
midlife,22-24 physical activity,25-28 education,29,30 head circumference,31,32 head trauma,33,34 brain reserve35 
and social and cognitive engagement,36-38 have been identified in epidemiological studies and additional 
risk factors are being investigated.39  Mounting evidence implicates sleep as one of these factors.  
Sleep and Normal Aging 
Structural alterations of sleep, including sleep maintenance difficulty, sleep latency increase, 
frequent nighttime and early morning awakenings, occur as part of the normal aging process.40  Various 
sleep stages also show some level of alteration with increasing age including a reduction in slow wave 
sleep (SWS) and a compensatory increase in sleep stages 1 and 2.40  Rapid-eye movement (REM) sleep 
changes are less distinct and seem to appear later with increasing age.41,42  Microstructural alterations such 
as decrease in K complexes and sleep spindles are also observed.43  Apart from these structural alterations 
of sleep, sleep-wake rhythm disturbances have also been described in the elderly. Greater tendency for 
daytime sleep and increased propensity to phase advancing are observed frequently.41  Circadian sleep-
wake rhythm disorders do not result from behavioral factors alone but also from neuro-hormonal 
modifications, especially melatonin whose plasma concentration declines with age.44  Psychiatric and 
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somatic pathologies, pharmacological treatments, decrease in physical activity and exposure to light also 
play a role in the origin of sleep disturbances in normal aging.40  Sleep disorders such as sleep-related 
breathing disorders (SRBD), restless legs syndrome (RLS) and periodic limb movements in sleep (PLMS) 
also increase significantly with age.41   
Sleep and Demented older adults 
Demented older adults exhibit significant sleep disturbance and degenerate sleep patterns, 
including shorter sleep duration and fragmented sleep,43,45-47 altered circadian rest/activity patterns,45 and 
elevated rates of sleep disordered breathing (SDB).48,49 It is estimated that about 45% of AD patients have 
sleep disturbances.50,51  When symptoms appear at an early stage of the disease, they are frequently 
associated with a more severe cognitive decline.50,52 Both circadian rhythm disruptions and sleep 
disturbances have a major impact on the quality of life of patients and their caregivers.53-56  They have 
been conventionally thought of as complications of various psychiatric co-morbidities50,57 secondary to 
disease pathology. However, researchers have begun to examine whether sleep and its related problems 
contribute to the risk of AD.58 Sources of sleep disturbance in AD are thought to include degeneration of 
neural pathways that regulate sleep-wake patterns and sleep architecture.50,57 Sleep disorders may also 
exacerbate cognitive symptoms through impairment of sleep-dependent memory consolidation 
processes.59,60 Interestingly, circadian and sleep disorders may have a causal role in the pathophysiology 
of AD, and could be critical to the goal of preventing AD, because effective interventions exist to 
improve sleep.61  
Previous narrative reviews 
There are few narrative review articles,40,62-64 that have examined this association with focus on 
different aspects of sleep disturbances and/or neurologic diseases. Palma et al.,62 focusing on sleep 
deprivation, reviewed how sleep loss constitutes a risk factor for various neurologic diseases including 
AD.  In discussing sleep loss and AD, they concluded that it was necessary to distinguish between the 
5 
 
possibility that the risk of AD is influenced by changes in rest activity patterns and sleep-wake cycles, 
through their effects on underlying neurodegenerative processes or the alternative explanation that rest 
activity and sleep-wake patterns are just markers of a subclinical neurodegenerative process. Slats et al.,63 
focusing on the role of hypocretin and melatonin, described the impairments of both sleep regulating 
systems and circadian rhythms in AD and their link to clinical symptoms. They further discussed how 
sleep regulating systems, especially neurotransmitters such as melatonin and hypocretin, could affect AD 
pathophysiology.  They concluded that there is substantial evidence of impairments in both sleep and 
circadian regulating mechanisms in AD pathophysiology, which may be linked directly to clinical 
symptoms in AD patients. Peter-Derex et al.,40 did a thorough clinical review of sleep and Alzheimer’s 
disease, observing that micro-architectural sleep alterations, nocturnal sleep fragmentation, decrease in 
nocturnal sleep duration, diurnal napping and inversion of the sleep-wake cycle are the main disorders 
observed in patients with AD.  Further, they noted that there is growing experimental and epidemiological 
evidence for a close reciprocal interaction between cognitive decline and sleep alterations. 
Objective of this systematic review 
To the best of our knowledge, there are no systematic review articles on sleep and AD or 
Dementia. In this context, we conducted a broad systematic review of all available studies examining any 
association of sleep and its related problems/disorders with Alzheimer’s disease, cognitive decline or 
dementia, and evaluated the evidence for a causal association. Recommendations for future directions of 
research are also proposed. 
METHODS 
We conducted this systematic review in accordance with the exemplified step-by-step guide for 
systematic reviews and meta-analysis by Pai et al.,65 and for the purpose of reporting, we adhered to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement by 
Moher et al.66 We also consulted the Cochrane handbook for systematic reviews of interventions.67  
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Identification of Eligible Studies 
Electronic search 
An extremely sensitive search strategy was developed and assisted with identification of all 
eligible published articles in scientific (medical, psychological and epidemiological) journals for all years 
up to November 2014. The electronic search strategy combined terms characterizing AD/AD 
pathogenesis, as the outcome variable, Sleep, as the exposure variable, and a third set specified various 
study types. All terms within each set were combined with the Boolean operator OR, and then all three 
sets were then combined using AND.  
Original published literature assessing associations of sleep and its related problems/disorders 
with Alzheimer’s disease, cognitive decline or dementia were identified by searching four bibliographic 
databases on November 21, 2014, namely: 
• Medline (through PubMed; all years 1946 - present) 
• Embase (through www.embase.com by Elsevier B.V. 2011; all years from 1947 - present) 
• Web of ScienceTM (Thomson Reuters 2014; all years from 1900 – present)  
• Cochrane library (i.e., the Cochrane Central Register of Controlled Trials; all years from 1900 - 
present). 
The terms Alzheimer, Mild Cognitive Impairment, Sleep, Sleep Disorders and Circadian Rhythm were 
identified as MeSH terms. Other MeSH search headings related to sleep included sleep loss, sleep 
deprivation, sleep apnea, sleep disruption, excessive daytime sleepiness, Obstructive Sleep Apnea (OSA), 
Sleep-Disordered Breathing, Rapid Eye Movement Behavioral Disorder, melatonin, and hypocretin.  
Search terms related to Alzheimer’s disease and AD pathogenesis included amyloid beta, amyloid 
cascade hypothesis, Amyloid Precursor Protein (APP) and APOE-ε4. MeSH terms associated with 
various study types included cross-sectional, case control, cohort (retrospective and prospective), 
Randomized Clinical Trials (RCTs), literature reviews, systematic reviews, and ecological studies. 
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Articles written in other languages other than English were also considered and screened with the help of 
Google translator.  
In PubMed, a search using Alzheimer’s disease and AD pathogenesis MeSH terms yielded 
136,119 articles; and a search using sleep and its related problems/disorders MeSH terms yielded 185,925 
articles. The combination of the Alzheimer’s disease and AD pathogenesis MeSH terms and sleep and its 
related problems/disorders MeSH with MeSH terms associated with various study types, yielded a total of 
904 publications. The PubMed search was adapted to searching the other databases. Table 1.1 provides a 
list of the search terms used. The complete search strategy including the saved search histories in the 
various databases is available on request.  
Searching other sources 
To locate additional relevant studies, the reference lists of articles identified through database 
searches and the Bibliographies of narrative review articles were examined. We also hand-searched the 
previous year’s issues (November 2013 to November 2014) of high ranking journals that published more 
than one relevant identified article during the initial search, including Sleep Medicine Reviews,      
Neurology, JAMA (Journal of American Medical Association), Sleep Medicine, American Journal of 
Alzheimer’s Disease and other Dementias, Sleep, Journal of Sleep Research, Journal of clinical sleep 
medicine, Journal of Alzheimer’s Disease, Brain, and Neurobiology of Aging. 
Selection criteria 
Type of study 
Original articles from observational studies (cross-sectional, case-control and 
retrospective/prospective cohort), Randomized Controlled Trials (RCT), and Animal Experimental 
studies were included in this systematic review. Articles identified in the search were first screened using 
titles and abstracts of the publications. Eligible studies for this review had to meet the following final 
study inclusion criteria: (1) They reported a primary or secondary data analysis using an appropriate 
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epidemiologic study design of any association of sleep and its related problems/disorders with 
Alzheimer’s disease, cognitive decline or dementia; (2) The diagnosis of Alzheimer's 
disease/dementia/cognitive decline was based on  a self-reported diagnosis, on meeting standardized 
criteria (e.g. International Classification of Disease-9 (ICD -9), Diagnostic Statistical Manual-IV (DSM-
IV)) or objective measures of Alzheimer pathology (e.g., Positron Emission Tomography (PET) scan); (3) 
The finding of  sleep and its related abnormalities/disorders was based on self-reported diagnosis or 
standardized  criteria/questionnaires (e.g., PQSI Pittsburg Sleep Quality Index (PQSI),68 Epworth 
Sleepiness Scale (ESS)) or objective measures (e.g., wrist actigraphy69 or polysomnography (PSG)), (4) 
Inclusion of a comparison group with or without varying levels of sleep disturbances/disorders or 
cognitive decline/dementia/AD, whichever is applicable, and (5) The study provided a valid measure of 
association between sleep and its related problems/disorders and Alzheimer’s disease, cognitive decline 
or dementia with 95% confidence intervals and/or p-values. Exclusion criteria included the following: (1) 
case series/reports, systematic and/or literature reviews, abstracts or editorials, (2) articles that did not 
examine an association between sleep and its related problems/disorders and Alzheimer’s disease, 
cognitive decline or dementia, and (2) any RCT that did not examine the cognitive effects of treating 
sleep and its related problems/disorders in AD.  
Sleep abnormalities and/or disorders 
Sleep abnormality and/or disorder was considered as the risk factor of interest in this systematic 
review. The international Classification of Sleep Disorders (ICSD-2)70 aptly describes and classifies sleep 
disorders, however, previous studies71,72 examining the association between sleep and workplace injuries 
made use of various concepts to define sleep problems in order to fit their study design. Accordingly, in 
this systematic review, we classified sleep based on the measured sleep parameter and eligible studies in 
this review were grouped on this basis. Sleep parameters including duration, quality, efficiency and/or 
disturbance were classified as sleep depth problems; circadian rhythm abnormalities, and excessive 
daytime sleepiness (EDS) were classified as sleep-wake cycle abnormalities; the apnea hypopnea index 
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(AHI) that measures hypoxia levels in sleep was used to refer to Sleep Disordered Breathing (SDB), 
Sleep Apnea (SA) and/or Obstructive Sleep Apnea Syndrome (OSAS); and lastly other sleep disorders 
referred to insomnia and Restless Leg Syndrome (RLS). Studies that examined multiple sleep parameters 
e.g., circadian rhythm abnormalities and Insomnia, were reviewed under the various sleep categories, 
however, were still counted as one study. 
Cognitive decline and/or Alzheimer’s disease Dementia 
The outcome of interest in this review was Cognitive Decline and/or Alzheimer’s disease. 
Eligible studies were expected to have diagnosed cognitive decline and/or Alzheimer's disease based on a 
self-reported diagnosis that met standardized criteria (e.g. International Classification of Disease-9 (ICD -
9), Diagnostic Statistical Manual-IV (DSM-IV)) or on objective measures of Alzheimer pathology (e.g., 
Positron Emission Tomography (PET) scan). AD is the most common form of Dementia accounting for 
up to 50-80% of dementia cases,1 as such studies that had dementia as an outcome were also considered. 
Studies that solely looked at specific forms of dementia other than AD e.g., vascular, Lewy body, 
frontotemporal dementia were excluded. 
Data Extraction 
An independent assessment of all the titles and abstracts of all eligible study identified by the 
search strategy was performed by two authors (OB, SS) using EndNote X6. Potential articles for the study 
were retrieved and examined for possible inclusion by the same two authors. Discordances that were 
unresolved in unison were referred to a third author (AB). Excel spreadsheet and extraction sheets created 
in Access (Microsoft Office version 2010) was then used for the data extraction. This was independently 
done by two reviewers (OB, JM), and extracted categories included the study design, study population, 
exposure assessment, outcome assessment, statistical methods and tests used, covariates as well as the 
main results of the study. Differences in the information extracted were resolved by a third author (MD) 
Reviewers were not blinded to the funding, authors, or institutions. 
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Assessment of study quality 
Study quality was assessed using an adaptation from previous systematic reviews73,74 and the 
modified version of the Newcastle-Ottawa scale (NOS) for quality assessment of the observational 
studies,75,76 with addition of new items relevant to this review (Table 1.2). Two review authors (OB, JM) 
assessed each included study separately. Any disagreement between the two review authors was settled 
by consensus, or where necessary, by a third party (YW). Parameters used for the quality assessment 
included well specified hypothesis, study design type, appropriately described sample population, sample 
size, definition of sleep and its related abnormalities, definition of Alzheimer's disease/dementia/cognitive 
decline, statistical analytical methods, and inclusion or approach used to adjust for potential confounders. 
The quality rating scale was adapted to specific study design, and each category had specific maximum 
number of awarded stars (Tables 1.3 – 1.6). Quality scores were awarded such that the minimum number 
of stars a study can get was 5. For cross-sectional studies, 16 stars was the maximum possible; for case-
control, cohort studies and RCTs 20 stars was the maximum possible, and for animal experimental studies 
15 stars was the maximum possible. Quality indicators of most significance for this review (given the 
highest weights) included appropriate definition of sleep and its related abnormalities, study population 
and adjustment for potential confounders (such as age, years of education, marital status, forced 
expiratory volume (FEV) in one second based on spirometry, self-reported history of physician’s 
diagnosis of asthma, number of hours of sleep and napping, and use of benzodiazepines, Chronic 
Obstructive Pulmonary Disease (COPD), nonfatal coronary heart disease including myocardial infarction, 
stroke, the ankle-brachial index, Apolipoprotein E-epsilon4 (APOE-ε4) genotype, Body Mass Index 
(BMI) and Depression). Studies were divided into three categories: low quality (< 50% of the maximum 
number of stars), medium quality (≈ 55-70% of the maximum number of stars), and high quality (75% or 
more of the maximum number of stars) (Tables 1.3 – 1.6).  
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Risk of Bias in Individual Studies 
Studies were thoroughly reviewed and the risk of bias within individual studies was assessed by 
examining the appropriateness of the study design as it relates to the study hypothesis, how each study 
defined and/or ascertained their exposure and/or outcome, and whether appropriate comparison was done 
with the unexposed participants. Appropriate identification and/or selection of study participants to 
minimize selection bias risk was also important. It was essential that diagnoses were properly assessed 
and/or validated, and that studies reported which diagnosis or symptomatology was utilized, and if using 
various databases, how overlapping data was handled. Study data were also assessed to determine if 
completeness and potential publication/reporting bias could be evaluated.  
Observational data from studies 
Evidence from the reviewed studies was harmonized and integrated using a narrative synthesis77 
and reported data is presented making use of accepted and recognized conventional guidelines78 
 
RESULTS 
Study Selection 
A total of 2341 publications were identified doing a literature search in PubMed, Embase, Web of 
Science, and Cochrane library (i.e., the Cochrane Central Register of Controlled Trials), with each 
yielding 904, 1026, 305 and 106 publications respectively (Figure 1.1). One thousand, one hundred and 
twenty duplicates were identified and removed of which 90% were from PubMed, and Embase. After 
duplicates were removed, 1221 publications were screened for titles resulting in the exclusion of 180 
publications because titles did not reflect an examination of an association between sleep and Alzheimer’s 
disease. The remaining 1041 publications were screened using the published abstracts resulting in the 
exclusion of 840 publications that were removed because they were either case series/reports or were 
systematic and/or literature reviews, abstracts or editorials. Two hundred and one full text articles were 
assessed for eligibility and 130 publications were further excluded, of which 105 publications identified 
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were excluded because they did not address an association between sleep and its related 
problems/disorders and Alzheimer’s disease, cognitive decline or dementia or did not estimated a measure 
of association that included 95% confidence intervals or p-values. Twenty-five RCTs were excluded 
because they did not examine cognitive effects of treating sleep and its related problems/disorders in AD. 
One study was included from a search of the reference lists of articles identified through database 
searches. Seventy-two articles met all eligibility criteria. 
Study Characteristics (Design and Quality) 
Among the 72 studies identified, 18 studies51,79-95 and 12 studies96-107 used a cross-sectional 
analysis and case-control design respectively, to examine the association of sleep alterations/disturbances, 
circadian rhythm abnormalities, and/or sleep disorders with  AD, cognitive decline and/or dementia; 22 
studies108-129 were prospective studies examining the relationship between sleep and cognitive outcomes; 
4 RCTs130-133 examined cognitive effects of treating sleep and its related problems/disorders in AD; and 
16 experimental studies134-149 examined the associations between sleep and AD pathology and/or AD 
biomarkers (Table 3). One110 of the prospective studies examining the relationship between sleep and 
cognitive outcomes was in Polish; the remaining studies were in English. In total 36 studies were assessed 
to be of high quality (16 experimental studies,134-149 3 RCTs,130,132,133 14 prospective studies,109,111,112,114-
116,118,119,121,122,124,126-128 and 3 cross-sectional studies79,83,86); 22 studies were assessed to be of medium 
quality (1 RCT,131 6 prospective studies,108,117,120,123,125,129 7 case-control studies,97-99,101,105-107 and 8 cross-
sectional studies51,84,85,88-90,93,94); and 14 studies were assessed to be of low quality (2 prospective 
studies,110,150 5 case-control96,100,102-104 and 7 cross-sectional studies80-82,87,91,92,95) (Table 1.3 – 1.6). Type of 
study, selection bias related to sampling, measurements of sleep and/or AD solely based on self-reporting, 
and insufficient adjustment for core confounders, were the main shortfalls. 
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Participants and setting 
The 72 studies included in the systematic review were published between 1998 and 2014. Human 
participants of the included studies were middle aged and elderly adults of both sexes with age ranging 
from 40 – 91 years cutting across North America (38 studies), Europe (22 studies), Australia (1 study), 
Asia (7 studies) and collaborations between continents (5 studies). Participants were drawn from settings 
that included communities (32 studies), hospital/patient population (20 studies), institutions e.g., nursing 
home residents (4 studies), and brain autopsies (1 study). In total, 50 studies included both sexes, 6 
studies were based on females, and three studies were based on males only. Fifteen experimental studies 
that made use of AD transgenic mice were also included.  
Sleep abnormalities and/or disorders 
There was a considerable amount of variation in the methods used by the studies to assess for 
sleep problems. Most studies (n=35) utilized objective measures (e.g., wrist actigraphy69 or 
polysomnography (PSG), while 11 studies utilized standardized questionnaires including the Pittsburg 
Sleep Quality Index (PQSI),68 Epworth Sleepiness Scale (ESS), Berlin questionnaire,151 Behavioral 
pathology in AD rating scale, the BEHAVE-AD,152 Women’s Health Initiative Insomnia Rating Scale 
(WHIIRS),153 and the International RLS Study Group questionnaire.154,155 Only five studies utilized self-
constructed questionnaires while 4 studies made use of Fluorescence Immuno Assays (FIA) to determine 
melatonin/hypocretin concentrations. The experimental studies (n=16) conducted cell culture, transfection 
and hypoxic treatment tests or utilized immuno-assays, Enzyme Linked Immuno-sorbent Assay (ELISA), 
Western Blot tests to determine melatonin concentrations and/or forced experimental mice into states of 
wakefulness. In total, 30 studies (i.e., 10 cross-sectional,51,79,80,82,84,85,88,92-94 5 case-control,96,98-100,105 9 
prospective cohort,109-111,116,118,120,122,125,126 1 retrospective cohort,123 4 experimental studies136,138,142 and 1 
RCT133)  examined sleep depth parameters, 23 studies examined sleep-wake /circadian rhythm 
abnormalities (i.e., 5 cross-sectional,87,89,91,95,102 4 case-control,97,101,106,107 6 prospective 
cohort,108,118,119,124,127,129 7 experimental studies134,135,137,140,143-145 and 1 RCT131), 16 studies examined 
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hypoxia states (AHI) in sleep apnea/sleep disordered breathing (i.e., 4 cross-sectional,81,83,86,90 1 case-
control,103 3 prospective cohort,125,128,150 1 retrospective cohort,112 2 RCTs,130,132 and 5 experimental 
studies139,141,147-149), 6 studies (i.e., 2 cross-sectional87,92 and 4 prospective cohort studies114,115,117,121) 
examined sleep as insomnia and 3 studies (i.e., 2 cross-sectional84,92 and 1 case-control104)  examined 
sleep as RLS. 
Cognitive decline and/or Alzheimer’s disease Dementia 
There was also great variability in the methods used to diagnose cognitive decline and/or 
Alzheimer’s disease Dementia. Most studies made use of self-reported diagnosis that met standardized 
criteria (e.g. International Classification of Disease-9 (ICD -9),156 Diagnostic Statistical Manual-IV 
Revised Text (DSM-IV TR),157 National Institute of Neurological and Communicative Disorders and 
Stroke/Alzheimer’s Disease and Related Disorders Association (NINCS–ARDRA).158  Mild Cognitive 
Impairment (MCI) was mostly diagnosed using the Petersen criteria. 159 Cognitive function was assessed 
by a battery of neuropsychological tests (mostly with the Mini Mental State Examination (MMSE), 160 
California Verbal Learning Test (short form),161 Rey-Osterrieth complex figure,162 Verbal Fluency, 
Wechsler Adult Intelligence Score (digit symbol, digit span).163 Emotional state was mostly assessed with 
the Geriatric Depression Scale164 and functioning in daily living with Functional Activities 
Questionnaire,165 and dementia severity was mostly assessed using the Clinical Dementia Rating Scale 
(CDR). Objective measures of Alzheimer pathology (e.g., Positron Emission Tomography (PET) scan for 
amyloid load (Aβ), Polymerase Chain reaction (PCR) for APOE genotyping), were also done. 
Study findings 
A. Sleep depth and cognitive decline and/or Alzheimer’s disease dementia 
In total, 30 studies (i.e., 10 cross-sectional,51,79,80,82,84,85,88,92-94 5 case-control,96,98-100,105 9 
prospective cohort,109-111,116,118,120,122,125,126 1 retrospective cohort,123 4 experimental studies136,138,142 and 1 
RCT133) examined the association between sleep depth (i.e., sleep quality, duration, sleep latency, sleep 
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efficiency and/or disturbance), and cognitive decline and/or Alzheimer’s disease Dementia. Table 1.7 
presents the results of the descriptive study characteristics, statistical methods and main findings of the 
studies. 
A.1 Cross-sectional studies 
Nebes et al88 examined the association between sleep quality (i.e., sleep duration, sleep latency 
and sleep efficiency) and cognitive performance while controlling for the effects of some common 
confounding conditions including anticholinergic drug burden and found that sleep quality was associated 
with cognition. The association was not explained by confounding factors such as cerebrovascular 
disease, depression, or medication usage. Blackwell et al79 (2006) examined the association between 
objectively measured fragmented sleep and decreased cognitive function in a cohort of 2,242 community-
dwelling women 65 years old or older with a baseline Cognitive Abilities Screening Instrument (CASI) 
score of >=74 points. The CASI is a composite of the Hasegawa Dementia Screening Scale, the Folstein 
Mini-Mental State Examination,160 and the Modified Mini-Mental State Test.166  They found that women 
with <70% sleep efficiency had a 61% higher risk of cognitive impairment when compared with women 
with sleep efficiency >=70%. Higher sleep latency was also associated with higher risk of cognitive 
impairment as was higher Wake after Sleep Onset (WASO). There was no significant relationship for 
total sleep time. Saint Martin et al93 examined the association between sleep quality, subjective 
cognitive complaints, and neuropsychological performance in a cohort of 272 healthy elderly subjects 
(mean age 74.8 ± 1.1 years) recruited from a population-based cross-sectional study on aging and 
cardiovascular morbidity, and found that in healthy elderly subjects subjective sleep quality and duration 
was not associated with subjective and objective cognitive performances, except for attention. However, 
in this study, sleep duration and quality were self-reported and the authors had no information on sleep 
structure and sleep fragmentation, two factors implicated in self-reported cognitive deficits.  
Guarnieri et al84 described the frequency and characteristics of sleep disturbances in a large 
cohort of persons with mild cognitive impairment or dementia and found that over 60% of the participants 
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had one or more sleep disturbances, almost invariably associated with each other but without any evident 
and specific pattern of co-occurrence. Persons with AD and those with MCI had the same frequency of 
any sleep disorder. This study suffered from considerable selection bias issues as patients were enrolled 
consecutively and selected for specific characteristics including the presence and type of sleep disorders. 
Moran et al51 using 215 attendees at a memory clinic who were diagnosed with AD found the prevalence 
of sleep disturbance in the sample to be 24.5%. Sleep disturbance in AD patients was also associated with 
other behavioral symptoms, notably aggressiveness. Pistacchi et al92 enrolled 236 patients (78 men and 
158 women) with different subtypes of dementia and investigated the frequency and characteristics of 
sleep disorders in the sample. Patients with MCI had a frequency of sleep disturbances of any type equal 
to that of patients with AD. Fetveit et al82 aimed to describe the characteristics of 24-hour sleep patterns 
in nursing home patients with dementia and to determine whether various degrees of dementia have any 
influence on total sleep duration. They found that sleep duration was positively correlated with the 
severity of dementia in nursing home patients. 
Studies that examine sleep associations with Alzheimer’s disease pathology or Alzheimer’s 
disease biomarkers are extremely important to help clarify and consolidate efforts at establishing that AD 
pathology might link poor sleep to cognitive outcomes. Since AD biomarkers are evident early in the 
Alzheimer’s disease process, such findings might help foster directed preventive efforts at a time when 
prevention may still be feasible.167 Spira et al94 examined the association between self-reported sleep 
variables and Aβ deposition in 70 community-dwelling older adults who were part of the Baltimore 
Longitudinal Study of Aging cohort. Participants underwent [11C]-Pittsburgh compound B PET (PiB 
PET) amyloid imaging and completed self-report sleep measures. The investigators found that self-
reported shorter sleep duration and poorer sleep quality both were associated with greater Aβ burden 
according to a cortical (i.e. global) measure of PiB uptake, and a measure of uptake in the precuneus – a 
region in which Aβ aggregates early in the Alzheimer’s disease course.168 Ju et al85 determined whether 
Aβ deposition in preclinical AD, prior to the appearance of cognitive impairment, is associated with 
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changes in quality or quantity of sleep in 142 cognitively normal middle-aged and older adults. They 
found that amyloid deposition was associated with poorer sleep quality, specifically poorer sleep 
efficiency (% time in bed that was spent asleep), compared to those without amyloid deposition. On the 
contrary, sleep quantity (i.e., total sleep time) did not vary between groups. Napping also frequently was 
associated with amyloid deposition. 
Craig et al80 investigated the monoamine-A-oxidase promoter polymorphism that may impact 
sleep/wake control by balancing the availability of serotonin, a precursor of melatonin. The authors found 
that the high-activity 4-repeat allele of the monoamine-A-oxidase variable number tandem repeat 
promoter polymorphism conferred increased susceptibility to sleep disturbance (p = .008). Nevertheless, 
it is worth noting that allelic variations in this gene have been associated with behavioral and personality 
traits in other contexts, which may explain this association.169 A quantitative sleep disturbance score was 
signiﬁcantly higher in the patients possessing MAO-A 4-repeat allele genotypes. APOE had no inﬂuence 
on the development of an altered sleep 
A.2 Case-control studies 
Hita-Yañez et al98 determined whether changes in polysomnographic (PSG) sleep patterns 
accompany subjective sleep complaints in patients with mild cognitive impairment (MCI), whether 
meaningful changes in objective sleep physiology are predicted by self-reported sleep measures in MCI 
patients, and whether incipient neurodegeneration contributes to exacerbate sleep misperception. Both 
PSG and self-reported sleep measures confirmed that sleep is altered in patients with MCI.  Whereas 
subjective sleep responses predicted fragmentation of slow wave sleep (SWS) in healthy elderly (HE) 
individuals, this relationship was not evident in MCI patients. Furthermore, patients with MCI showed 
significant discrepancies in the estimation of sleep onset latency when compared with HE subjects. This 
study compared PSG sleep data recorded in 1 night with subjective sleep quality over the past few months 
to establish relationships between objective and subjective sleep in HE subjects and patients with MCI. 
This approach implicitly assumes that PSG data obtained from one single night is representative of a 
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typical night in the past few months. PSG sleep studies were performed without previous adaptation of 
participants to the sleep laboratory. As such, authors note that results might have been affected by the 
first-night effect (i.e., differences observed on the first PSG sleep recording in comparison with 
consecutive ones), which has previously been demonstrated to affect older patients more than younger 
ones.170-172  
The ApoE4 allele is a known susceptibility gene for AD,9,173-177 especially in homozygous 
cases.178 In another study, Hita-Yañez et al99 determined if impaired sleep patterns appear years before 
AD diagnosis and whether changes in sleep patterns parallel memory decline as well as its relationship 
with the Apolipoprotein E (APOE) e4 genotype in 25 Mild Cognitive Impairment (MCI) patients (7 
females, mean age: 70.5 ± 6.8 yr) and 25 healthy old (HO) volunteers (13 females, mean age: 67.1 ± 5.3 
yr). The study results showed a significant shortening of rapid eye movement (REM) sleep together with 
increased fragmentations of slow-wave sleep in MCI patients relative to healthy elders. Reduction of 
REM sleep in MCI patients with APOE e4 was more noticeable than in e4 non-carriers. Changes in sleep 
patterns were not correlated with memory performance in MCI patients. Instead, increased REM sleep 
was associated with enhanced immediate recall in MCI e4 non-carriers. 
Chen et al96 investigated changes in muscular activity, which may indicate a deficiency of 
Acetylcholine (ACh), among patients with cognitive impairment, and recruited 9 controls without 
dementia, 6 patients with mild cognitive impairment (MCI), and 6 patients with mild Alzheimer's disease 
(AD). None of the participants had sleep complaints, and all AD patients were receiving cholinesterase 
inhibitors. All participants underwent PSG examination using surface electromyographic (sEMG) 
recording of both legs. A one-way analysis of variance (ANOVA) test was used to analyze the differences 
in root mean square (rms) amplitude, peak frequency, and mean frequency among the three groups and 
the results showed that all rms, mean frequencies, and peak frequencies increased significantly (p<0.05) 
in MCI patients. The authors concluded that a deficiency of Ach may result in an increase sEMG activity 
in MCI patients, and that because cholinesterase inhibitors are capable of suppressing sEMG activity in 
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AD patients, an increase in sEMG activity is associated with a deficiency of Ach, which could be an early 
indicator of dementia.  Hot et al100 examined relationships between episodic memory deficits and 
electroencephalography [EEG] abnormalities occurring during sleep in patients with early AD.  
Polysomnographic sleep acquisition was performed and included continuous recordings of EEG. Results 
showed that relative to age-matched controls, AD patients presented faster mean theta frequency in both 
REM sleep and slow wave sleep [SWS]. In AD patients, a correlative analysis revealed that faster theta 
frequency during SWS was associated with better delayed episodic recall. Authors concluded that the 
results suggest that changes in theta rhythm during REM and SWS are a relevant index of brain 
impairments in the early stage of AD whereas sleep architecture is not, and that changes in theta activity 
during SWS are related to episodic memory performance.  
Sanchez-Espinosa et al105 examined associations between changes in physiological sleep and 
plasma Aβ concentrations in 21 healthy old (HO) adults and 21 amnestic Mild Cognitive Impairment 
(aMCI) subjects. They further assessed whether these two factors were associated with cortical volume 
loss in each group. Sleep parameters were assessed with PSG. The investigators found significant 
relationships between disrupted slow-wave sleep (SWS) and increased plasma levels of Aβ42 among 
aMCI, but not HO subjects. They also found correlations between shortened rapid-eye movement (REM) 
sleep in aMCI and thinning of the posterior cingulate, precuneus, and post-central gyrus; whereas higher 
levels of Aβ40 and Aβ42 accounted for grey matter (GM) loss of posterior cingulate and entorhinal 
cortex, respectively. 
A.3 Cohort studies 
Keage et al118 investigated the effect of self- reported sleeping behaviors and incidence of 
cognitive impairment over two and 10 years in two healthy aged English populations. Napping behavior 
was found to be negatively associated with incident cognitive impairment, with those who napped more 
being less likely to be cognitively impaired at two years (OR = 0.38, 95% CI 0.22–0.67) and 10 years 
(OR = 0.48, 95% CI 0.29–0.78). Short night time sleep duration (<= 6.5 h) increased the risk of incident 
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cognitive impairment over 10 years (OR = 2.02, 95% CI 1.17–3.48). The effect of long sleep duration (>= 
9 h) failed to reach significance at both two and 10 years. The study did not account for relationships 
between sleep and cognition with medication, cardiovascular factors, and metabolic diseases (other than 
BMI). In addition, only cognitively healthy individuals were included at baseline so that the prognostic 
effect of these sleep measures in those cognitively impaired or demented at baseline cannot be 
extrapolated. Tworoger et al125 examined the association of sleep duration, snoring, and difficulty 
sleeping with cognitive function in a cohort of community-dwelling women. Results showed that women 
sleeping ≤5 hours/night scored worse than women sleeping 7 hours/night (mean difference on global 
score combining all cognitive tests = 0.15 standard units, 95% CI: -0.28, -0.02). Women who regularly 
had difficulty falling or staying asleep scored 0.11 units lower on the global score (95% CI: -0.22, 0.01) 
compared with those who rarely had difficulty sleeping. These differences were equivalent to the mean 
differences in score observed between participants who were 4 to 5 years apart in age. Authors found no 
associations with snoring or with any of the sleep variables and cognitive decline over 2 years. In a 
unique study, Virta et al126 investigated the association between midlife sleep characteristics (mean age 
52 years) and late life cognitive function and dementia 18–26 years later in 2,336 members of the Finnish 
Twin cohort who were at least 65 years of age, and found that reports of short (<7 h) and long (>8 h) 
sleep duration, poor sleep quality, and use of hypnotic medications for more than 60 days per year were 
associated with lower cognitive composite scores in old age; with long sleep being associated with 
roughly 1.8 times the odds of developing AD. In this study, questionnaire data from 1981 were used in 
the assessment of sleep characteristics, use of hypnotics, and covariates at baseline and between 1999 and 
2007, and participants were assigned a linear cognitive score with a maximum score of 51 based on a 
telephone interview (mean score 38.3, SD 6.1). Some of the associations differed by participant 
characteristics, including Apolipoprotein E (APOE) e4 allele status, sex, and age, suggesting that poor 
sleep may differentially affect cognition in different populations. The study revealed an association 
between midlife sleep length and cognitive performance and AD based on medical records. With a mean 
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follow-up time of above 20 years, temporality can be assessed between sleep disturbance and cognitive 
outcomes, thereby providing evidence of a potential causal link from poor sleep to cognitive decline. 
Song et al122 examined the associations between sleep stage distributions and subsequent decline 
in cognitive function in community-dwelling men aged 67 or older (n = 2,601) who were free of probable 
dementia at the time of sleep evaluation. Follow-up averaged 3.4 years. Sleep stages were identified by 
in-home polysomnography at the initial sleep visit. The average percent of time spent in stages of sleep 
were as follows: N1, 6.7% ± 4.1%; N2, 62.6% ± 9.5%; N3, 11.3% ± 8.9%; and R, 19.4% ± 6.6%. The 
authors found that increased time in Stage N1 and less time in Stage R were associated with worsening 
cognitive performance in older men over time. Blackwell et al111 (2014) examined associations of 
objectively- and subjectively-measured sleep with subsequent cognitive decline over 3.4 ± 0.5 y in 2,822 
cognitively intact community-dwelling older men (mean baseline age 76.0 ± 5.3 y). Diminished 
actigraphic sleep efficiency (i.e. spending a lower proportion of time in bed asleep), greater nighttime 
wakefulness, greater number of long wake episodes, and poor self-reported sleep quality measured by a 
score greater than 5 on the Pittsburgh Sleep Quality Index (PSQI) were all associated with subsequent 
cognitive decline. However, there was no association between sleep duration and cognition. 
Sterniczuk et al123 examined whether self-reported sleep problems in individuals who were not 
demented at baseline, are early independent markers of risk for developing AD or dementia over an 
approximately 4-year period. Data on four sleep variables (sleeping problems and fatigue in past 6 
months, sleep medication use, and ‘recent trouble sleeping or a change in pattern’) were collected, and the 
authors created a composite ‘sleep disturbance index’ from those items. The authors found a 23% greater 
odds of dementia or Alzheimer’s disease among participants with higher scores on the sleep disturbance 
index compared to those with lower scores after adjusting for age, sex, education, body mass index 
(BMI), and cognition. Also, individual sleep items independently predicted AD or dementia and mortality 
within ~4 years. Benito-León et al109 using a population-based study of 3,857 people without dementia 
aged 65 years and older (NEDICES [Neurological Disorders in Central Spain]) examined whether long 
sleep duration was associated with increased risk of dementia mortality. In a Cox model that adjusted for 
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numerous demographic factors and comorbidities, the hazard ratio for dementia mortality in long sleepers 
was 1.63 (p = 0.03). Hahn et al116 examined a subjective report of change (reduced duration and/or 
depth) in sleep pattern in relation to subsequent risk of incident all-cause dementia and Alzheimer disease 
(AD) over a 9-year follow-up. Participants included 214 Swedish adults aged 75 and over who were 
dementia-free both at baseline and at first follow-up (3 years later). Results showed that reduced sleep 
was associated with a 75% increased all-cause dementia risk (hazard ratio: 1.75; 95% confidence interval: 
1.04-2.93; Wald = 4.55, df = 1, p = 0.035) and double the risk of AD (hazard ratio: 2.01; 95% confidence 
interval: 1.12-3.61; Wald = 5.47, df = 1, p = 0.019) after adjusting for age, gender, education, lifestyle and 
vascular factors. However, results did not hold after adjusting for depressive symptoms, which was 
measured with only one self-reported item. Findings are limited by the fact that the study did not include 
objective longitudinal data on sleep. Bidzan et al110 found that patients in the preclinical period of 
dementia were more likely to experience sleep disturbances and with greater intensity. The study was 
conducted in Poland using 150 care centers residents age 55 and older. The presence of dementia was 
excluded in the participants. After a follow-up period of 7 years, diagnosis of AD was established in 25 
participants, while 111 people formed the control group.  
Lim et al120 examined whether better sleep consolidation attenuates the relationship of the APOE 
genotype to the risk of incident AD and the burden of AD pathology, in 698 community-dwelling older 
adults without dementia (mean age, 81.7 years; 77% women) of the Rush Memory and Aging Project. 
Participants were followed for up to 6 years. They found that better sleep consolidation attenuated the 
effect of APOE genotype on incident AD and development of neurofibrillary tangle pathology, and 
concluded that assessment of sleep consolidation may identify APOE+ individuals at high risk for 
incident AD, and interventions to enhance sleep consolidation should be studied as potentially useful 
means to reduce the risk of AD and development of neurofibrillary tangles in APOE ε4+ individuals. 
A.4 Experimental studies 
Mander et al142 determined whether regional brain atrophy, reduced slow wave activity (SWA) 
during non–rapid eye movement (NREM) sleep and impaired long-term retention of episodic memories, 
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independently recognized features of aging, are inter-related. The authors found that “age-related medial 
prefrontal cortex (mPFC) gray-matter atrophy was associated with reduced NREM SWA in older adults 
and statistically mediated the impairment of overnight sleep–dependent memory retention. Moreover, this 
memory impairment was further associated with persistent hippocampal activation and reduced task-
related hippocampal-prefrontal cortex functional connectivity, potentially representing impoverished 
hippocampal-neocortical memory transformation”. Together, these data support a model in which age-
related mPFC atrophy diminishes SWA, the functional consequence of which is impaired long-term 
memory. Such findings suggest that sleep disruption in the elderly, mediated by structural brain changes, 
represents a contributing factor to age-related cognitive decline in later life. At a translational level, data 
from this study endorses the possibility that improvements of SWA in older adults, through physiological, 
behavioral or pharmacological means may represent a treatment target for minimizing the cognitive 
decline associated with deficient long-term memory retention in later life.  
Studies in AD mouse models support an association between sleep deprivation and AD 
pathology. Kang et al138 in their study used in-vivo micro-dialysis in amyloid precursor protein (APP) 
transgenic (Tg2576) mice (i.e. mice that overexpress mutant familial AD APP genes) and demonstrated 
that both acute and chronic sleep deprivation alters brain interstitial fluid (ISF) Aβ diurnal rhythm. The 
study also provided evidence of effects of hypocretin signaling on Aβ metabolism in studies of humans. 
Circadian rhythm mean peak levels between 7 p.m. and 9 p.m. in human CSF Aβ levels were 28% higher 
than the mean trough levels, which occurred between 9 a.m. and 11 a.m. A similar rhythm was found in 
mice, with increased Aβ levels in brain interstitial fluid (ISF) while awake, compared to the sleep, both in 
wild type C57BL6 mice and human APP transgenic mice, Tg2576. After being sleep deprived, mice spent 
more time sleeping resulting in reductions in ISF Aβ levels. This suggests an association between 
wakefulness, and increased ISF Aβ. Moreover, infusing the ventricle with a dual hypocretin receptor 
antagonist resulted in suppressed ISF Aβ levels and the natural diurnal variation of Aβ was abolished. In 
addition, hypocretin infusion led to significant decreases in ISF Aβ levels. The amount of ISF Aβ also 
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significantly increased during acute sleep deprivation and during orexin infusion in multiple sub-regions 
of the cortex. Remarkably, systemic treatment with infusion of a dual orexin receptor antagonist once 
daily for 8 weeks decreased the Aβ plaque formation in aged, sleep deprived, APP transgenic mice. This 
finding suggests that Aβ diurnal rhythm is related to sleep/wake regulation and that sleep deprivation 
increases Aβ levels and promotes subsequent Aβ plaque formation in APP transgenic mice. Rothman et 
al146 compared male AD transgenic mice that were subjected to 6-hours/day sleep for 6-weeks to controls 
(>7-hour/day sleep). Biochemical (immunoblot) outcomes were compared to mice undergoing daily cage 
transfers (large cage control; LCC) as well as control mice that remained in their home cage (control; 
CTL). Mice subjected to 6-hours/day sleep displayed a non-significant increase of ∼80% and a two- fold 
increase of both Aβ and P-Tau levels respectively in the cortex (P <0.22). Significant positive correlations 
between cortical Aβ and p -Tau levels and circulating corticosterone were seen and possibly indicate a 
potential role for glucocorticoids in mediating behavioral and biochemical changes observed after sleep 
restriction in a mouse model of AD. Di Meco et al136 evaluated the functional and biological 
consequences on 3xTg mice that underwent 4 hours sleep restraint per day for 8 weeks. Starting at the age 
of 8 months, mice were randomized to 2 groups, one underwent a 20/ 4-hour light and/or dark cycle for 2 
months (4 males and 5 females), the other was kept on a normal light and/or dark cycle, as controls (5 
males and 4 females). Compared to controls, behavioral assessment showed that sleep deprived mice had 
a significant decline in their learning and memory. Differences in the levels of soluble amyloid-b peptides 
between the groups were not observed, however reductions in tau phosphorylation, with a significant 
increase in its insoluble fraction was observed. Sleep deprivation also resulted in lower levels of 
postsynaptic density protein 95 and increased glial fibrillary acidic protein levels.  Finally, although total 
levels of the transcription factor cellular response element binding protein were unchanged, its 
phosphorylated form was significantly diminished in brains of sleep-deprived mice when compared with 
controls. The authors noted that their mice were relatively young in age and that the observed absence of 
effect on the Aβ levels provides support for their hypothesis that sleep deprivation is not a simple 
biomarker of the underlying neurodegenerative disease, but a direct contributor to its pathogenesis. 
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A.5 Randomized Controlled Trials 
Ooms et al133 conducted an RCT to determine the effect of 1 night of total sleep deprivation on 
cerebrospinal fluid Aβ42 protein levels in healthy middle-aged men. Participants were cognitively normal 
middle-aged men (40-60 years of age) with normal sleep (n = 26) recruited from the local population. 
Participants were randomized to 1 night with unrestricted sleep (n = 13) or 1 night of total sleep 
deprivation (24 hours of wakefulness) (n = 13). Sleep was monitored using continuous polysomnographic 
recording from 3 PM until 10 AM. Cerebrospinal fluid samples were collected using an intrathecal 
catheter at defined times to compare cerebral Aβ42 concentrations between evening and morning. A night 
of unrestricted sleep led to a 6% decrease in Aβ42 levels of 25.3 pg/mL (95% CI [0.94, 49.6], P = .04), 
whereas sleep deprivation counteracted this decrease. A difference of 75.8 pg/mL of Aβ42 was shown 
between the unrestricted sleep and sleep deprivation group (95% CI [3.4, 148.4], P = .04) when 
accounting for the individual trajectories of Aβ42 over time. Individual evening and morning trajectories 
of Aβ42 concentrations varied between the sleep deprivation and unrestricted sleep groups (P = .04) in 
contrast to stable Aβ40, tau, and total protein levels. 
B. Sleep wake-cycle/circadian rhythm and Cognitive decline and/or Alzheimer’s disease Dementia 
Table 1.8 presents the results of the descriptive study characteristics, statistical methods and main 
findings of studies that examined the association between sleep-wake /circadian rhythm abnormalities and 
cognitive decline and/or AD. In total, there were 23 studies (i.e., 5 cross-sectional,87,89,91,95,102 4 case-
control,97,101,106,107 6 prospective cohort,108,118,119,124,127,129 7 experimental studies134,135,137,140,143-145 and 1 
RCT131). 
B.1 Cross-sectional studies 
Oosterman et al89 examined whether nocturnal sleep and the circadian organization of the sleep-
wake rhythm had predictive value for cognitive functioning in home-dwelling elderly people and found 
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an association between the rest-activity rhythm and cognitive performance independent of age. Rest-
activity was assessed using actigraphy, and mental speed, memory, and executive function were evaluated 
using a battery of standardized cognitive tests. The authors noted that majority of the subjects suffered 
from at least one cardiovascular risk factor. Merlino et al87 examined the relationship between disturbed 
sleep and cognitive impairment in the elderly and found that among sleep disturbances, excessive daytime 
sleepiness was independently associated with the presence of dementia. In addition, the frequency of 
excessive daytime sleepiness increased progressively across the different categories of cognitive decline, 
as measured by means of MMSE and Global Deterioration Scale (GDS)179 scores.  
Pat-Horenczyk et al91 examined differences in hour-by-hour sleep/wakefulness profiles between 
severely and mild to moderately demented patients and assessed how many elderly patients remained 
almost fully asleep or nearly fully awake in each hour of a 24-hour period. They found that patients with 
mild to moderate dementia showed a disproportionate amount of wakefulness during the night, in contrast 
to patients with severe dementia showing a disproportionate amount of sleepiness during the day. They 
also found that with the progression of dementia both the capacity to maintain sleep and the capacity to 
maintain wakefulness were impaired, resulting in almost complete fragmentation of sleep/wakefulness 
during the night and day. Sleep/wakefulness patterns were recorded using actigraphy and levels of 
dementia were assessed by the Mini-Mental State Examination (MMSE). This study suggests that sleep 
disturbances parallel the severity of dementia\.  However, patients were not evaluated for type of 
dementia nor were records available to check whether patients had Alzheimer’s disease or dementia of 
other types. Yesavage et al95 examined indices of sleep/wake function collected from individuals with 
AD in relation to relevant polymorphisms in circadian clock-related genes in two cohorts of AD 
participants. [Cohort 1 (n=124): individuals with probable AD recruited from the Stanford/Veterans 
Affairs NIA Alzheimer’s Disease Core Center (n=81) and the Memory Disorders Clinic at the University 
of Nice School of Medicine (n=43). Cohort 2 (n=176): individuals with probable AD derived from the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) data set]. Adjusting for multiple tests, none of the 
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candidate gene SNPs were significantly associated with the amount of wake after sleep onset, a marker of 
sleep consolidation, and no relationships likely to be of clinical relevance were detected. The authors 
therefore concluded that it was unlikely that a relationship with a clinically meaningful correlation exists 
between the circadian rhythm-associated SNPs and WASO in individuals with AD. 
A pacemaker located in the suprachiasmatic nucleus (SCN) which serves as a master clock180,181 
organizes circadian regulation of sleep and wakefulness mechanisms. Melatonin, N-acetyl-5-
methoxytryptamine, is one of the most important timing signals generated by the SCN and is mostly 
known for its relation to circadian rhythms and sleep. Naismith et al102 examined whether patients with 
mild cognitive impairment (MCI) had significant alterations in the timing of melatonin secretion onset 
and amount as well as changes in sleep architecture.  They found that patients with MCI had advanced 
timing of their melatonin secretion onset relative to controls, but the levels of melatonin secreted did not 
differ between groups. The MCI group also had greater wake after sleep onset (WASO) and increased 
rapid eye movement sleep latency. There were differential associations between dim light melatonin onset 
and cognition between the two groups, with earlier dim light melatonin onset being associated with poorer 
memory performance in MCI patients. Participants’ sleep-wake behavior for the 14-nights prior to 
commencing the in-laboratory portion of the protocol was assessed using actigraphy and sleep diaries. 
Assessment of circadian function (melatonin rhythm timing and levels) and sleep architecture were 
examined using melatonin and polysomnographic (PSG) assessments on separate nights.  
B.2 Case-control studies 
Two studies conducted in the Netherlands investigated the circadian rhythm of hypocretin-1 
(Hypocretin-1 and -2 are hypothalamic neuropeptides, also known as orexins, that form an important 
regulating system acting on the sleep–wake cycle182,183) in Alzheimer’s disease.  Fronczek et al97 
assessed whether the neurodegenerative process of AD affects hypothalamic hypocretin/orexin neurons. 
Investigators quantified the total number of hypocretin-1 immuno-reactive neurons in postmortem 
hypothalami of AD patients (n = 10) and matched controls (n = 10) and measured hypocretin-1 
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concentrations in postmortem ventricular cerebrospinal fluid (CSF) of 24 AD patients and 25 controls. 
The numbers and levels of hypocretin-1 immunoreactive neurons and cerebrospinal fluid (CSF) 
hypocretin-1 respectively, were significantly lower (i.e., 40% decreased cell number, and 14% lower CSF 
hypocretin-1 levels respectively) in AD patients compared to controls. (p = 0.038). These findings 
indicate that the hypocretin system is affected in advanced AD. Slats et al107 examined the association 
between Hypocretin-1 and Amyloid-β42 CSF levels in 6 patients with AD (59-85 yrs., MMSE 16-26) and 
6 healthy volunteers (64-77 yrs.). The authors could show no difference in CSF hypocretin-1 circadian 
rhythm between AD and controls. However, lower mean CSF Aβ42 levels were significantly associated 
with lower hypocretin-1 levels. The authors postulated that this finding might suggest a relationship 
between AD pathology and hypocretin disturbance, which could hold possibilities for treatment of AD 
related sleep disorders.107  
Schmidt et al106 investigated cerebrospinal fluid (CSF) levels of melanin-concentrating hormone 
(MCH) and hypocretin-1 (HCRT-1, orexin-A) in patients with Alzheimer’s disease (AD) and Healthy 
subjects (HS) and the potentially causal relationship between these polypeptides and CSF levels of the 
AD marker total Tau (T-tau), hyper phosphorylated tau (P-tau) and Ab42, cognitive performance and 
behavioral symptoms in AD. The study was carried out in 33 patients with mild to severe AD and 33 
subjects without any psychiatric or neurological disorder (HS). A significant main effect of diagnosis 
(p=0.01) on MCH levels was found between AD and HS. MCH correlated with T-tau (p=0.01) and P-tau 
(p=0.05) in the AD but not in the HS. CSF-MCH correlated negatively with MMSE scores in the AD 
(p=0.05) and was increased in more severely affected patients (MMSE≤20) compared to HS (p=0.001) 
and BPSD-positive patients compared to HS (p=0.05). For CSF-HCRT- 1, a significant main effect of sex 
(p=0.05) with elevated levels in females was found whereas diagnosis and the sex*diagnosis interaction 
were not significant. These results should stimulate additional research on the role of the hypothalamus in 
AD pathogenesis and development of behavioral disturbances in AD. Future studies should include 
repeated MCH/HCRT-1 level measurements in combination with sleep-wake-actigraphy and assessment 
of sleep by standardized questionnaires, histochemical determinations of MCH in animal and post-
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mortem tissues. Liu et al101 analyzed data from 85 patients with AD (mean age, 75 ± 1.1 yr) and 82 age-
matched controls (mean age, 76 ± 1.4 yr), to determine melatonin levels in postmortem cerebrospinal 
fluid in relation to aging, AD, and APOE ε4 genotype. They found that melatonin levels in AD patients 
expressing APOE e3/4 was significantly higher than that in patients expressing APOE e4/4 (p = 0.02). 
CSF melatonin levels were significantly lower and about half of those in control subjects (p=.00126). 
B.3 Cohort studies 
Walsh et al127 using a study cohort of 1,287 community-dwelling older women (82.8 ± 3.1 y) 
who were free of dementia at the baseline visit and were followed for 5 years, found that weaker circadian 
activity rhythms (CAR) patterns were associated with lower cognitive function, especially poorer 
executive function. Keage et al118 found that daytime sleepiness was significantly associated with 
incident cognitive impairment over 10 years (OR = 2.43, 95% CI 1.24–4.75). Anderson et al108 also 
examined the association between subjective and objective measures of sleep and wakefulness and other 
health parameters in a 421 men and women, aged 87–89. The study was nested in the Newcastle 85+ 
Study, a population-based longitudinal study of health and ageing in the very old. Sleep-wake parameters 
were assessed subjectively with the Pittsburgh Sleep Questionnaire Inventory (PSQI) and the Epworth 
Sleepiness Score (ESS), while wrist actigraphy was used as an objective measure. The authors found that 
impaired sleep–wake cycles were significantly associated with cognitive impairment, disability, 
depression, increased number of falls, body mass index and arthritis but not with any other specific 
disease markers or decreased survival. The subjective sleep questionnaires did not differentiate well 
between objectively determined disturbance of sleep–wake cycles and those with normal cycles. Tranah 
et al124 studied whether measured circadian activity rhythms are prospectively associated with incident 
dementia or mild cognitive impairment (MCI) in 1,282 community-dwelling older women. They found 
that older women with decreased circadian activity rhythm amplitude and robustness and delayed rhythms 
had a higher likelihood of developing dementia or MCI when comparing those in the lowest quartile of 
amplitude (OR =1.57, 95% CI, 1.09–2.25) or rhythm robustness (OR=1.57, 95%CI, 1.10–2.26) compared 
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to women in the highest quartile. An increased risk of dementia or MCI (OR=1.83, 95% CI, 1.29–2.61) 
also was found for women whose timing of peak activity occurred later in the day (after 3:51PM) when 
compared to those with average timing (1:34PM–3:51PM). Lim et al119 tested the hypothesis that sleep 
fragmentation is associated with incident Alzheimer’s disease (AD) and the rate of cognitive decline 
among 737 older adults without dementia at baseline, and reported that those with significant actigraphic 
sleep fragmentation (in the 90th percentile) had a 1.5-fold increased risk of developing AD as compared 
with those with low sleep fragmentation (10th percentile). A Cox regression model controlling for age, 
sex, and education, also revealed that a higher level of sleep fragmentation was associated with an 
increased risk of incident AD (HR = 1.22, 95%CI 1.03-1.44, P = 0.02 per 1 SD increase in sleep 
fragmentation). In an earlier prospective study Yesavage et al129 determined if sleep parameters in AD 
patients change over time as a function of APOE carrier status in 44 subjects, of which 25 were APOE ε4 
carriers and 19 were non-ε4 carriers. Participants had been assessed at least during 2 stages of cognitive 
impairment, defined as a decline from one stage of AD to another. They found that among APOE ε4 
carriers, wake after sleep onset was associated with lower cognitive function; for non-ε4 subjects, 
increases in WASO and declines in total sleep time, sleep efficiency, and the amplitude of the rest/activity 
circadian rhythm over time were associated with lower cognitive function. 
B.4 Experimental studies 
Craig et al134 explored the effects of acute and chronic disruption of circadian rhythms on 
memory using a phase shifting schedule that can continually challenge the rats’ circadian system by using 
repeated phase shifts and recovery sessions. Twenty-four male Long Evans hooded rats (300–400 g) 
obtained from Charles River (Saint-Constant, PQ) were used for all studies. They were divided into three 
groups: acutely phase shifted rats (acute; n = 8), chronically phase shifted rats (chronic; n = 8), control 
rats for water maze testing (control; n=7) and control rats for fear conditioning (control; n = 14). The 
authors demonstrated a significant learning and memory deficit on a spatial version of the water maze 
task (used for behavioral testing in the animals) in the chronically phase shifted, but not in the acutely 
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phase shifted animals. Moreover, they did not find any impairment in fear conditioning suggesting that 
chronic phase shifting predominantly affects hippocampal memory. They proposed that chronic circadian 
disruption may play a role in the development of age-related cognitive deficits and dementia in the 
elderly. Jyoti et al137 characterized sleep, electroencephalogram (EEG) disturbances and cognitive 
dysfunction in transgenic mice carrying transgenes for amyloid-protein precursor (APPswe) and 
presenilin 1 (PSEN1A246E) at 5 (pre-plaque) and 20 months, relative to PSEN1 and wild-type (WT) 
mice, using a novel wireless microchip device. The study findings suggested that APP/PSEN1 mice 
exhibit abnormalities in activity and sleep architecture preceding amyloid plaque deposition as well as 
age-related changes in cortical EEG power. Though not fully recapitulating the profile of AD patients, 
this suggests activity and EEG recordings are sensitive and translational biomarkers in murine models. 
Several anti-amyloidogenic effects of melatonin have been demonstrated in vitro and in animal 
studies. Pappolla et al144 examined the interactive ability of melatonin with Aβ1–40 and Aβ1–42 to 
determine whether melatonin inhibits the progressive formation of β-sheets and amyloid fibrils. These 
investigators found that melatonin crosses the blood-brain barrier, is relatively devoid of toxicity, and 
concluded that it may constitute a potential new therapeutic agent in Alzheimer’s disease. Olcese et al143 
examined the potential for long-term melatonin treatment to protect Alzheimer’s transgenic mice against 
cognitive impairment and development of β-amyloid (Aβ) neuropathology. Authors administered 
melatonin (100 mg/L drinking water) to AD transgenic (Tg) mice from 2–2.5 months of age to their 
killing at age 7.5 months. Findings revealed that melatonin suppresses Aβ aggregation in brain 
homogenates. Inflammatory cytokines such as tumor necrosis factor (TNF)-α were decreased in 
hippocampus (but not plasma) of Tg+ melatonin mice. Finally, the cortical mRNA expression of three 
antioxidant enzymes (SOD-1, glutathione peroxidase, and catalase) was significantly reduced to non-Tg 
levels by long-term melatonin treatment in Tg mice. Lahiri et al140 examined the effects of dietary 
melatonin on brain levels of nitric oxide synthase, synaptic proteins and amyloid beta-peptides (Aβ) in 
mice. They found that dietary melatonin supplementation led to a significant reduction in levels of toxic 
32 
 
cortical Aβ of both short and long forms that are involved in amyloid deposition and plaque formation in 
Alzheimer's diseases. However, melatonin supplements did not significantly change cerebral cortical 
levels of nitric oxide synthase or synaptic proteins such as synaptophysin and SNAP-25.  
Deregulation of protein kinases/protein phosphatases is responsible for tau hyper 
phosphorylation. Among them, glycogen synthase kinase-3 (GSK-3) is a known tau kinase that plays a 
crucial role in AD pathology.184 In-vivo and in-vitro tau phosphorylation can be undertaken by GSK-3 
and over-expression of GSK-3 leads to tau hyper phosphorylation.185,186 In an Alzheimer’s-affected brain, 
GSK-3 is activated in pretangle neurons and accumulates in paired helical filaments.187 Under the above 
premise, Deng et al135 carried out an in-vitro study on N2a (Neuro-2a: a fast growing neuroblastoma cell 
line) cells that were grown and differentiated in 96-well culture plates at density of 1.5×105 cells in 100 
μL. Cells were exposed to various concentrations of wortmannin (an indirect GSK-3 activator) for 2 h at 
37 ºC in the presence or absence of a 12-h-preincubation with melatonin 25, 50, and 100 μmol/L or 
Vitamin E (VE). The authors explored the underlying mechanism of tau hyper phosphorylation in an 
Alzheimer's affected brain and the possible arresting strategies. One of the findings of the study was that 
preincubation of the cells with melatonin or vitamin E attenuated differentially wortmannin induced 
oxidative stress as well as GSK-3 over-activation and tau hyper phosphorylation. The authors concluded 
that wortmannin might be an effective tool for reproducing AD-like tau hyper phosphorylation cell model 
and that melatonin/vitamin E can effectively protect the cells from wortmannin-induced impairments. 
Contrary to the above findings on the possible therapeutic value of melatonin on cortical Aβ level 
reduction, Quinn et al145 examined the effect of chronic melatonin therapy initiated after the appearance 
of plaques in Tg2576 mice and failed to demonstrate any effect, as chronic melatonin therapy did not alter 
amyloid burden or oxidative damage after 4-months of treatment. Variations in melatonin dose, age of 
treatment initiation, and species of Aβ measured could possibly have accounted for the different results. 
Quinn et al. noted that one of the prior studies used a lower dose and still found an effect at this dose 
could not have accounted for the different result. The age at treatment initiation varied across the studies 
and might possibly explain the different results. Another study188 using similar Tg2576 mice initiated 
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treatment at 4 months of age (prior to the appearance of hippocampal and cortical plaques) also found 
diminished Aβ and nitrotyrosine at 7–8 months, but no significant difference in histologically detectable 
Aβ or brain nitrotyrosine in animals at 15 months of age. The Quinn et al study initiated treatment at 14 
months. 
B.5 Randomized Controlled Trial 
Asayama et al131 conducted a double blind study to examine the effects of melatonin on the 
sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type of dementia. The subjects 
were 9 persons given a placebo (PLA), and 11 given melatonin (3 mg) (MLT). The drugs were given at 
8:30pm each day for 4 weeks. Melatonin administration improved sleep time and night activity 
significantly, but had no significant effect with regard to improving daytime naps and activity. Melatonin 
administration improved cognitive and non-cognitive functions significantly. Melatonin seemed to be 
useful for care of the Alzheimer type of dementia patients 
C. Hypoxia (Apnea Hypopnea Index) and Cognitive decline and/or Alzheimer’s disease 
Sixteen studies (i.e., 4 cross-sectional,81,83,86,90 1 case-control,103 3 prospective cohort,125,128,150 1 
retrospective cohort,112 2 RCTs,130,132 and 5 experimental studies139,141,147-149) examined hypoxia states 
(AHI) in sleep apnea/sleep disordered breathing and its association with cognitive decline and/or AD. 
Table 1.9 presents the results of the descriptive study characteristics, statistical methods and main 
findings of the studies. 
C.1 Cross-sectional studies 
Kadotani et al86 conducted a cross-sectional study to determine whether genetic variation at the 
level of APOE is associated with Sleep Disordered-Breathing (SDB) in a probability based sampling of 
791 middle-aged adults, mean age of 49 and age range 32-68. They found that independent of age, sex, 
body mass index, and ethnicity, participants with APOE epsilon4 had a significantly higher risk of 
moderate-to-severe Sleep Disordered-Breathing (apnea-hypopnea index (AHI) ≥15%) (P =.003). 
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Participants with APOE epsilon4 also had a significantly higher mean (SEM) apnea-hypopnea index 
(p=.01). These effects increased with the number of APOE epsilon4 alleles carried. In a similar study, 
Gottlieb et al83 examined the association of the APOE e4 allele with Obstructive Sleep Apnea/Hypopnea 
(OSAH) in a community-dwelling cohort, exploring age dependency of the association. The investigators 
conducted a genetic association study, nested within a prospective cohort study of the cardiovascular 
consequences of OSAH. APOE e4 allele was associated with increased odds of OSAH (OR 1.41, 95% CI 
1.06 to 1.87, p = 0.02) after controlling for age, sex and body mass index (BMI). The effect was greater in 
subjects < 75 (OR 1.61, CI 1.02 to 2.54) as in those ≥75 years old (OR 1.32, CI 0.91 to 1.90). Exploratory 
analyses revealed that the strongest effect of APOE e4 was in subjects age <65 (OR 3.08, CI 1.43 to 
6.64), and was stronger in those with hypertension or cardiovascular disease than in those without. The 
authors therefore concluded that the APOE e4 allele is associated with increased risk of OSAH, 
particularly in individuals under age 65.83 Osorio et al90 examined the interaction between sleep-
disordered breathing and Apolipoprotein E genotype on cerebrospinal ﬂuid biomarkers for Alzheimer’s 
disease in a total of 95 cognitively normal elderly participants who were analyzed for SDB severity. 
Among the 95 participants, 25 were considered free of SDB (apnea and/or hypopnea with 4% O2-
desaturation index (AHI4%) < 5) and were included as normal controls, 51 had mild SDB (AHI4% 5-
14.99), and 19 had moderate to severe SDB (AHI4% > 15). Results showed that in ApoE3+ subjects, 
significant differences were found between sleep groups for p-tau and t-tau (p=0.017, p = 0.043 
respectively), and the AHI4% was significantly correlated with p-tau (p = 0.023), t-tau (p = 0.021), and 
Aβ-42 (p = 0.021). In ApoE2+ subjects, the AHI4% was significantly correlated with lower levels of CSF 
Aβ-42 (p = 0.004), identical to ApoE4+ subjects where there was also a trend toward lower CSF Aβ-42 
levels.  
Lastly, Djonlagic et al81 examined the effect of aging on sleep-dependent motor memory 
consolidation in patients with and without OSA. Participants included 44 patients (19–68 years) who had 
been referred by a physician for a baseline polysomnography (PSG) evaluation and were assigned either 
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to the OSA group (AHI>5/h), or control (Non-OSA) group (AHI<5/h). All subjects performed the 
Psychomotor Vigilance Task (PVT) and the Motor Sequence Learning Task (MST) in the evening and 
again in the morning after their PSG. Results showed that healthy sleepers displayed a greater degree of 
sleep-dependent overnight improvement on the MST, an effect not diminished by increasing age. The 
existence of untreated obstructive sleep apnea was associated with an aging-related cognitive deficit, 
otherwise not present in individuals without OSA. Other research has linked OSA to a greater risk of 
developing dementia. Future studies are therefore necessary to determine if the restriction of memory 
consolidation is tied to or has a role to play in the onset of neurodegenerative disease. 
C.2 Case-control studies 
O’Hara et al103 investigated the relationship between obstructive sleep apnea/hypopnea (OSAH) 
and cognition in 36 older adults, i.e., 18 APOE epsilon4 carriers, and 18 non-carriers. These authors 
found that higher levels of AHI were associated with lower memory scores in the APOE epsilon4 carriers 
only. Minimum oxygen saturation (MinSaO2) did not differ significantly between the groups, but was 
lower than 90% in both, indicative of the occurrence of hypoxia. MinSaO2 was not associated with 
cognition, although there was a non-significant trend for minSaO2 to negatively impact memory in the 
APOE epsilon4 carriers only. 
C.3 Cohort studies 
Cohen-Zion et al150 examined changes in cognitive function associated with Sleep Disordered 
Breathing (SDB) in 46 participants aged 65 and older who completed visits 3 and 4. The original cohort 
included community-dwelling elders age 65 and older with high risk for SDB studied from 1981 through 
1985 and then followed every 2 years. The study results suggest that declining cognitive function is 
associated primarily with increases in daytime sleepiness. Although cognitive decline was also associated 
with increases in respiratory disturbance index (RDI: defined as number of apneas plus hypopneas per 
hour of sleep), this association did not hold in a more inclusive model which also included variable of 
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SDB, oximetry, sleep and subjective report. The findings could suggest that any relationship between 
SDB and cognitive function may be mediated by the effect of SDB on daytime sleepiness. Tworoger et 
al125 found no associations with snoring, sleep duration, and difficulty sleeping and cognitive decline over 
2 years. Chang et al112 in a retrospective matched-control cohort study estimated and compared the risk 
of dementia in Sleep Apnea (SA) and non-SA patients among persons aged 40 and above over a 5-year 
follow-up period. Overall findings suggest that SA patients had a 70% greater risk of developing 
dementia within 5 years of diagnosis compared to non-SA age- and sex-matched patients, after adjusting 
for other risk factors (95% confidence interval (CI) = 1.26-2.31; P < .01).  
Yaffe et al128 examined the prospective relationship between sleep disordered breathing (SDB), 
and cognitive impairment and investigated potential mechanisms of this association. Using data from 298 
women without dementia (mean [SD] age: 82.3 [3.2] years), the authors found that women with SDB had 
an 85% increased risk of developing MCI or dementia compared to women without SDB after adjusting 
for age, race, body mass index, education, smoking status, presence of diabetes, presence of hypertension, 
medication use (antidepressants, benzodiazepines, or non- benzodiazepine anxiolytics) and baseline 
cognitive scores (adjusted OR=1.85, 95% CI 1.11-3.08). Measures of disordered breathing i.e., elevated 
oxygen desaturation index (≥15 events/hour) and high percentage (>7%) of sleep time in apnea or 
hypopnea, were both associated with risk of developing MCI or dementia (adjusted OR=1.71, 95% CI 
1.04 − 2.83 and adjusted OR=2.04, 95% CI 1.10 − 3.78, respectively). Sleep fragmentation measures 
(arousal index and wake after sleep onset) or sleep duration (total sleep time) were not associated with 
risk of cognitive impairment.  
C.4 Experimental studies 
Shiota et al147 examined the direct effect of intermittent hypoxia (IH) in pathophysiology of AD 
in-vivo and in-vitro. In-vivo, 15 male triple transgenic AD mice were exposed to either chronic 
intermittent hypoxia (CIH) or normoxia (5% O2 and 21% O2 every 10 min, 8 h/day for 4 weeks). In-
vitro, human neuroblastoma SH-SY5Y cells stably expressing wild-type amyloid-β protein precursor 
were exposed to either IH (8 cycles of 1% O2 for 10 min followed by 21% O2 for 20 min) or normoxia. 
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Results showed that CIH significantly increased levels of Aβ42 but not Aβ40 in the brains of mice 
without the increase in hypoxia-inducible factor 1, alpha subunit (HIF-1α) expression. Furthermore, CIH 
significantly increased intracellular Aβ-42 in the brain cortex. There were no significant changes in 
cognitive function. IH significantly increased levels of Aβ42 in the medium of SH-SY5Y cells without 
the increase in the HIF-1α expression. CIH directly and selectively increased levels of Aβ42 in the AD 
model. Kaushal et al139 hypothesized that acute short-term Intermittent hypoxia (IH) and sleep 
fragmentation (SF) (major manifestations of sleep apnea), as well as their combination (IH+SF) may 
reveal unique susceptibility in sleep integrity in a murine model of AD. They found that slow wave sleep 
(SWS) was significantly decreased, and rapid eye movement (REM) sleep was almost suppressed during 
acute exposure to IH alone and IH+SF for 6 h in hApoE4 animals, with milder effects in WT controls. 
Reduced delta power during SWS did not show post exposure rebound in hApoE4 unlike WT controls. IH 
and IH+SF induced hypothermia was more prominent in hApoE4 than wild type (WT) controls. Mice 
subjected to SF also showed sleep deficits but without hypothermia. “hApoE4 mice, unlike WT controls, 
exhibited increased sleep propensity, especially following IH and IH+SF, suggesting limited ability for 
sleep recovery in hApoE4 mice.” These findings affirm the probable impact of IH and SF in adjusting 
sleep architecture and sleep homeostasis including sustenance of body temperature. In addition, the 
increased susceptibility and defined recovery capability of hApoE4 mice to sleep apnea suggests that 
early identification and treatment of sleep apnea in AD patients may permit interventions to slow AD 
progression. 
Zhang et al149 investigated the possibility of a direct molecular link between hypoxic insults and 
Amyloid Precursor Protein (APP) processing and found that acute hypoxia increased the expression and 
the enzymatic activity of β-secretase (BACE1) (Aβ is derived from the β-amyloid precursor protein 
(APP) by sequential proteolytic cleavages from β-secretase (BACE1) and presenilin-1 (PS1)/γ-secretase) 
by up-regulating the level of BACE1 mRNA, resulting in increases in the APP C-terminal fragment-β 
(βCTF) and Aβ. Hypoxia had no effect on the level of PS1, APP, and tumor necrosis factor--converting 
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enzyme (TACE, an enzyme known to cleave APP at the α-secretase cleavage site). Sequence analysis, 
mutagenesis, and gel shift studies revealed binding of Hypoxia Inducible Factor-1 (HIF-1) to the BACE1 
promoter. Overexpression of HIF-1 α increased BACE1 mRNA and protein level, whereas down-
regulation of HIF-1 α reduced the level of BACE1. Hypoxic treatment failed to further potentiate the 
stimulatory effect of HIF-1α overexpression on BACE1 expression, suggesting that hypoxic induction of 
BACE1 expression is primarily mediated by HIF-1α. Lastly, the authors observed significant reduction in 
BACE1 protein levels in the hippocampus and the cortex of HIF-1α conditional knock-out mice. These 
results provide evidence that hypoxia/HIF-1α plays a vital role in balancing the amyloidogenic processing 
of APP.  It also provides a molecular mechanism to explain increased incidence of AD following cerebral 
ischemic and stroke injuries. Following in the same line of thought, Li et al141 investigated molecular 
mechanisms underlying hypoxia mediated AD using AD transgenic mice. The authors demonstrated that 
repeated hypoxia increased β-amyloid (Aβ) generation and neuritic plaque formation by elevating β-
cleavage of APP in APPswe + PS1A246E transgenic mice. They also found that hypoxia enhanced the 
expression of APH-1a, a component of ɣ-secretase complex, which in turn may lead to increase in ɣ-
cleavage activity. Furthermore, these authors demonstrated that repeated hypoxia treatment can activate 
macroautophagy, which may contribute to the increases in Aβ production. Taken together, the results 
suggest an important role of hypoxia in modulating the APP processing by facilitating both β- and ɣ-
cleavage which may result in a significant increase of Aβ generation. Sun et al148 constructed a series of 
deletion luciferase reporter plasmids containing human BACE1 gene promoter regions to investigate 
whether BACE1 is one of the downstream target genes of the hypoxia signaling pathway. In the study, 
authors found that hypoxia significantly increased BACE1 gene expression, resulting in increased β-
secretase activity and Aβ production. Furthermore, hypoxia treatment markedly increased Aβ deposition 
and potentiated the memory deficit in AD transgenic mice. The results demonstrate that hypoxia can 
facilitate AD pathogenesis, and they provide a molecular mechanism to link vascular factors to AD. 
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C.5 Randomized Controlled Trials         
 Ancoli-Israel et al130 examined whether treatment of obstructive sleep apnea (OSA) with 
continuous positive airway pressure (CPAP) in patients with Alzheimer's disease (AD) would result in 
improved cognitive function. Participants were randomized to either therapeutic CPAP for six weeks or 
placebo CPAP for three weeks followed by therapeutic CPAP for three weeks. A comparison of subjects 
randomized to 3 weeks of therapeutic versus placebo CPAP suggested no significant improvements in 
cognition. A comparison of pre- versus post-treatment neuropsychological test scores after 3 weeks of 
therapeutic CPAP in both groups showed a significant improvement in cognition. Similarly, Kushida et 
al132 determined the neurocognitive effects of continuous positive airway pressure (CPAP) therapy on 
patients with obstructive sleep apnea (OSA) in a 6-month, randomized, double-blind, 2-arm, sham-
controlled, multicenter trial. The results showed that CPAP treatment improved both subjectively and 
objectively measured sleepiness, especially in individuals with severe OSA (AHI >30). CPAP use also 
resulted in mild, transient improvement in the most sensitive measures of executive and frontal-lobe 
function for those with severe disease, which suggests the existence of a complex OSA-neurocognitive 
relationship. 
D. Insomnia and cognitive decline and/or Alzheimer’s disease 
Six studies (i.e., 2 cross-sectional87,92 and 4 prospective cohort studies114,115,117,121) examined the 
association between insomnia and cognitive decline and/or AD. Table 1.10 presents the results of the 
descriptive study characteristics, statistical methods and main findings of the studies. 
D.1 Cross-sectional studies 
Pistacchi et al92 in their study found that patients with MCI had a frequency of sleep disturbances 
of any type equal to that of patients with AD  and presented mostly with insomnia. In the study insomnia 
occurred more frequently in AD. In their cross-sectional study examining the association between 
multiple sleep parameters including insomnia and cognitive impairment in the elderly, Merlino et al87 did 
not find an association between insomnia, the most common sleep complaint in their sample, and the 
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presence of cognitive decline. These studies assessed the presence of sleep disorders by means of 
subjective symptoms and not using objective instruments, such as wrist actigraphy or polysomnography. 
Polysomnography is essential for a correct diagnosis of some sleep disturbances. In particular, sleep 
disordered breathing can be diagnosed only by means of polysomnographic recordings. Because 
assessment of sleep parameters was based on a structured interview, obtaining self-reported description of 
sleep characteristics from subjects with significant cognitive impairment becomes challenging and 
questionable.  
D.2 Cohort studies 
Examining whether self-reported symptoms of insomnia independently increase risk of cognitive 
decline in older adults, Osorio et al121 and Cricco et al114 found that there is a greater risk of Alzheimer's 
disease in adults with self-reported insomnia. Osorio et al121 examined the relationship between insomnia 
and AD in 346 cognitively normal older adults evaluated during multiple visits over 7.7 years of follow-
up.  Insomnia was collected only during the normal cognition stage and screened using items 4, 5, and 6 
from the Hamilton Depression Rating Scale (HAM-D). Participants who reported insomnia had an 
increased odds of 2.39 of developing AD when compared to the non-insomnia group. (OR = 2.39, 95% 
confidence interval (CI) = 1.03–5.55). Depression did not confound the association, and individuals with 
insomnia showed a faster progression to dementia (chi-square = 3.94, P = .047). Cricco et al114 found in 
their study sample that self-reported symptoms of insomnia independently predicted incident cognitive 
decline in older men, but not in women. Compared to those with no insomnia at the third annual follow 
up (FU3) those reporting symptoms of insomnia at both baseline and FU3 had an adjusted odds ratio 
(AOR) of 1.49 (95% CI = 1.03–2.14) for cognitive decline among non-depressed men. Men with 
insomnia at FU3 only were not at increased risk (OR = 1.16, 95% CI = 0.82–1.65). These relationships 
were not found in women. Men and women with depressive symptoms at FU3 were at increased risk for 
cognitive decline independent of insomnia. Participants included over 6,000 community-dwelling men 
and women age 65 and older from the prospective cohort of the four sites of the Established Populations 
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for Epidemiologic Studies of the Elderly (EPESE) in Iceland. The authors noted that sleep complaints 
data were only available at 3-year intervals, making misclassification of exposure in some cases more 
likely, e.g., some participants classified as experiencing chronic sleep disturbances may have had 
transient episodes of sleep difficulty during follow-up but may have had undisturbed sleep over the period 
between follow-ups. Likewise, incident cases could have had symptoms for up to 3 years. Thus, the odds 
ratios found in this study can be considered conservative estimates of risk. 
Using the Maastricht Ageing Study (MAAS) cohort in Netherlands, Jelicic et al117 examined 
whether subjective sleep complaints (i.e., extent to which an individual was distressed by difficulties with 
falling asleep, waking up too early and by a restless or disturbed sleep) in a population-based sample of 
838 middle aged and older adults (≥ 50 years) predicted cognitive decline over a period of 3 years. 
Results showed that subjective sleep complaints were negatively associated with cognitive performance at 
follow-up (β = -0.05 95% CI: -0.09 to -0.00, p = 0.03). Foley et al115 examined the longitudinal 
association between sleep disturbances (insomnia and daytime sleepiness) and incidence of dementia and 
cognitive decline in 2346 Japanese-American men aged 71 to 93 in the Honolulu-Asia Aging Study 
(HAAS). Sleep disturbances were assessed by a questionnaire that asked whether participants were sleepy 
during the day or had insomnia (defined as “usually” having trouble falling asleep or waking up far too 
early and not going back to sleep). Individuals were screened for possible dementia using the CASI. 
Dementia was diagnosed according to less-restrictive diagnostic criteria developed by Cummings et al.189 
for very mild dementia and more-restrictive diagnostic criteria for mild or more severe dementia from the 
Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-IIIR).190 Results 
from the study showed that participants with excessive daytime sleepiness at baseline (8%) were twice as 
likely to be diagnosed with incident dementia than were those not reporting daytime sleepiness [adjusted 
odds ratio (OR) = 2.19, 95% confidence interval (CI) = 1.37–3.50] and about 40% more likely to have a 9 
or more point drop in their CASI score between examinations [OR = 1.44, 95% CI =1.01–2.08]. Insomnia 
was not associated with cognitive decline or incidence of dementia. The authors noted that there was lack 
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of information to identify persons with sleep disordered breathing, which has been shown to affect 
cognitive performance191,192 and has a 25% prevalence in older persons.193 
E. Restless Leg Syndrome and cognitive decline and/or Alzheimer’s disease 
Table 1.11 presents the results of the descriptive study characteristics, statistical methods and main 
findings of the 3 studies (i.e., 2 cross-sectional84,92 and 1 case-control104) that examined any association 
between restless leg syndrome and cognitive decline and/or AD.  
E.1 Cross-sectional 
Restless legs syndrome (RLS) can inhibit falling asleep or being able to stay asleep. RLS 
incidence is higher in women and increases with age.194 Depression, antidepressant drug intake, renal 
failure, and peripheral neuropathy, are known risk factors for RLS and also increase with age. Guarnieri 
et al84 reported a 6% prevalence of RLS in MCI and Demented (AD/non-AD patients) assessed by the 
international RLS study group155,195 questionnaire.  However, in cognitively impaired individuals, 
assessing RLS by use of a questionnaire might be arduous. Another study196 reported an RLS prevalence 
of 24% in 59 demented individuals using specific guidelines of probable RLS that  emphasizes behavioral 
indicators and supportive features such as dopaminergic responsiveness, patient’s past history, and 
presence of periodic limb movements, in cognitively impaired elderly.197 Pistacchi et al92 enrolled 236 
patients (78 men and 158 women) with different subtypes of dementia and showed that RLS was one of 
the most common symptoms in MCI patients.  
E.2 Case-control studies 
Given the degree of chronic sleep deprivation that RLS patients’ experience, Pearson et al104 
hypothesized that RLS patients would exhibit decreased cognitive performance particularly on the more 
pre-frontal cortical functioning (PFC) focused cognitive tasks relative to age matched controls with 
relatively less or no impairments on other cognitive tasks. Results showed that RLS patients compared to 
controls showed significant (P<0.05) and sizeable (20–40%) deficits on Verbal Fluency tests and the Trail 
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Making tests. The authors concluded that RLS patients have statistically significant specific cognitive 
deficits and show cognitive deficits similar to those seen with 36 h total sleep deprivation. 
DISCUSSION 
The purpose of this systematic review was to examine the association of sleep and its related 
problems/disorders with Alzheimer’s disease, cognitive decline or dementia and to evaluate the evidence 
for a causal association. We systematically and critically synthesized and evaluated data from 72 original 
publications. Study quality was assessed using an adaptation from previous systematic reviews73,74 and the 
modified version of the Newcastle-Ottawa scale (NOS) for quality assessment of the observational 
studies,75,76 with addition of new items relevant to this review. Appropriateness of study design, study 
populations, study samples, size of the study sample, exposure and outcome measurement, statistical 
analytic design, adjustment of potential sources of confounding, variations in study populations, and 
numerous sources of bias were considered. Epidemiological studies can assess risk and contribute to 
understanding of possible causation but possess built-in limitations related to their design. Consistency of 
results, dose-response relationships and temporality play a crucial role in determining causation; it is 
however necessary to consider high quality studies when accepting or rejecting causal associations 
between exposure and outcome. Out of the 72 studies reviewed, only 14 studies were assessed to be of 
low quality, while 58 studies were of medium to high quality, signifying that the publications reviewed in 
this systematic review were mostly satisfactory in their design.  
In this comprehensive review of seventy-two studies, there is strong evidence that sleep and its 
related abnormalities/disorders are associated with cognitive decline and/or Alzheimer’s disease 
independent of other factors. Summarizations of sectional findings already discussed in the sections above 
are provided below. 
A. Sleep depth and Cognitive decline and/or Alzheimer’s disease 
44 
 
The vast majority of the cross-sectional studies reviewed demonstrated an association between 
sleep depth and cognitive decline and/or AD and/or Dementia. The association between sleep quality and 
cognition was not explained by confound factors such as cerebrovascular disease, depression, or 
medication usage.88 Objectively measured disturbed sleep was consistently related to poorer cognition, 
whereas total sleep time was not. Sleep duration during the 24-h day was positively correlated with the 
severity of dementia in nursing home patients,82 however, in a community-dwelling of women 65 years 
old or older, there was no significant relationship for total sleep time with poorer cognition. These 
findings may suggest that it is disturbance of sleep rather than quantity that affects cognition in demented 
patients, while both sleep disturbance and duration affect cognition in the healthy elderly. 
It is important to note that one cross-sectional study93 reported no significant differences between 
good sleepers (GS) (PSQI <= 5) and poor sleepers (PSQI >= 5) in any of the objective cognitive function 
tests except for the Trail Making Test A (TMA-A), processing speed being longer in the PS group (p < 
0.001), and as such concluded that in healthy elderly subjects subjective sleep quality and duration was 
not associated with subjective and objective cognitive performances, except for attention. However, in 
this study, sleep duration and quality were self-reported and the authors had no information on sleep 
structure and sleep fragmentation, two factors implicated in self-reported cognitive deficits. 
Cross-sectional studies examining the association between sleep depth and AD pathology also 
demonstrate an association. Both Spira et al94 and Ju et al85 showed that amyloid deposition in the 
preclinical stage of AD appears to be associated with worse sleep quality. Spira et al also demonstrated an 
association with sleep duration, however, Ju et al did not. The contrasted findings could possibly be due 
to the variations in Aβ42 burden assessment. In Ju et al Aβ42 was measured using the Alzheimer Disease 
Research Center (ADRC) Biomarker Core using enzyme linked immunosorbent assay while Spira et al 
measured β-amyloid burden, using carbon 11–labeled Pittsburgh compound B positron emission 
tomography distribution volume ratios (DVRs). 
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Results from reviewed case-control studies examining sleep depth and cognitive decline and/or 
AD suggest that sleep disruptions are evident years before diagnosis of AD and that sleep is significantly 
impaired in patients with MCI at both the objective and subjective level.98,99 This may have implications 
for sleep being used as a surrogate marker of preclinical Alzheimer disease and for early detection of 
dementia and/or therapeutic management of sleep complaints in MCI patients.  
Case-control studies reviewed show an association between sleep depth and AD pathology 
demonstrating that increased plasma Aβ42 levels are significantly associated with fragmented SWS in 
amnestic MCI subjects,105 thereby suggesting that sleep disruptions may signal Aβ burden in persons at 
increased risk for AD, and that changes in theta rhythm during REM and SWS are a relevant index of 
brain impairments in the early stage of AD, and that a deficiency of Ach may result in an increase of 
sEMG activity in MCI patients. Since cholinesterase inhibitors are capable of suppressing sEMG activity 
in AD patients, it is possible that an increase in sEMG activity is associated with a deficiency of Ach, 
which could be an early indicator of dementia 
All cohort studies (prospective  and retrospective) that evaluated the relationship between sleep 
depth parameters and cognitive decline and/or AD reveal that sleep depth parameters increase the risk of 
cognitive decline and/or developing AD. Both subjective and objective sleep assessments yield similar 
outcomes of a relationship between sleep depth parameters and cognitive decline and/or AD independent 
of other factors including depression/depressive symptoms.109,111,122 These findings suggest that sleep 
depth parameters such as daytime napping, and night-time sleep duration, may be modifiable behaviors 
open to intervention strategies, or, clinical indicators of future decline in older individuals. However, after 
adjusting for depressive symptoms, Hahn et al116 could no longer show that self-reported sleep problems 
may increase the risk for dementia. However, the authors measured depressive symptoms with only one 
self-reported item. They also noted that they did not include longitudinal data on sleep. Research with 
longitudinal sleep data is definitely preferable. Also, the relatively small sample size (n=214) may have 
biased the results toward a Type II error, particularly in the more refined analyses.  
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The only cohort study reviewed,120 examining the relationship between sleep depth parameters 
and AD pathology show that better sleep consolidation attenuates the effect of APOE genotype on 
incident AD and development of neurofibrillary tangle pathology. Assessment of sleep consolidation may 
identify APOE+ individuals at high risk for incident AD, and interventions to enhance sleep consolidation 
should be studied as potentially useful means to reduce the risk of AD and development of neurofibrillary 
tangles in APOE ε4+ individuals. 
Experimental studies and RCTs evaluated the relationship between sleep depth parameters and 
AD pathology and all demonstrate that sleep deprivation, or prolonged wakefulness, interferes with a 
physiological morning decrease in Aβ42 and that chronic sleep deprivation increases cerebral Aβ42 
levels, which elevates the risk of Alzheimer disease. Interestingly, Kang et al138 showed that orexin may 
play a role in the pathogenesis of Alzheimer’s disease and Rothman et al146 demonstrated significant 
positive correlations between cortical Aβ and p -Tau levels and circulating corticosterone. The latter 
finding might suggest a probable role for glucocorticoids in mediating behavioral and biochemical 
changes observed after sleep restriction in a mouse model of AD. 
B. Circadian Rhythm/sleep-wake abnormalities and cognitive decline and/or Alzheimer’s 
disease 
All cross-sectional studies that evaluated any association between circadian Rhythm/sleep-wake 
abnormalities and cognitive decline and/or Alzheimer’s disease demonstrated that an association between 
the rest-activity rhythm and cognitive performance was present in elderly people. They also showed that 
with the progression of dementia, excessive daytime sleepiness, the capacity to maintain sleep and the 
capacity to maintain wakefulness are impaired, and result in complete fragmentation of sleep/wakefulness 
during the night and day.87,89,91 However, it is unlikely that a relationship with a clinically meaningful 
correlation exists between the circadian rhythm-associated SNPs and WASO in individuals with AD.95 
All case-control studies that examined any association between circadian Rhythm/sleep-wake 
abnormalities and cognitive decline and/or Alzheimer’s disease showed that circadian misalignment and 
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sleep disruption was evident in patients with MCI, and was consistent with changes observed in 
Alzheimer’s disease. Such findings could be a marker for disease trajectory, and may even be implicated 
in disease pathogenesis.  
Case-control studies that examined any association between circadian rhythm/sleep-wake 
abnormalities and AD pathology demonstrated that the hypocretin system was affected in advanced AD, 
and that CSF melatonin levels was lower in AD patients than in old control subjects. CSF melatonin 
levels from APOE-e3/4 genotype patients were significantly higher than those from the APOE-e4/4 
genotype, suggesting a relationship between melatonin levels and signs and symptoms of AD.97,101,107 An 
interesting study by Schmidt et al106 reported that cerebrospinal fluid melanin concentrating hormone 
(CSF-MCH) correlated with T-tau (p=0.01) and P-tau (p=0.05) in the AD and that CSF-MCH correlated 
negatively with MMSE scores in the AD (p=.001). These results add to preclinical studies and may allow 
further research on the role of the hypothalamus in pathology and occurrence of behavioral disturbances 
in AD. The authors noted that future investigations, including repeated MCH/HCRT-1 level 
measurements in combination with sleep-wake-actigraphy and assessment of sleep by questionnaires, 
histochemical determinations of MCH in animal and post-mortem tissues are warranted to understand the 
hypothalamic impact in AD in greater detail. 
All prospective cohort studies in this systematic review that examined the relationship between 
circadian rhythm/sleep-wake abnormalities and cognitive decline and/or AD revealed associations 
between the two, with older, healthy individuals with decreased circadian activity rhythm amplitude and 
robustness, and delayed rhythms demonstrating increased risks of developing dementia and MCI. 
Yesavage et al129 also showed that sleep-wake APOE status is associated with the progression of 
sleep/wake disturbances in AD  
Most experimental studies demonstrated anti-amyloidogenic effects of melatonin either in-vitro 
and/or in-vivo in animal studies. These results suggest that melatonin can provide a combination of 
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antioxidant and anti-amyloidogenic features that can be explored either as a preventive or therapeutic 
treatment for AD or as a model for development of anti-amyloidogenic indole analogs.  
It is important to note that Quinn et al145 examined the effect of chronic melatonin therapy 
initiated after the appearance of plaques in Tg2576 mice and failed to demonstrate any effect, as chronic 
melatonin therapy did not alter amyloid burden or oxidative damage after 4-months of treatment. 
Variations in melatonin dose, age of treatment initiation, and species of Aβ measured could possibly have 
accounted for the different results. Quinn et al. noted that one of the prior studies used a lower dose and 
still found an effect at this dose could not have accounted for the different result. The age at treatment 
initiation varied across the studies and might possibly explain the different results. Another study188 using 
similar Tg2576 mice initiated treatment at 4 months of age (prior to the appearance of hippocampal and 
cortical plaques) also found diminished Aβ and nitrotyrosine at 7–8 months, but no significant difference 
in histologically detectable Aβ or brain nitrotyrosine in animals at 15 months of age. The Quinn et al 
study initiated treatment at 14 months. 
Melatonin administration improved cognitive and non-cognitive functions significantly, and 
seemed to be useful for care of the Alzheimer type of dementia patients as shown in the RCT conducted 
by Asayama et al.131 
C. Hypoxia (Apnea Hypopnea Index) and Cognitive decline and/or Alzheimer’s disease 
Cross-sectional studies in our review that examined the association between hypoxemia and 
cognitive decline and/or AD all showed that an association exists between SDB/OSA and CSF 
Alzheimer’s disease-biomarkers in cognitively normal elderly individuals, thereby suggesting that 
existing therapies for SDB such as continuous positive airway pressure could delay the onset to MCI or 
dementia in normal elderly individuals. Cross-sectional studies in our review also showed that the APOE 
£4 allele was associated with increased risk of SDB/OSAH, particularly in individuals under age 65.83,86 
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The only case-control study that evaluated the association between hypoxemia and cognitive 
decline and/or AD also demonstrated that nocturnal sleep apnea/hypopnea was associated with lower 
memory performance in APOE e4 carriers.103 
Most cohort studies (retrospective and prospective) evaluated in our study revealed that 
OSA/SDB may be a risk factor for dementia, with some suggesting that this relationship could be gender-
dependent, age-dependent, and time-dependent.112,128,150 In contrast, Tworoger et al125 in their study 
found no associations between snoring or any of the sleep variables examined (average sleep duration, 
snoring frequency, and difficulty sleeping over the previous 4 weeks) and cognitive decline over 2 years. 
All 5 experimental studies that examined an association between hypoxemia and AD pathology 
demonstrated an association between hypoxia and AD biomarkers. Two studies148,149 found that hypoxia 
significantly increased BACE1 gene expression, resulting in increased β-secretase activity and Aβ 
production. Overexpression of HIF-1 α increased BACE1 mRNA and protein level, whereas down-
regulation of HIF-1 α reduced the level of BACE1. Hypoxic treatment failed to further potentiate the 
stimulatory effect of HIF-1α overexpression on BACE1 expression, suggesting that hypoxic induction of 
BACE1 expression is primarily mediated by HIF-1α. Furthermore, hypoxia treatment markedly increased 
Aβ deposition and potentiated the memory deficit in AD transgenic mice. These results provide evidence 
that hypoxia/HIF-1α plays a vital role in balancing the amyloidogenic processing of APP, that hypoxia 
can facilitate AD pathogenesis, and they provide a molecular mechanism to link vascular factors to AD. 
Two other studies141,147 demonstrated that repeated hypoxia increased β-amyloid (Aβ) generation 
and neuritic plaque formation by elevating β-cleavage of AD transgenic mice. They also found that 
hypoxia enhanced the expression of APH-1a, a component of ɣ-secretase complex, which in turn may 
lead to increase in ɣ-cleavage activity. Furthermore, these authors demonstrated that repeated hypoxia 
treatment can activate macroautophagy, which may contribute to the increases in Aβ production. Taken 
together, the results suggest an important role of hypoxia in modulating the APP processing by 
facilitating both β- and ɣ-cleavage which may result in a significant increase of Aβ generation 
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Both RCTs130,132 that evaluated the cognitive effects of CPAP treatment demonstrated that CPAP 
improved both subjectively and objectively measured sleepiness, especially in individuals with severe 
OSA (AHI >30). CPAP use resulted in mild, transient improvement in the most sensitive measures of 
executive and frontal-lobe function for those with severe disease, which suggests the existence of a 
complex OSA-neurocognitive relationship. 
D. Insomnia and Cognitive decline and/or Alzheimer’s disease 
All the 4 prospective studies reviewed that examined the association between insomnia 
parameters and cognitive decline and/or AD revealed that there is a greater risk of cognitive decline 
and/or Alzheimer's disease in adults with insomnia and/or insomnia like symptoms. The only study that 
did not find an association was cross-sectional and assessment of sleep parameters was based on a 
structured interview, obtaining self-reported description of sleep characteristics from subjects with 
significant cognitive impairment. 
E. Restless Leg Syndrome and Cognitive decline and/or Alzheimer’s disease 
All 3 studies (2 cross-sectional and 1 case-control) that evaluated RLS and cognitive decline 
and/or AD associations concluded that RLS patients have statistically significant specific cognitive 
deficits. Pearson et al104 showed that RLS patients compared to controls showed significant (P<0.05) and 
sizeable (20–40%) deficits on Verbal Fluency tests and the Trail Making tests. 
Summary of evidence 
1. Sleep is associated with cognitive decline and/or AD/AD pathology 
Taken together, the cross-sectional studies reviewed in this study generally provide support for an 
association of sleep and poor cognitive outcomes, including AD and dementia. They show that 
individuals with AD , dementia or MCI are more likely to have several indicators of sleep problems, 
including sleep depth problems such poor sleep quality, sleep efficiency, sleep latency and sleep 
51 
 
deprivation; sleep-wake/circadian rhythm abnormalities, excessive daytime sleepiness and OSA/SDB. 
However a significant limitation of cross-sectional studies is that causal inferences cannot be made 
because the temporal sequence of sleep and circadian disruption, neurodegeneration, and cognitive 
decline cannot be assessed. In addition, depression or its symptoms may be important mediators or 
confounders of the association between sleep variables and dementia, and should be considered in these 
studies.116 However, not all studies clearly addressed the role of depression with certain studies having a 
history of depression as an exclusion criteria without considering current depression which might well be 
important when one is examining factors in relation to circadian rhythm. Some studies51,87,93 assessed the 
presence of sleep disorders by means of subjective symptoms and not using objective instruments, such as 
polysomnography, thereby limiting the credibility of information obtained from subjects with an 
important cognitive impairment. Polysomnography is essential for a correct diagnosis of some sleep 
disturbances. In particular, sleep disordered breathing can be diagnosed only by means of 
polysomnographic recordings. Other studies made use of tools that provided limited information on sleep 
maintenance, and no detail of sleep times or other sleep parameters and others had very small sample size.
 Furthermore, the association between sleep and Alzheimer’s disease pathology, measured by 
Alzheimer’s disease biomarkers such as Aβ and Phosphorylated Tau accumulations, has not been 
extensively investigated in humans’ in-vivo. The above study findings linking sleep to AD pathology 
definitely complement those linking poor sleep to cognitive decline and dementia, however, because of 
the cross-sectional nature of the studies, we cannot establish temporality and consequently causality, as 
we are unable to infer whether this pathology might cause or result from poor sleep. As such, Aβ 
deposition may be a cause and/or occur as a complication during the progression of AD, and/or sleep 
disturbance and Aβ plaques may have a shared cause. It is therefore evident that prospective 
observational studies are needed to better understand the temporal order of sleep disturbance and AD 
pathogenesis and/or biomarkers. This will aid efforts to better evaluate potential opportunities for targeted 
and effective prevention.  
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Altogether, it can also be seen that studies suggest that sleep variables interact with the APOE 
genotype to affect Alzheimer’s disease-related outcomes. Notably, an association between sleep 
disturbance especially Sleep Disordered Breathing (SDB) and CSF Alzheimer’s disease-biomarkers in 
cognitively normal elderly individuals is evident. Current treatments for SDB such as continuous positive 
airway pressure (CPAP) could interrupt the onset of mild cognitive impairment (MCI) or dementia in 
normal elderly individuals. 
2. Sleep problems precede the onset of cognitive impairment 
Taken together, these prospective studies provide support that sleep problems precede the onset 
of cognitive impairment, including AD and dementia. Some of the findings suggest interactions by age, 
and/or sex.112,114,126 These findings require replication, and if these associations are causal, prevention 
efforts may need to be targeted differently at specific ages or in different populations. It is however 
important to note that longitudinal studies of dementia are prone to miss both prevalent and incident cases 
because full neurological evaluations are not conducted on all participants, especially when selected 
participants refuse further neuropsychological testing and examination or die over the course of follow-
up.198-200 An important limitation of most of the prospective studies is the length of the follow up. Only 4 
studies had greater than 5 years follow up. Although longitudinal studies can assess temporality, AD is a 
lifelong disease process and preclinical AD is very much present prior to the onset of symptomatic AD, 
therefore, reverse causation might have actually been the case in these studies since a <5 year follow-up 
period may not be sufficient and thus may not reflect the true prospective nature of AD biomarkers and/or 
cognitive decline, as certain participants may already have had the disease but were asymptomatic. Also 
self-reported data on sleep duration may be subject to bias, including the existence of a change in the 
typical sleep duration anticipating the onset of dementia. On the other hand, objective sleep measures are 
particularly useful in studies of sleep, aging, and cognition since self-report sleep measures do not 
necessarily correlate with objectively measured sleep, and discrepancies between these modes of 
assessment may be more pronounced among older adults with cognitive impairment.108,201 
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3. Sleep problems may lead to increased AD pathology or may have their effects on dementia 
through other pathways 
Altogether, it can be seen that experimental studies provide the most compelling evidence of the 
plausibility of causal associations between sleep deprivation and AD pathology and/or AD biomarkers, 
but typically are performed in animals. The power of experimental mice models to mirror the extremely 
complex physiological and biochemical processes in humans is a matter of dispute because of inherent 
translational limitations of these models imposed by variations in size and physiology, as well as 
differences in the homology of targets between mice and humans. However, from the above study 
findings it is clear that alteration of the sleep-wake cycle and circadian rhythm regulation could be 
important players in the onset and development of sporadic AD. Therefore, amending and/or 
improvement of sleep-wake cycle abnormalities could be a viable therapeutic strategy for AD at risk 
individuals. Both animal experimental studies and RCTs also demonstrate that hypoxemia might 
contribute to cognitive dysfunction in severe cases, however, in mildly affected patients,192,202 the 
interacting effect of cognitive reserve,203  intelligence level,204 and depression205,206 needs to be 
considered. We also see from the above study findings that disrupted melatonin levels could be a 
surrogate origin of sleep pathology, as decline in melatonin levels are known to occur with aging and this 
decline is enhanced with AD, even in preclinical stages. Studies also show that melatonin’s cognitive 
benefits could involve its anti-Aβ aggregation, anti-inflammatory, and/or antioxidant properties. Findings 
provide reinforcement for long-term melatonin therapy as a primary or complementary strategy for 
abating the progression of Alzheimer disease. Also as a result of the fact that the age at treatment 
initiation of melatonin might play a role in its ability to suppress Aβ levels, the implication for human 
studies could be that melatonin is probably unlikely to have a role in the treatment of established cerebral 
amyloidosis characteristic of AD. If this is found to be true, then clinical trials of melatonin will have to 
focus on prevention rather than treatment of established cerebral amyloidosis. 
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LIMITATIONS 
Several methodological concerns must be considered when interpreting the findings of this 
systematic review. First, as with any systematic review, one limitation relates to the potential bias 
introduced in the paper selection process. To minimize this bias, we adhered strictly to the guidelines and 
recommendations in the Cochrane handbook67 whenever possible. We also ensured that studies were not 
restricted by language to guard against language bias. Secondly, the possible bias introduced by the 
individual studies that were included is a further limitation. Various study designs were rated low for 
assigning the grade of evidence.207 In addition to study design, conclusions made from the poor quality 
studies could introduce possible bias. We included both high- and low-quality studies in the 
summarization of findings because both mostly came to the same conclusion, therefore possibly 
indicating that the study quality might not have influenced the overall conclusion. Thirdly, there was 
considerable variation between the studies in the assessment methods used to verify sleep problems and 
cognitive decline and/or AD/Dementia, suggesting heterogeneity that could possibly raise some questions 
about the comparability of results across studies. Our research question focused on a broad concept of 
sleep problems based on having any sleep problem symptoms. Thus, we assumed a common underlying 
concept by making general conclusions regarding sleep problems and cognitive decline and/or AD. 
Fourthly, as in any systematic review, publication bias may have affected the representativeness of the 
included studies by over reporting significant findings. Non assessment of publication bias with a funnel 
plot is a limitation. Lastly the possibility of a “file drawer” effect exists because exclusion and inclusion 
criteria are always subjective. 
 
CONCLUSION AND FUTURE DIRECTIONS 
In summary, there is substantial evidence providing support for sleep and its related abnormalities 
as a potential cause of cognitive decline, dementia, and Alzheimer’s disease pathology. Ample evidence 
linking sleep impairments and circadian regulating mechanisms directly to clinical symptoms in AD 
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patients exist. Future research is needed to make clear the contribution of the different genetic, 
neurodegenerative and environmental factors to sleep impairment. There is also growing experimental 
and epidemiological evidence for close reciprocal interaction between cognitive decline and sleep 
alteration, however, long-term longitudinal studies are required to better understand the relationship 
between chronic sleep deprivation, circadian rhythm/sleep-wake abnormalities, sleep-disordered 
breathing, sleep disorders like OSAS and cognitive decline. Future studies need to be able to define causal 
pathways more definitively so we can be clear for example, whether neurodegeneration is leading to both 
sleep changes and memory changes, or whether aging is contributing to OSA and/or sleep architecture 
changes that in turn affect memory, and/or whether the effect of aging on sleep architecture predisposes to 
both apnea and memory impairment. Thus, further research that examines these basic mechanisms as well 
as employing clinical/translational approaches are needed. More research with objective sleep measures, 
Alzheimer’s disease biomarkers, and cognitive measures are also needed. There is also significant 
evidence from in vitro and animal studies for an important role of both melatonin and hypocretin in 
modulating AD pathophysiology. Although the exact underlying mechanisms are unknown as of yet, 
future studies examining the role of lack of sleep and circadian rhythm deterioration as causative factors 
in the onset of AD, especially human studies, are needed, as their findings can be promising for the 
development of new prevention and/or treatment opportunities. 
RESEARCH AGENDA AND GAPS IN THE LITEARTURE I INTEND TO ADDRESS 
The need for a meta-analysis to quantify the effect of sleep problems/disorders on cognitive 
impairment and AD. This would allow for efficient integration of existing information from various 
studies enabling us to establish whether the literature is consistent and can be generalized across 
populations, settings, and/or whether findings vary significantly by particular subsets.  
AIM I: To conduct a meta-analysis to quantify the aggregate effect of sleep problems and/or 
disorders on cognitive decline and Alzheimer's disease. 
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The need to be able to define causal pathways more definitively so we can be clear for example, 
whether neurodegeneration is leading to both sleep changes and memory changes, or whether aging is 
contributing to OSA and/or sleep architecture changes that in turn affect memory, and/or whether the 
effect of aging on sleep architecture predisposes to both apnea and memory impairment. One way to be 
able to do this is to conduct more research examining relationships between OSA (preferably with 
objective sleep measures) and Alzheimer’s disease biomarkers, and/or cognitive measures. This led to the 
following study aims: 
AIM IIa: To examine whether the presence of Obstructive Sleep Disordered Breathing is 
associated with CSF P-Tau, Hippocampal atrophy and β-amyloid burden in older adults with 
MCI and AD. 
AIM IIb: To examine the effect of Obstructive Sleep Apnea on longitudinal changes of 
Alzheimer's disease biomarkers in cognitive normal, mild cognitive impairment and Alzheimer's 
disease patient 
The need for clarity in understanding and appreciating the heterogeneity of OSA and its outcomes 
in distinct age groups especially as it relates to cognitive function, subsequent cognitive decline and AD. 
One way to do this is to integrate decades of research examining OSA and cognition; OSA and 
subsequent cognitive decline; and OSA and AD; with particular focus in appreciating the heterogeneity of 
OSA and its outcomes in distinct age groups. 
AIM III: To conduct a Review titled "Obstructive Sleep Apnea: A Distinct Physiological 
Phenotypic Risk Factor in older adults with Cognitive decline and Alzheimer’s disease" 
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Table 1.1    Literature Search Terms for the Systematic Review of Sleep and Alzheimer’s disease 
Sleep Related Alzheimer's Disease Related Alzheimer's disease pathology related Study Types 
Sleep (MeSH) Alzheimer's disease Dementia Amyloid beta  Cross sectional 
Sleep loss Cognitive Decline Amyloid beta deposition/generation Prevalence studies 
Sleep deprivation Cognitive Impairment Alzheimer's disease pathogenesis Experimental studies 
Sleep disruption Mild Cognitive Impairment (MeSH) Amyloid Precursor Protein Randomized Control Trials 
Sleep apnea MCI Amyloid cascade hypothesis Incidence studies 
Obstructive sleep apnea aMCI Inflammation Epidemiologic studies 
Sleep Disordered Breathing Cognition P-Tau Case control 
Excessive Daytime sleepiness Alzheimer (MeSH) Phosphorylated Tau Prospective Cohort 
Sleep Disorders (MeSH)  Hippocampal atrophy Retrospective cohort 
Rapid Eye Movement Behavioral Disorder  Apolipoprotein E  Historical cohort 
NREM Slow wave sleep  APOE4 Closed cohort 
Hypoxia   Case-Comparison  
Sleep Dependent Memory   Nested case control 
Sleep quality   Case-Referent Study  
Sleep function   Matched case control 
Wakefulness   Cochrane database of systematic reviews  
Circadian Rhythm (MeSH)   Meta-analysis 
Melatonin   Synthesis 
Hypocretin     Research integration 
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Table 1.2:  Scoring system for quality of paper of the Systematic Review of Sleep and 
Alzheimer's disease 
·         Hypotheses (maximum possible=1 star) 
o   The hypothesis/research question of the study not clearly described 
o   The hypothesis/research question of the study clearly described ¨ 
·         Sampling (maximum possible= 2 stars)a 
o   Sample source and size  
Ø  Routine data=0 
Ø  Sample size: less than 50 per comparison groups 
Ø  Sample size: more than 50 per comparison groups ¨ 
o   Type of sampling  
Ø  Consecutive patients or opportunistic 
Ø  Random representative of populations studied ¨ 
·         Type of Study (maximum possible=3 stars) 
o   Ecological Study  
o   Case-control/Cross-sectional ¨ 
o   Retrospective/Prospective Cohort ¨¨ 
o   Randomized Control Trial/Experimental ¨¨¨ 
·         Selection (Cohort studies) (maximum possible=4 stars)  
                      o Representativeness of the exposed cohort 
       Ø  Truly representative of the average distribution of sleep problems in the community ¨ 
       Ø  Somewhat representative of the average distribution of sleep problems in the community ¨ 
       Ø  Selected group of users e.g., nurses, volunteers 
       Ø  No description of the derivation of the cohort 
       o Selection of the non-exposed cohort 
       Ø  Drawn from the same community as the exposed cohort ¨ 
       Ø  Drawn from a different source 
       Ø  No description of the derivation of the non-exposed cohort 
                   o   Length of follow up of cohorts to determine outcome 
       Ø  Follow up period greater than 5 years ¨ 
       Ø  Follow up period less than 5 years  
                    o   Adequacy of follow up of cohorts (Likelihood to introduce bias) 
       Ø  Complete follow up- all subjects accounted for ¨ 
       Ø  Follow up rate ≥ 50% and description of loss to follow up subjects 
       Ø  Follow up rate  < 50% and no description of loss to follow up subjects 
       Ø  Follow up rate not mentioned 
Table continues 
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Table 1.2 continued 
·         Selection (Case-control studies) (maximum possible=4 stars)  
                        o Is the case definition adequate? 
Ø  Yes, with independent validation ¨ 
Ø  Yes, e.g., record linkage or based on self-reports ¨ 
Ø  No description  
                      o Representativeness of the cases 
       Ø  Consecutive or obviously representative series of cases  ¨ 
       Ø  Potential for selection biases or not stated 
                       o   Selection of controls 
       Ø  Community controls ¨ 
       Ø  Hospital controls 
       Ø  No description of source 
                       o   Non response rate 
       Ø  Same rate for both groups ¨ 
       Ø  Non respondents described 
       Ø  Rate different and no designation 
·         Selection (Experimental studies) (maximum possible=4 stars)  
                        o  Appropriate description of experimental mice/population 
Ø  Yes, with transgenic status described ¨ 
Ø  No description  
                      o Appropriate description of experimental procedures 
       Ø  Yes, with application of standard protocols   ¨ 
       Ø  Standardized protocols not adhered to. 
                       o   Controls or comparison group 
       Ø  Comparison group present ¨ 
       Ø  No controls used 
                       o   Comparability of experimental conditions 
       Ø  Mice/population in both groups exposed to similar experimental conditions except for exposure/intervention ¨ 
       Ø  Experimental conditions not described 
       Ø  Conditions different and no designation 
Table continues 
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Table 1.2 continued 
·         Methodology (maximum possible=5 stars) 
o   Definition/ Operationalization of Alzheimer's Disease/Dementia/Cognitive Decline(2)b 
Ø  No standardized measures (e.g. self-reported diagnosis)  
Ø  Standardized  Operationalized criteria (e.g. ICD-9, ICD-10, DSM-IV)* ¨ 
Ø  Objective measures (e.g., PET scan, MRI) *  ¨¨ 
o   Definition/Operationalization of Sleep and its related abnormalities/disorders 
Ø  No standardized measures (e.g. self-reported diagnosis) =0 
       Ø  Standardized  Operationalized criteria/questionnaire (e.g. ICD-9, ICD-10, DSM-IV, PSQI, ESS)^ ¨ 
Ø  Objective measures (e.g., Actigraph, Polysomnography)^ ¨¨ 
o   Study Population (Not applicable to Animal Experimental studies) 
Ø  No appropriate description of study population  
Ø  In-patient non-population based  
Ø  Study population is population based ¨ 
·         Statistical analyses and results (maximum possible=5 stars) 
o   Statistical analysis  
Ø  Statistical methods not described =0 
Ø  Statistical methods clearly described ¨ 
o   Statistical outcomes  
Ø  Statistical outcome not clearly reported  
Ø  Statistical outcomes clearly reported (e.g. OR, RR, CIs) ¨ 
o   Other explanatory variables in the analysis (e.g. confounders) (4)c 
Ø  No explanatory variables involved 
Ø  Age and/or gender  controlled for ¨ 
Ø  Age, gender, SES and risk factors (sleep related and AD related covariates) ¨¨ 
o   Results  
Ø  Research questions/hypotheses not clearly answered/tested 
Ø  Research questions/hypotheses clearly answered/tested ¨ 
a: Sample size values. The sample size value of 50 participants per group has been chosen as these permits reasonable estimates of rates of 
CF. Not Applicable to Animal Experimental studies 
b: ICD-9/10 International Classification of Disease version 9/10; DSM-IV Diagnostic Statistical Manual-IV; PQSI Pittsburg Sleep Quality 
Index; ESS Epworth Sleepiness Scale 
c: Adjustment for confounding variables. From an overview of studies on sleep and Alzheimer's Disease; Age, years of education, marital 
status, forced expiratory volume in one second based on spirometry, self-reported history of physician’s diagnosis of asthma, number of hours 
of sleep and napping, and use of benzodiazepines. Chronic obstructive pulmonary disease, Nonfatal coronary heart disease including 
myocardial infarction, Stroke, The ankle-brachial index calculated as the mean of the posterior tibial pressure on each side divided by the 
mean of the two right brachial pressures. Apolipoprotein E genotype, BMI and Depression were all-important covariates to adjust for. Not 
Applicable to Animal Experimental studies 
* Must be independent blind assessment or made use of record linkage to receive a star 
^ Must be use of secure record (eg surgical records) or made use of  structured interview where blind to case/control status to receive a star 
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Table 1.3 : Quality Assessment of Cross-sectional studies 
First Author, Country, Year Published 
(Reference) 
Hypotheses 
(maximum 
possible=1 star) 
Sampling 
(maximum 
possible=2 stars) 
Type of Study 
(maximum 
possible=3 
stars) 
Methodology 
(maximum 
possible=5 stars) 
Statistical 
Analysis 
(maximum 
possible=5 stars) 
Total (maximum 
possible=16 
stars) 
Quality Rating 
Blackwell, United States, 2006 () 
 ♦  ♦ ♦  ♦  ♦ ♦ ♦ ♦  ♦ ♦ ♦ ♦ ♦ 13 High 
Nebes, United States, 2009 () 
 ♦  ♦  ♦  ♦ ♦ ♦  ♦ ♦ ♦ ♦ 10 Medium 
Saint Martin, France, 2012  () 
 ♦  ♦ ♦  ♦  ♦ ♦ ♦  ♦ ♦ ♦ ♦ 10 Medium 
Guarnieri, Italy, 2012 () 
 ♦  ♦  ♦  ♦ ♦  ♦ ♦ ♦ ♦ 9 Medium 
Moran, Ireland, 2005 () 
 ♦  ♦  ♦  ♦ ♦  ♦ ♦ ♦ ♦ 9 Medium 
Pistacchi, Italy, 2014 () 
 ♦  ♦  ♦  ♦ ♦  ♦ ♦ ♦ 8 Low 
Fetveit, Norway, 2006 () 
 ♦ 
 
 ♦  ♦ ♦ ♦  ♦ ♦ 7 Low 
Ju, United States, 2013 () 
 ♦ 
 
 ♦  ♦ ♦ ♦ ♦  ♦ ♦ ♦ 9 Medium 
Spira, United States, 2013 () 
 ♦ 
 
 ♦  ♦ ♦ ♦  ♦ ♦ ♦ ♦ ♦ 10 Medium 
Craig, Northern Ireland, UK, 2006 () 
 ♦  ♦  ♦  ♦ ♦ ♦  ♦ ♦ 8 Low 
Oosterman, Netherlands, 2009 () 
 ♦ 
 
 ♦  ♦ ♦ ♦  ♦ ♦ ♦ ♦ 9 Medium 
Merlino, Italy, 2010 () 
 ♦  ♦  ♦  ♦ ♦  ♦ ♦ ♦ 8 Low 
Pat-Horenczyk, United States, 1998 () 
 ♦ 
 
 ♦  ♦ ♦ ♦  ♦ ♦ 7 Low 
Yesavage, United States & France, 2011 () 
 ♦  ♦  ♦  ♦ ♦ ♦  ♦ ♦ 8 Low 
Gottlieb, United States, 2004 () 
 ♦  ♦ ♦  ♦  ♦ ♦ ♦ ♦ ♦  ♦ ♦ ♦ ♦ 13 High 
Kadotani, United States, 2001 () 
 ♦  ♦ ♦  ♦  ♦ ♦ ♦ ♦  ♦ ♦ ♦ ♦ 12 High 
Osorio, United States, 2014 () 
 ♦ 
 
 ♦  ♦ ♦ ♦ ♦  ♦ ♦ ♦ ♦ 10 Medium 
Djonlagic, United States, 2014 ()   ♦     ♦   ♦ ♦ ♦   ♦ ♦ ♦  8  Low 
 
83 
 
Table 1.4: Quality Assessment Scores of Case-control studies 
First Author, Country, Year 
Published (Reference) 
Hypotheses 
(maximum 
possible=1 star) 
Sampling 
(maximum 
possible=2 stars) 
Type of Study 
(maximum 
possible=3 
stars) 
Selection (Case-
control study) 
(maximum 
possible=4 stars)  
Methodology 
(maximum 
possible=5 
stars) 
Statistical 
Analysis 
(maximum 
possible=5 
stars) 
Total 
(maximum 
possible=20 
stars) 
Quality Rating 
Chen, Taiwan, 2011 () ♦ 
 
♦ ♦♦♦ ♦♦♦ ♦♦ 10 Low 
Hita-Yañez, Spain, 2013 () ♦ 
 
♦ ♦♦♦ ♦♦♦ ♦♦♦ 11 Medium 
Hita-Yañez, Spain, 2012 () ♦ 
 
♦ ♦♦♦ ♦♦♦♦ ♦♦♦ 12 Medium 
Hot, France, 2011 () ♦ 
 
♦ ♦♦ ♦♦♦ ♦♦ 9 Low 
Sanchez-Espinosa, Spain, 2014 () ♦ 
 
♦ ♦♦♦♦ ♦♦♦♦ ♦♦♦ 13 Medium 
Naismith, Australia, 2014 () ♦ 
 
♦ ♦♦♦ ♦♦♦ ♦♦ 10 Low 
Fronczek, Netherland, 2012 () ♦ 
 
♦ ♦♦♦ ♦♦♦♦ ♦♦ 11 Medium 
Slats, Netherlands, 2012 () ♦ 
 
♦ ♦♦ ♦♦♦♦ ♦♦♦♦ 12 Medium 
Schmidt, Germany, 2013 () ♦ 
 
♦ ♦♦ ♦♦♦♦ ♦♦♦ 11 Medium 
Liu, Netherlands and China, 1999 () ♦ ♦ ♦ ♦♦ ♦♦♦♦ ♦♦♦ 12 Medium 
O’Hara, United States, 2005 () ♦ 
 
♦ ♦♦ ♦♦♦♦ ♦♦ 10 Low 
Pearson, United States, 2006 ()  ♦    ♦  ♦♦  ♦♦♦  ♦♦♦  10 Low  
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Table 1.5: Quality Assessment Scores of Cohort studies/Randomized Clinical Trials 
First Author, Country, Year 
Published (Reference) 
Hypotheses 
(maximum 
possible=1 star) 
Sampling 
(maximum 
possible=2 
stars) 
Type of 
Study 
(maximum 
possible=3 
stars) 
Selection 
(Cohort studies) 
(maximum 
possible=4 stars)  
Methodology 
(maximum 
possible=5 stars) 
Statistical 
Analysis 
(maximum 
possible=5 
stars) 
Total 
(maximum 
possible=20 
stars) 
Quality 
Rating 
Keage, Australia, & United Kingdom 
2012 () 
♦ ♦♦ ♦♦ ♦♦♦♦ ♦♦♦ ♦♦♦♦ 16 High 
Tworoger, United States, 2006 () ♦ ♦♦ ♦♦ ♦♦ ♦♦♦ ♦♦♦♦ 14 Medium 
Virta, Finland, 2013 () ♦ ♦♦ ♦♦ ♦♦♦♦ ♦♦♦ ♦♦♦ 15 High 
Song, United States, 2014 () ♦ ♦♦ ♦♦ ♦♦♦ ♦♦♦ ♦♦♦♦ 15 High 
Blackwell, United States, 2014 () ♦ ♦♦ ♦♦ ♦♦♦ ♦♦♦ ♦♦♦♦♦ 16 High 
Sterniczuk, Canada, 2013 () ♦ ♦♦ ♦♦ ♦♦♦ ♦♦ ♦♦♦♦ 14 Medium 
Benito-León, Spain, 2014 () ♦ ♦♦ ♦♦ ♦♦♦♦ ♦♦ ♦♦♦♦♦ 16 High 
Hahn, United States, 2013 () ♦ ♦ ♦♦ ♦♦♦♦ ♦♦ ♦♦♦♦♦ 15 High 
Bidzan, Poland, 2011 () ♦ 
 
♦♦ ♦♦ ♦♦ ♦♦ 9 Low 
Lim, Canada, 2013 () ♦ ♦ ♦♦ ♦♦♦ ♦♦♦ ♦♦♦ 13 Medium 
Ooms, Netherlands, 2014 () ♦ ♦ ♦♦♦ ♦♦ ♦♦♦♦ ♦♦♦♦ 15 High 
Walsh, United States 2014 () ♦ ♦♦ ♦♦ ♦♦♦ ♦♦♦ ♦♦♦♦ 15 High 
Anderson, United Kingdom, 2014 () ♦ ♦♦ ♦♦ ♦♦ ♦♦♦ ♦♦♦ 13 Medium 
Tranah, United States, 2011 () ♦ ♦♦ ♦♦ ♦♦♦ ♦♦♦ ♦♦♦♦♦ 16 High 
Lim, United States, 2013 () ♦ ♦♦ ♦♦ ♦♦ ♦♦♦ ♦♦♦♦♦ 15 High 
Yesavage, United States, 2004 () ♦ 
 
♦♦ ♦♦ ♦♦♦♦ ♦♦ 11 Medium 
Asayama, Japan, 2003 () ♦ ♦ ♦♦♦ ♦♦ ♦♦♦ ♦♦♦♦ 14 Medium 
Cohen-Zion, United States, 2001 () ♦ 
 
♦♦ ♦♦ ♦♦♦ ♦♦♦ 10 Low 
Chang, Taiwan, 2013 () ♦ ♦♦ ♦♦ ♦♦♦ ♦♦♦ ♦♦♦♦ 15 High 
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Yaffe, United States, 2011 () ♦ ♦ ♦♦ ♦♦ ♦♦♦♦ ♦♦♦♦♦ 15 High 
Kushida, United States, 2012 () ♦ ♦ ♦♦♦ ♦♦ ♦♦♦♦ ♦♦♦♦ 15 High 
Ancoli-Israel, United States, 2008 () ♦ ♦ ♦♦♦ ♦♦ ♦♦♦♦ ♦♦♦♦ 15 High 
Cricco, Iceland, 2001 () ♦ ♦♦ ♦♦ ♦♦ ♦♦♦ ♦♦♦♦♦ 15 High 
Jelicic, The Netherlands, 2002 () ♦ ♦♦ ♦♦ ♦♦ ♦♦♦ ♦♦♦ 13 Medium 
Foley, United States, 2001 () ♦ ♦♦ ♦♦ ♦♦ ♦♦♦ ♦♦♦♦♦ 15 High 
Osorio, United States, 2011 ()  ♦  ♦♦  ♦♦  ♦♦♦  ♦♦♦  ♦♦♦♦  15  High 
 
Table 1.6: Quality Assessment Scores of Experimental studies 
First Author, Country, Year Published 
(Reference) 
Hypotheses 
(maximum 
possible=1 
star) 
Type of Study 
(maximum 
possible=3 stars) 
Selection 
(Experimental 
studies) 
(maximum 
possible=4 stars)  
Methodology 
(maximum 
possible=4 
stars) 
Statistical 
Analysis 
(maximum 
possible=3 
stars) 
Total 
(maximum 
possible=15 
stars) 
Quality Rating 
Rothman, United States, 2013 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
Di Meco, United States, 2014 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
Kang, United States, 2009 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
Mander, United States, 2013 ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦♦♦♦  ♦ ♦  13 High 
Craig, Canada, 2008 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
Jyoti, Scotland, UK, 2010 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
Quin, United States, 2005 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
DENG. China, 2005 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
Papolla, United States, 1998 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
Olcese, United States, 2009 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
Lahiri, United States, 2004 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
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Shiota, Japan, 2013 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
Kaushal, United States, 2012 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
Sun, Canada, China, United States, 2006 
() 
♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
Li, China, 2009 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
Zhang, China, 2007 () ♦  ♦ ♦ ♦ ♦♦♦♦  ♦♦♦♦  ♦  13 High 
 
Table 1.7. Sleep Depth and Cognitive/Alzheimer's Disease Measures: Descriptive Study Characteristics, and Main Findings 
First Author, 
Country, Year 
Published (Reference) 
Study Design  Sample size N Study Population 
Sleep Depth 
Assessment 
Cognitive/AD Measures 
Assessment 
Conclusion 
Blackwell, United 
States, 2006 () 
Cross sectional N=2,242 
Community-dwelling women 
65 years old or older  
Actigraphy 
Mini-Mental State 
Examination (MMSE) and 
the Trail Making B Test 
(Trails B) 
Objectively measured 
disturbed sleep was 
consistently related to 
poorer cognition, whereas 
total sleep time was not.  
Nebes, United States, 
2009 () 
Cross-sectional  N=157 
Participants were 65–80 years 
old community volunteers  
Pittsburgh Sleep 
Quality Index 
[PSQI]  
 Repeatable Battery for the 
Assessment of 
Neuropsychological Status 
(RBANS).  Test of 
Nonverbal Intelligence 
(TONI)) 
 Sleep problems may 
contribute to performance 
variability between 
elderly individuals but 
only in certain cognitive 
domains. 
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Guarnieri, Italy, 2012 () Cross-sectional  N= 431  
Participants were patients 
enrolled consecutively in 10 
Italian neurological centers: 
204 had Alzheimer’s disease 
(AD), 138 mild cognitive 
impairment (MCI), 43 vascular 
dementia (VaD), 25 
frontotemporal dementia and 
21 Lewy body dementia 
(LBD) or Parkinson’s disease 
dementia (PDD).  
 PSQI, Berlin 
questionnaire and 
the International 
Restless Leg 
Syndrome (RLS) 
Study Group 
questionnaire  
 DSM-IV-TR criteria. AD 
and Vascular Dementia 
(VaD) were diagnosed 
respectively according to 
NINCS-ARDRA and 
NINDS-AIREN criteria. 
LBD and PDD, 
frontotemporal dementia 
(FTD) and MCI were 
diagnosed according to 
specific consensus 
guidelines 
A careful clinical 
evaluation of sleep 
disorders should be 
performed routinely in the 
clinical setting of persons 
with cognitive decline. 
Instrumental supports 
should be used only in 
selected patients 
Pistacchi, Italy, 2014 () Cross-sectional  N= 236 
236 patients (78 men and 158 
women) were enrolled with 
different subtypes of dementia: 
(AD), (VaD), mixed dementia 
(MCI), dementia with Lewy 
bodies (DLB),  (PDD), and 
frontotemporal lobar 
degeneration (FTLD) 
 PSQI, Berlin 
questionnaire and 
the International 
Restless Leg 
Syndrome (RLS) 
Study Group 
questionnaire  
DSM-IV-TR criteria . AD 
and VaD were diagnosed 
respectively according to 
NINCS-ARDRA and 
NINDS-AIREN criteria . 
LBD and PDD, 
frontotemporal dementia 
(FTD) and MCI were 
diagnosed according to 
specific consensus 
guidelines . 
Findings demonstrate that 
sleep disturbance was 
related to dementia 
Fetveit, Norway, 2006 
() 
Cross-sectional  N=23  
Nursing home residents with 
varying degree of dementia 
Actigraphy 
Grades of dementia were 
assessed by Mini-Mental 
Status Examination Score 
(MMSE) and Clinical 
Dementia Rating (CDR). 
Sleep duration during the 
24-h day was positively 
correlated with the 
severity of dementia in 
nursing home patients.  
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Ju, United States, 2013 
() 
Cross-sectional  N=142 
 Longitudinal studies of 
memory and aging at the 
Washington University Knight 
Alzheimer Disease Research 
Center (ADRC). The  Adult 
Children Study, in which all 
were age 45-75 years at 
baseline and 50% have a 
parental history of sAD.  
Actigraphy 
 Aβ42 was measured by the 
Alzheimer's Disease 
Research Center (ADRC) 
Biomarker Core using 
enzyme linked 
immunosorbant assay 
(INNOTEST; Innogenetics, 
Ghent, Belgium). 
Amyloid deposition in the 
preclinical stage of AD 
appears to be associated 
with worse sleep quality, 
but not with changes in 
sleep quantity. 
Spira, United States, 
2013 () 
Cross-sectional  N= 70 
Participants were adults (mean 
age, 76 [range, 53-91] years) 
from the neuroimaging sub-
study of the Baltimore 
Longitudinal Study of Aging, 
a normative aging study. 
Self-reported sleep 
variables: The 5-
item Women’s 
Health Initiative 
Insomnia Rating 
Scale (WHIIRS) 
β-Amyloid burden, 
measured by carbon 11–
labeled Pittsburgh 
compound B positron 
emission tomography 
distribution volume ratios 
(DVRs). 
Among community-
dwelling older adults, 
reports of shorter sleep 
duration and poorer sleep 
quality are associated with 
greater Aβ burden.  
Craig, Northern 
Ireland, UK, 2006 () 
Cross-sectional  N=426 
Subjects were identified from 
outpatient memory-clinic 
records based at the Belfast 
City Hospital Trust, Mater 
Infirmorum, and Holywell 
Hospital. Patients fulfilled the 
criteria for probable AD. 
A validated 
neuropsychological 
assessment tool, 
the 
Neuropsychiatric 
Inventory with 
Caregiver Distress 
(NPI-D), was 
employed to record 
sleep disturbances 
during the course 
of the dementing 
illness. 
Outpatient memory-clinic 
records. DNA extracted 
from peripheral blood 
leukocytes was analyzed 
for the APOE and MAO-A 
30 bp VNTR 
polymorphisms 
Sleep disturbance in AD 
is common and distressing 
and is associated with 
genetic variation at MAO-
A. 
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Hita-Yañez, Spain, 
2012 () 
Case-control N=50 
Twenty-five MCI patients (7 
females, mean age: 70.5 ± 6.8 
yr) and 25 healthy old (HO) 
volunteers (13 females, mean 
age: 67.1 ± 5.3 yr) 
Polysomnography 
(PSG) 
ApoE genotype was 
determined by conventional 
PCR (polymerase chain 
reaction) methods. The 
diagnosis of MCI was 
based on consensus criteria. 
Global cognitive status was 
assessed with the Mini 
Mental State Examination 
(MMSE). 
 Sleep disruptions are 
evident years before 
diagnosis of AD, which 
may have implications for 
early detection of 
dementia and/or 
therapeutic management 
of sleep complaints in 
MCI patients. 
Chen, Taiwan, 2011 () Case-control N=21 
Authors recruited 9 controls 
without dementia, 6 patients 
with mild cognitive 
impairment (MCI), and 6 
patients with mild Alzheimer's 
disease (AD). None of the 
participants had sleep 
complaints, and all AD 
patients were receiving 
cholinesterase inhibitors. 
Polysomnography 
(PSG) 
MMSE.  NINCDS-
ADRDA. All patients with 
AD were taking acetyl 
cholinesterase inhibitors 
(AChEI) 
A deficiency of Ach may 
result in an increase of 
sEMG activity in MCI 
patients. 
Hita-Yañez, Spain, 
2013 () 
Case-control N=50 
Twenty-five patients with MCI 
(7 females, mean age: 70.5 ± 
6.8 y) and 25 HE subjects (13 
females, mean age: 67.1 ± 5.3 
y) were enrolled in the study, 
 Overnight PSG 
recordings and 
self-reported sleep 
measures were 
obtained 
The diagnosis of MCI was 
based on consensus criteria. 
Global cognitive status was 
assessed with the Mini 
Mental State Examination 
(MMSE). 
Sleep is significantly 
impaired in patients with 
mild cognitive 
impairment at both the 
objective and subjective 
level, which may be used 
as a surrogate marker of 
preclinical Alzheimer 
disease.  
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Hot, France, 2011 () Case-control N=28 
Fourteen un-medicated AD 
patients (seven men and seven 
women; mean age (±SD): 76.7 
± 3.8 years) participated in this 
study  
Polysomnography 
(PSG) 
Episodic memory was 
assessed with an original 
task derived from Grober 
and Buschke’s procedure 
(1987).This task consisted 
in learning 15 words, 
presented by series of three 
on separate cards 
Changes in theta rhythm 
during REM and SWS are 
a relevant index of brain 
impairments in the early 
stage of AD, and are 
related to episodic 
memory performance. 
Sanchez-Espinosa, 
Spain, 2014 () 
Case-control N=21 
Participants were primarily 
recruited from older people's 
associations, normal 
community health screening, 
and hospital outpatient 
services. 
Polysomnography 
(PSG) 
Neuropsychological 
testing; diagnostic criteria 
of aMCI proposed by 
Petersen et al. Plasma Aβ 
levels. Cerebral MRI 
acquisition, image 
preprocessing and cortical 
thickness estimation was 
done for each participant 
Increased plasma Aβ42 
levels are significantly 
associated with 
fragmented SWS in aMCI 
subjects, suggesting that 
sleep disruptions may 
signal Aβ burden in 
persons at increased risk 
for AD. Reduced REM 
sleep and plasma Aβ 
levels in aMCI subjects 
were significantly related 
to thinning of cortical 
regions targeted by AD 
neuropathology. 
Keage, Australia, & 
United Kingdom 2012 
() 
Prospective cohort N= 2012  
The Medical Research 
Council Cognitive Function 
and Ageing Study (CFAS), a 
longitudinal multi-center 
population-based study of 
ageing and dementia 
(www.cfas.ac.uk). . Follow-up 
time: 10-years                                             
Self-reported 
measures . 
MMSE 
Daytime napping, night-
time sleep duration, and 
excessive daytime 
sleepiness may be 
modifiable behaviors 
open to intervention 
strategies, or, clinical 
indicators of future 
decline in older 
individuals. 
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Tworoger, United 
States, 2006 () 
Prospective cohort  N= 1844  
Participants (all women) were 
members of the Nurses’ 
Health Study cohort aged 70 
to 81 years at initial cognitive 
interview in 2000. Follow-up 
period: 2years 
Self-reported 
measures . 
Women completed six tests 
of cognitive function 
encompassing general 
cognition, verbal memory, 
category fluency, and 
attention. Tests were 
repeated 2 years later.  
Diminished cognition is a 
risk factor for dementia. 
However, the lack of an 
association with 
prospective cognitive 
decline warrants further 
investigation 
Virta, Finland, 2013 () Prospective cohort N= 2,336  
The subjects of the current 
study were members of the 
older Finnish Twin Cohort, 
consisting of same-sex twin 
pairs born in Finland prior to 
1958 with both co-twins alive 
in 1967. Follow-up time: 18-
26years 
Self-reported 
measures . 
Between 1999 and 2007, 
participants were assigned 
a linear cognitive score 
with a maximum score of 
51 based on a telephone 
interview (mean score 38.3, 
Standard Deviation (SD) 
6.1).  
This is the first study 
indicating that midlife 
sleep length, sleep quality, 
and use of hypnotics are 
associated with late life 
cognitive function. . 
Song, United States, 
2014 () 
Prospective cohort  N = 2,601  
The Osteoporotic Fractures 
in Men Study (MrOS). 
Participants were age 65 and 
older and free of probable 
dementia at sleep visit. 
Follow-up averaged 3.4 years 
Sleep stages were 
identified by in-
home 
polysomnography 
at the initial sleep 
visit (2003-2005). 
Cognitive outcomes were 
assessed with the Trail 
Making Test Part B and 
Modified Mini-Mental 
State Examination (3MS) at 
sleep visit and two follow-
up 
Increased time in Stage 
N1 and less time in Stage 
R are associated with 
worsening cognitive 
performance in older men 
over time 
Blackwell, United 
States, 2014 () 
Prospective Cohort N=2822 
The Osteoporotic Fractures 
in Men Study (MrOS). 
Participants were age 65 and 
older  (mean age 76.0 ± 5.3 
y)and free of probable 
dementia at sleep visit. 
Follow-up averaged 3.4 ± 0.5 
y. 
Actigraphy 
Clinically significant 
cognitive decline: five-
point decline on the 
Modified Mini-Mental 
State examination (3MS), 
change score for the Trails 
B test time in the worse 
decile. 
Among older community-
dwelling men, reduced 
sleep efficiency, greater 
nighttime wakefulness, 
greater number of long 
wake episodes, and poor 
self-reported sleep quality 
were associated with 
subsequent cognitive 
decline. 
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Sterniczuk, Canada, 
2013 () 
Retrospective 
Cohort 
N= 28,697   
The Survey of Health, 
Ageing and Retirement in 
Europe (SHARE) (N = 
30,038). Follow-up period: 
4.3years 
Self-reported sleep 
measures 
Alzheimer’s 
disease/Dementia was 
reported by the participants 
themselves and/or by a 
proxy respondent 
.Cognition was assessed 
using performance-based 
cognitive tests 
These findings indicate 
that sleep disturbance may 
exist prior to the 
manifestation of other 
typical symptoms 
observed in AD (e.g., 
memory loss).   
Benito-León, Spain, 
2014 () 
Prospective cohort N= 3,857   
Neurological Disorders in 
Central Spain (NEDICES) 
Study, a longitudinal, 
population-based survey  
followed for a median of 12.5 
years 
Self-reported sleep 
measures 
ICD-9 codes for deaths that 
occurred before 1999 and 
ICD-10 codes for deaths 
occurring thereafter. 
Self-reported long sleep 
duration was associated 
with 58% increased risk 
of dementia-specific 
mortality in this cohort of 
elders without dementia. 
Hahn, United States, 
2013 () 
Prospective cohort N= 214 
The population-based 
Kungsholmen Project, a 
longitudinal study of aging and 
dementia among adults aged 
75 years and older residing in 
Kungsholmen district, 
Stockholm, Sweden.  Follow-
up time: Up to 9-years 
Comprehensive 
Psychopathological 
Rating Scale 
(CPRS) 
DSM-III-Revised and AD 
diagnosis was made using 
the NINCDS-ADRDA 
criteria 
Self-reported sleep 
problems may increase 
the risk for dementia, and 
depressive symptoms may 
explain this relationship.  
Bidzan, Poland, 2011 () Prospective cohort N=150  
Care centers residents age 55 
and older, who had had the 
presence of dementia excluded 
(n = 2910).. Follow-up time: 
7-years 
The 
Neuropsychiatric 
Inventory-Nursing 
Home (NPI-NH) 
scale and the 
Association for 
Methodology and 
Documentation in 
Psychiatry 
(AMDP) scale. 
Alzheimer’s disease 
Assessment Scale 
Cognitive (ADAS-cog) 
scale. Dementia in the 
Alzheimer’s disease was 
diagnosed based on the 
NINCDS-ADRDA criteria. 
The patients in the 
preclinical period of 
dementia experienced 
sleep disturbances more 
frequently and with 
greater intensity, which in 
combination with other 
factors may have some 
prognostic value. 
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Lim, Canada, 2013 () Prospective cohort N= 698 
Participants were community-
dwelling older adults without 
dementia (mean age, 81.7 
years; 77% women) in the 
Rush Memory and Aging 
Project.   follow-up period of 
up to 6 years. 
Actigraphy 
Neuropsychometric tests. 
NINCDS-ADRDA criteria. 
Autopsies were performed 
on 201 participants who 
died, and β-amyloid (Aβ) 
and neurofibrillary tangles 
were identified by 
immunohistochemistry and 
quantified. Peripheral blood 
lymphocytes were used for 
DNA extraction, and 
APOE genotype was 
determined 
Better sleep consolidation 
attenuates the effect of 
APOE genotype on 
incident AD and 
development of 
neurofibrillary tangle 
pathology. 
Rothman, United 
States, 2013 () 
Experimental Not Applicable 
Male 3xTgAD mice were 
subjected to sleep 
restriction(SR) for 6h/day for 6 
weeks using the modified 
multiple platform technique, 
and behavioral(Morris water 
maze, fear conditioning, open 
field)  
Mice were tested 
in the Morris water 
maze (MWM)  
Hippocampal and cortical 
Aβ and P-Tau 
concentrations were 
obtained 
Significant positive 
correlations between 
cortical Aβ and p -Tau 
levels and circulating 
corticosterone indicate a 
potential role for GCs in 
mediating behavioral and 
biochemical changes 
observed after sleep 
restriction in a mouse 
model of AD 
Di Meco, United States, 
2014 () 
Experimental Not Applicable 
A total of 18 mice were kept in 
a pathogen-free environment, 
on a 12-hour light and/or dark 
cycle and had access to food 
and water ad libitum. Starting 
at the age of 8 months, mice 
were randomized to 2 groups, 
one underwent a 20/ 4-hour 
light and/or dark cycle for 2 
months (4 males and 5 
females), the other was kept on 
a normal light and/or dark 
cycle, as controls (5 males and 
4 females).  
The locomotor 
cage test was used 
to record the sleep-
wake cycle of the 
animals. The fear 
conditioning tests. 
The Morris water-
maze test 
Mouse brain homogenates 
were extracted in radio-
immuno-precipitation assay 
(RIPA) buffer and were 
prepared for 
immunohistochemistry. 
Cd-5 kinase (Cdk-5) 
activity was carried out. 
Authors conclude that 
alteration of the sleep-
wake cycle and circadian 
rhythm regulation could 
be important players in 
the onset and 
development of sporadic 
AD. Correction of sleep-
wake cycle aberrations 
could be a viable 
therapeutic strategy for 
individuals bearing this 
risk factor.  
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Kang, United States, 
2009 () 
Experimental Not Applicable 
Both wild-type mice and 
human APP transgenic 
(Tg2576) mice 
Mice were forced 
into wakefulness 
for 6 hours at the 
beginning of the 
second 12-hour 
light period when 
they would 
naturally be asleep.  
Authors monitored 
hippocampal Aβ levels 
using in vivo micro dialysis 
in both wild-type mice and 
human APP transgenic 
(Tg2576) mice, which 
express a mutated form of 
human amyloid precursor 
protein (APP). ISF Aβ was 
assessed in Tg2576 mice at 
3 months of age, several 
months earlier than Aβ 
deposition begins.  
Sleep-wake cycle and 
orexin may play a role in 
the pathogenesis of 
Alzheimer’s disease. 
Mander, United States, 
2013 
Experimental N=33 
A group of cognitively normal 
older adults (n=18 mean age 
20.4 ± 2.1) and a group of 
healthy young adults (n=15 
mean age 72.1 ± 6.6) 
Measured with 
Polysomnogram 
(PSG), starting at 
their habitual bed 
time  to minimize 
the influence of 
age-related 
circadian 
differences. 
Approximately 2 h post-
awakening, participants 
performed an event-related 
fMRI scanning session 
while performing a long-
delay (10 h) recognition 
test 
Together, these data 
support a model in which 
age-related mPFC atrophy 
diminishes SWA, the 
functional consequence of 
which is impaired long-
term memory. 
Ooms, Netherlands, 
2014 () 
Randomized 
Controlled Trial 
N=26 
The Alzheimer, 
Wakefulness, and Amyloid 
Kinetics (AWAKE) study at 
the Radboud Alzheimer 
Center, a randomized clinical 
trial that took place between 
June 1, 2012, and October 1, 
2012.  
Sleep was 
monitored using 
continuous 
polysomnographic 
recording from 3 
PM until 10 AM.  
Cerebrospinal fluid, Aβ42, 
P-tau, and T-tau were 
deter-mined using the 
xMAP-based Innobia assay 
(Innogenetics) and CSF 
Aβ40 was measured using 
an enzyme-linked immuno-
sorbent assay  
Sleep deprivation, or 
prolonged wakefulness, 
interferes with a 
physiological morning 
decrease in Aβ42.  
Chronic sleep deprivation 
increases cerebral Aβ42 
levels, which elevates the 
risk of Alzheimer disease. 
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Table 1.8. Sleep-wake cycle abnormalities and Cognitive/Alzheimer's Disease Measures: Descriptive Study Characteristics,  and Main 
Findings 
First Author, 
Country, Year 
Published 
(Reference) 
Study Design  
Sample 
size N 
Study Population 
Sleep-wake cycle 
Assessment 
Cognitive/AD Measures 
Assessment 
Conclusion 
Oosterman, 
Netherlands, 2009 
() 
Cross-sectional 
(Correlational) 
N= 144  
Study was part of a larger study on the 
eﬀects of cardiovascular risk factors, and 
participants  (90 males and 54 females, 
aged 69.5 ± 8.5 years (mean ± SD), range 
50–91)  were recruited among people 
visiting the outpatient clinic (of 
cardiology, internal medicine, or 
neurology) of the Saint Lucas Andreas 
Hospital in Amsterdam, the Netherlands. 
Wrist Actigraphy 
 Mental speed: Stroop test 
(Stroop, 1935). The Word (W) 
and Color (C) cards of the 
Stroop test Memory: 15-words 
test. The Dutch version (Saan 
and Deelman, 1986) of the 
Auditory Verbal Learning Test 
(Rey, 1964) .Digit span 
forward (Wechsler, 1987).  
An association between the rest-
activity rhythm and cognitive 
performance is present in elderly 
people. 
Merlino, Italy, 
2010 () 
Cross-sectional  N=750 
Subjects aged 65 years or older, living 
independently or in an institution, who 
resided in the seventh district of Udine, 
Italy were recruited. 
Sleep disorders were 
investigated with a 
battery of standardized 
questions and 
questionnaires 
The diagnosis of dementia was 
made according to the DSM-
IV-TR criteria . AD and VaD 
were diagnosed respectively 
according to NINCS-ARDRA 
and NINDS-AIREN criteria . 
LBD and PDD, frontotemporal 
dementia (FTD) and MCI were 
diagnosed according to specific 
consensus guidelines . 
Excessive daytime sleepiness 
was significantly related to 
dementia. Insomnia, was not 
associated with the presence of 
cognitive decline.   
Pat-Horenczyk, 
United States, 1998 
() 
Cross-sectional  N= 67 
Nursing home residents  (mean age = 85.7 
years).  There were 46 severely demented 
patients, and 21 mild-moderately 
demented patients 
Actigraphy 
Levels of dementia were 
assessed by Mini-Mental State 
Examination (MMSE)  
With the progression of 
dementia, both the capacity to 
maintain sleep and the capacity 
to maintain wakefulness are 
impaired, and result in complete 
fragmentation of 
sleep/wakefulness during the 
night and day. 
Yesavage, United 
States & France, 
2011 () 
Cross-sectional  N=300 
Two cohorts of AD participants. Cohort 1 
(n=124): individuals with probable AD 
recruited from the Stanford/Veterans 
Affairs NIA Alzheimer’s Disease Core 
Center (n=81) and the Memory Disorders 
Clinic at the University of Nice School of 
Medicine (n=43). Cohort 2 (n=176): 
individuals with probable AD derived 
from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) data set. 
 Wrist actigraphy data for 
seven days in Cohort 1 
and by the 
Neuropsychiatric 
Inventory (NPI-Q) for 
Cohort 2. 
Diagnosis of probable AD by 
NINCDS-ADRDA criteria 
based on relevant neurological, 
medical, neuroimaging, and 
neuropsychological 
assessments. 
It is unlikely that a relationship 
with a clinically meaningful 
correlation exists between the 
circadian rhythm-associated 
SNPs and WASO in individuals 
with AD. 
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Naismith, 
Australia, 2014 () 
Case-control N=58 
Participants (30 patients with MCI and 28 
age-matched controls) were recruited from 
a specialist ‘Healthy Brain Ageing’ Clinic, 
at the Brain & Mind Research Institute, 
Sydney, Australia. 
Actigraphy. 
Polysomnographic (PSG) 
assessments, on separate 
nights. Salivary 
melatonin was assessed 
to determine dim light 
melatonin onset (DLMO) 
A clinical diagnosis of MCI 
was obtained using Petersen’s 
criteria  
Circadian misalignment and 
sleep disruption is evident in 
patients with MCI, and is 
consistent with changes observed 
in Alzheimer’s disease. Such 
findings could be a marker for 
disease trajectory, and may even 
be implicated in disease 
pathogenesis. 
Fronczek, 
Netherland, 2012 () 
Case-control N=49 
Ten patients with AD (Braak 5 or 6) and 
10 non-demented controls (Braak 0 or 1) 
were matched for sex, age, postmortem 
delay (PMD), and fixation time 
(hypothalamus group). 
Hypocretin-1 
immunocytochemistry 
and neuron quantification 
and measurement in 
ventricular CSF was 
done.  
Clinical diagnosis and 
Neuropathological examination 
according to van de Nes et al. 
1993 and Braak et al. 1998 
Hypocretin system is affected in 
advanced AD. This is reflected in 
a 40% decreased cell number, 
and 14% lower CSF hypocretin-1 
levels. 
Slats, Netherlands, 
2012 () 
Case-control N=12 
Six patients with AD (59-85 yrs, MMSE 
16-26) and six healthy volunteers (64-77 
yrs). 
CSF hypocretin-1 was 
measured using a 
commercially available 
RIA kit (Phoenix 
Pharmaceuticals, 
Belmont, CA).  
CSF Aβ42 was determined 
using the xMAP-based Innobia 
assay (Innogenetics NV, Ghent, 
Belgium) CSF Aβ40 using 
ELISA (the Genetics Company, 
Schlieren, Switzerland).Total 
protein level in CSF was 
analyzed using the Lowry 
method. 
 Mean Aβ42 levels and mean 
hypocretin-1 levels and 
amplitude may suggest a 
relationship between AD 
pathology and hypocretin 
disturbance, which could hold 
possibilities for treatment of AD 
related sleep disorders. 
Schmidt, Germany, 
2013 () 
Case-control N=66 
33 patients with mild to severe AD and 33 
subjects without any psychiatric or 
neurological disorder (HS) that were 
consecutively recruited to participate in 
the study. 
Melanin-concentrating 
hormone (MCH) and 
hypocretin-1 (HCRT-1, 
orexin-A) were measured 
using a fluorescence 
immunoassay (FIA)  
 Consortium to Establish a 
Registry for Alzheimer’s 
Disease (CERAD), Wechsler 
Memory Scale-Revision 
(WMS-R), clock drawing test, 
and Trail Making Test (TMT), 
a MRI head-scan, genotyping 
of ApoE4 and determination of 
Ab42, T-tau and P-tau in the 
CSF. 
This report on MCH in patients 
with AD adds to preclinical 
studies and may allow further 
research on the role of the 
hypothalamus in pathology and 
occurrence of behavioral 
disturbances in AD. 
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Liu, Netherlands 
and China, 1999 () 
Case-control N=167 
Autopsies were performed within the 
framework of The Netherlands Brain 
Bank. Ventricular postmortem CSF was 
obtained at autopsy, 1–12 h after death, 
from 85 patients with AD (mean age, 75 ± 
1.1 yr) and 82 age-matched controls 
(mean age, 76 ± 1.4 yr) without a primary 
neurological or psychiatric disease. 
Melatonin in postmortem 
CSF was measured by a 
direct RIA 
ApoE genotyping. The 
genotype of each extracted 
DNA sample was determined 
by polymerase chain reaction 
(PCR)  
CSF melatonin levels fromApoE-
€3/4 genotype patients were 
significantly higher thanthose 
from the ApoE-€4/4 genotype, 
suggesting a relationship between 
melatonin levels and signs and 
symptoms of AD. CSF melatonin 
levels was lower in AD patients 
than in old control subjects. 
Walsh, United 
States 2014 () 
Prospective 
Cohort 
N=1287 
1,287 community-dwelling older women 
(82.8 ± 3.1 y) participating in an ongoing 
prospective study who were free of 
dementia at the baseline visit. Follow-up 
time: 5 years 
Actigraphy 
Modified Mini-Mental Status 
Examination (3MS), California 
Verbal Learning Task (CVLT), 
digit span, Trail Making Test B 
(Trails B), categorical fluency, 
and letter fluency. 
Weaker Circadian Activity 
Rhythm patterns are associated 
with worse cognitive function, 
especially executive function, in 
older women without dementia.  
Keage, Australia, & 
United Kingdom 
2012 () 
Prospective 
cohort 
N= 2012  
The Medical Research Council 
Cognitive Function and Ageing Study 
(CFAS), a longitudinal multi-center 
population-based study of ageing and 
dementia (www.cfas.ac.uk). Follow-up 
time: 10-years                                              
Self-reported sleep 
measures 
MMSE 
Excessive daytime sleepiness 
may be modifiable behaviors 
open to intervention strategies, 
or, clinical indicators of future 
decline in older individuals. 
Anderson, United 
Kingdom, 2014 () 
Prospective 
Cohort 
N= 421 
The study was nested in the Newcastle 
85+ Study, a population-based 
longitudinal study of health and ageing in 
the very old. Follow-up time: 2 years 
Pittsburgh Sleep 
Questionnaire Inventory 
(PSQI) and the Epworth 
Sleepiness Score (ESS) 
as subjective measures of 
sleep and wake.  
Cognition assessed by the 
Mini-Mental State Examination 
(MMSE) 
Abnormal sleep–wake patterns 
are associated with cognitive 
impairment 
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Tranah, United 
States, 2011 () 
Prospective 
Cohort 
N=1282  
Women were participants of the Study of 
Osteoporotic Fractures (SOF), a 
longitudinal epidemiologic study of 
10,366 community-dwelling women age 
65 years or older. Follow-up time: 4.9 
years 
Circadian activity 
rhythms were measured 
with the Sleep-Watch-O 
(Sleep-Watch-OVR, 
Ambulatory Monitoring, 
Inc., Ardsley, NY) 
actigraph. 
 Modified Mini-Mental State 
Examination (3MS);  
California Verbal Learning 
Test (CVLT) delayed recall; 
Informant Questionnaire on 
Cognitive Decline in the 
Elderly (IQCODE);  self-
reported previous dementia 
diagnosis 
Older, healthy women with 
decreased circadian activity 
rhythm amplitude and 
robustness, and delayed rhythms 
have increased odds of 
developing dementia and MCI 
Lim, United States, 
2013 () 
Prospective 
Cohort 
N=737 
Rush Memory and Aging Project 
(MAP)which is an ongoing community-
based cohort study of aging which began 
in 1997. Follow-up period was up to 6 
years (mean 3.3 years). 
Actigraphy 
Battery of Neuropsychological 
Tests 
Sleep fragmentation in older 
adults is associated with incident 
AD and the rate of cognitive 
decline. 
Yesavage, United 
States, 2004 () 
Prospective 
Cohort 
N=44 
To be included in the current analysis, the 
patient must have been assessed during at 
least 2 stages of cognitive impairment, 
defined as a decline from one stage of AD 
to another.   
Actigraphy 
APOE genotypes were then 
determined. Diagnosis of 
probable AD by NINCDS-
ADRDA criteria and a score of 
15 or higher at entry on the 
Mini-Mental State Exam 
(MMSE). .  
APOE status is associated with 
the progression of sleep/wake 
disturbances in AD 
Craig, Canada, 
2008 () 
Experimental 
Not 
Applicable 
Twenty-four male Long Evans hooded 
rats (300–400 g) obtained from Charles 
River (Saint-Constant, PQ) were used for 
all studies. They were divided into three 
groups: acutely phase shifted rats (acute; n 
= 8), chronically phase shifted rats 
(chronic; n = 8), control rats for water 
maze testing (control; n=7) and control 
rats for fear conditioning (control; n = 14). 
In order to create a state 
of circadian disruption a 
two-stage phase shifting 
session which lasted 16 
days was used.  
Rats underwent Behavioral 
Testing on a 6 day version of 
the water maze task, followed 
by 3 days of testing on a fear 
conditioning task. They then 
underwent a Rapid Acquisition 
Task training in three stages.  
Authors propose that chronic 
circadian disruption may play a 
role in the development of age-
related cognitive deficits and 
dementia in the elderly 
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Jyoti, Scotland, 
UK, 2010 () 
Experimental 
Not 
Applicable 
 APP/PSEN1 and  PSEN1 Transgenic 
mice. Transgenic mice were singly housed 
and assigned to the following groups, 
depending upon age (5 or 20 months) and 
genotype: 1) APP/PSEN1 [5 months: n = 
8; 20 months: n = 6]; 2) PSEN1 [5 
months: n = 8; 20 months: n = 11]; 3) WT 
[5 months: n = 9; 20 months: n = 8]. 
Circadian activity was 
recorded in PhenoTyper 
home cages (Noldus, The 
Netherlands) through 
video observation 
techniques and XY 
coordinates recorded over 
7 consecutive days. 
Authors characterized sleep, 
electroencephalogram (EEG) 
disturbances i.e., 
endophenotypes of Alzheimer’s 
disease (AD) patients alongside 
cognitive dysfunction in 
transgenic mice carrying 
transgenes for amyloid-protein 
precursor (APPswe) and 
presenilin 1 (PSEN1A246E) at 
5 (pre-plaque) and 20 months, 
relative to PSEN1 and wild-
type (WT) mice, using a novel 
wireless microchip device. 
 APP/PSEN1 mice exhibit 
abnormalities in activity and 
sleep architecture preceding 
amyloid plaque deposition as 
well as age-related changes in 
cortical EEG power.  
Quinn, United 
States, 2005 () 
Experimental 
Not 
Applicable 
Transgenic mice that were bred from a 
breeding pair of Tg2576 mice  
Plasma melatonin  
Soluble and formic acid 
extractable beta amyloid 
determination was done and Aβ 
burden in hippocampus and 
cerebral cortex was quantified 
with NIH image.  
Melatonin failed to produce anti-
amyloid or antioxidant effects 
when initiated after the age of 
amyloid plaque deposition. These 
findings diminish the possibility 
that melatonin will be useful for 
the treatment of established 
Alzheimer’s disease. 
DENG. China, 
2005 () 
Experimental 
Not 
Applicable 
N2a cells were grown and differentiated in 
96-well culture plates at density of 
1.5×105 cells in 100 μL. Cells were 
exposed to various concentrations of 
wortmannin for 2 h at 37 ºC in the 
presence or absence of a 12-h-
preincubation with melatonin 25, 50, and 
100 μmol/L or Vitamin E (VE). 
Dimethylsulfoxide (Me2SO, 0.01%), in 
which wortmannin, melatonin and VE 
were dissolved, served as a vehicle 
control. 
Western blot, P-labeling 
and the detection of 
malondialdehyde level 
and superoxide dismutase 
activity  
MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl-tetrazolium 
bromide), crystal violet assay, 
phase-contrast, dead end 
colorimetric apoptosis 
detection system (TUNEL) and 
electron microscopy were used 
to detect cell viability, 
morphology and apoptosis 
Wortmannin is an effective tool 
for reproducing Alzheimer-like 
tau hyperphosphorylation cell 
model and melatonin/vitamin E 
can effectively protect the cells 
from wortmannin-induced 
impairments 
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Papolla, United 
States, 1998 () 
Experimental 
Not 
Applicable 
Aliquots of Aβ1–40 and Aβ1–42 at a 
concentration of 250 μm in 5 mm Tris-
HC1, pH 7.4, were incubated at room 
temperature  
Melatonin or the 
melatonin analog 5-
hydroxy-N-acetyl-
tryptamine (NAT) 
(Sigma) orN-t-butyl-α-
phenylnitrone (PBN) 
(Sigma),  
Peptides Aβ1–40 and Aβ1–42 
were synthesized in the W. M. 
Keck Foundation (Yale 
University, CT), and their 
purity was evaluated by amino 
acid sequence and laser 
desorption mass spectrometry.  
Melatonin can provide a 
combination of antioxidant and 
anti-amyloidogenic features that 
can be explored either as a 
preventive or therapeutic 
treatment for AD or as a model 
for development of anti-
amyloidogenic indole analogs. 
Olcese, United 
States, 2009 () 
Experimental 
Not 
Applicable 
 APP + PS1 double transgenic (Tg) mice 
Authors administered 
melatonin (100 mg/L 
drinking water) to 
APP + PS1 double 
transgenic (Tg) mice 
from 2–2.5 months of age 
to their killing at age 
7.5 months.  
Mice were initially genotyped 
at the time of weaning and then 
had confirmatory genotyping 
within several months 
thereafter, with further 
confirmation via plasma Ab40 
expression. 
Results are consistent with a 
melatonin-facilitated removal of 
Aβ from the brain. Inflammatory 
cytokines such as tumor necrosis 
factor (TNF)-α were decreased in 
hippocampus (but not plasma) of 
Tg+ melatonin mice.  
Lahiri, United 
States, 2004 () 
Experimental 
Not 
Applicable 
Male B6C3F1 mice, a hybrid between 
C57BL/6 and C3H from Harlan Labs 
(Indianapolis, IN, USA), aged 6 months 
(young group), 12 months (middle-aged 
group) and 27 months (old group), were 
housed two or three per cage and were 
maintained on a 12 hr light/dark cycle in a 
temperature controlled (22 ± 1°C) room.  
An ELISA procedure was 
used for the quantitative 
measurement of 
melatonin in serum  
A sensitive enzyme-linked 
immunosorbent assay (ELISA) 
test for measuring levels of Aβ-
40 was performed in the 
murine brain homogenates. 
ELISA test was also performed 
using the IBL assay reagents 
for the quantitative 
determination of Aβ-42 in the 
murine brain homogenates.  
Melatonin supplementation may 
retard neurodegenerative changes 
associated with brain aging. 
Depletion of melatonin in the 
brain of aging mice may in part 
account for this adverse change. 
Asayama, Japan, 
2003 () 
Randomized 
Controlled Trial 
N=20 
The subjects were 9 persons given a 
placebo (PLA), and 11 given melatonin (3 
mg)(MLT). The drugs were given at 20: 
30 each day for 4 weeks. 
Actigraph data from 18 
patients (PLA8, MLT10) 
Diagnosis of AD via CT or 
MRI and a clinical diagnosis 
based on DSM IV criteria and 
the NINCDS-ADRDA criteria, 
Dementia severity was assessed 
by the Clinical Dementia 
Rating Scale (CDR), Cognitive 
funcion was assessed by the 
Alzheimer's Disease 
Assessment Scale (ADAS) the 
MMSE 
Melatonin administration 
improved sleep time and night 
activity significantly, but no 
significant effect with regard to 
improving daytime naps and 
activity. Melatonin 
administration improved 
cognitive and non-cognitive 
functions significantly.  
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Table 1.9. Sleep Disordered Breathing/Sleep Apnea and Cognitive/Alzheimer's Disease Measures: Descriptive Study 
Characteristics, Statistical Methods and Main Findings 
First Author, Country, Year 
Published (Reference) 
Study Design  
Sample 
size N 
Study Population Hypoxia Assessment 
Cognitive/AD Measures 
Assessment 
Conclusion 
Gottlieb, United States, 2004 
() 
Cross sectional N=1,775 .  
Participants were aged 40 to 
100 years from the Sleep 
Heart Health Study (SHHS) 
a longitudinal cohort study of 
the relation of sleep-
disordered breathing to CVD. 
Obstructive Sleep 
Apnea/Hypopnea (OSAH) 
was defined as an Apnea 
Hypopnea Index (AHI) ≥ 
15. 
APOE was genotyped 
The APOE £4 allele is 
associated with increased 
risk of OSAH, 
particularly in individuals 
under age 65. 
Kadotani, United States, 2001 
() 
Cross-sectional  N=791 
Probability based sampling of 
791 middle-aged adults, mean 
age of 49 and age range 32-68 
Nocturnal Polysomnography 
with Sleep Disordered 
Breathing defined as AHI ≥ 
15 
APOE was genotyped 
A significant proportion 
of Sleep Disordered 
Breathing is associated 
with APOE £4 allele in 
the general population 
Osorio, United States, 2014 () Cross-sectional  N=95 
Ninety-ﬁve cognitively normal 
elderly participants were 
recruited at NYU Center for 
Brain Health  ongoing 
between 2009 and 2013. 
Among the 95 participants, 
25 were considered free of 
SDB (AHI4% < 5) and were 
included as normal controls, 
51 had mild SDB (AHI4% 
5-14.99), and 19 had 
moderate to severe SDB 
(AHI4% > 15). 
CSF measures of 
phosphorylated-tau (p-
tau), total-tau (t-tau), and 
amyloid beta 42 (Ab-42), 
as well as ApoE allele 
status 
There is an association 
between SDB and CSF 
Alzheimer’s disease-
biomarkers in cognitively 
normal elderly 
individuals.. 
Djonlagic, United States, 
2014 () 
Cross-sectional  N=44 
Participants (19–68 years) 
who had been referred by a 
physician for a baseline 
polysomnography (PSG) 
evaluation. 
Based on their PSG, patients 
were assigned either to the 
OSA group (AHI>5/h), or 
control (Non-OSA) group 
(AHI<5/h). 
Psychomotor Vigilance 
Task (PVT) and the Motor 
Sequence Learning Task 
(MST) 
The presence of untreated 
obstructive sleep apnea is 
associated with an aging-
related cognitive deficit, 
otherwise not present in 
individuals without OSA.  
102 
 
O’Hara, United States, 2005 
() 
Case-control N=36 
Twelve men and 24 women 
participated. All were over age 
60, with a mean age of 70.6 
(SD = 8.1), a mean of 16.1 
(SD = 2.4) years of education, 
and a mean Mini-Mental State 
Examination (MMSE) of 28.7 
(SD = 1.2; range 27 to 30). 
Eighteen had an APOE €4 
allele, and 18 were non-
carriers 
The apnea-hypopnea index 
(AHI), i.e., the average 
number of apneas or 
hypopneas per hour of 
estimated sleep measured 
OSAH severity in each 
subject. 
APOE genotyping. 
MMSE; the Rey Auditory 
Verbal Learning Test of 
immediate verbal recall 
(RAVLT1); short-term 
free recall (RAVLT6) and 
30-minute delayed free-
recall (RAVLT Delayed); 
the Stroop Color and 
Word (SCW) measure of 
attention and cognitive 
flexibility; and the 
Symbol-Digit Modalities 
Test (SDMT) of 
information processing 
speed. 
Nocturnal sleep 
apnea/hypopnea is 
associated with lower 
memory performance in 
APOE €4 carriers 
Cohen-Zion, United States, 
2001 () 
Prospective 
cohort 
N=46 
Community-dwelling people 
age 65 and older with high risk 
for SDB were originally 
studied from 1981 through 
1985 and then followed every 
2 years.  Follow-up period: 
2years 
Subjects’ sleep was recorded 
using the Modified 
Respitrace/Medilog system, 
which measured thoracic 
and abdominal respiration, 
tibialis electromyogram 
(EMG), and wrist activity 
(to discriminate sleep/wake 
states). 
MMSE 
The results of this study 
could theoretically 
suggest that any 
relationship between 
SDB and cognitive 
function may be mediated 
by the effect of SDB on 
daytime sleepiness. 
Tworoger, United States, 
2006 () 
Prospective 
cohort 
 N = 1844 
Participants were  women 
aged 70 to 81 years at initial 
cognitive interview in 2000 
and members of the Nurses’ 
Health Study cohort. Follow-
up period: 2years 
Authors collected 
information about average 
sleep duration and snoring 
frequency on questionnaires 
in 1986 and 2000;  
Women completed six 
tests of cognitive function 
encompassing general 
cognition, verbal memory, 
category fluency, and 
attention. Tests were 
repeated 2 years later.  
Associations between 
sleep patterns and initial 
cognitive function may be 
clinically relevant given 
that diminished cognition 
is a risk factor for 
dementia. However, the 
lack of an association 
with prospective 
cognitive decline was 
seen 
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Chang, Taiwan, 2013 () 
Retrospective 
cohort 
N=8484 
Longitudinal Health 
Insurance Database 2005 
(LHID2005) in Taiwan, 1414 
patients with Sleep Apnea 
(SA) aged 40 years  Follow-
up period: 5years 
 Diagnoses of SA [ICD-9-
Codes 327.23, 780.51, 
780.53, 780.57] between 
January 2003 and December 
2005. Clinically assessed 
including only cases in 
which patients obtained ≥2 
SA diagnoses in outpatient 
visits or ≥1 inpatient service. 
 ICD-9 code 
SA may be a gender-
dependent, age-
dependent, and time-
dependent risk factor for 
dementia 
Yaffe, United States, 2011 () 
Prospective 
cohort 
N=298 
Study of Osteoporotic 
Fractures.  Follow-up 
period: 2.3 years 
Sleep disordered breathing 
was defined as an apnea-
hypopnea index of 15 or 
more events per hour of 
sleep.  
Diagnostic and Statistical 
Manual of Mental 
Disorders (Fourth Edition) 
criteria. MCI was 
diagnosed using the 
modified criteria by 
Peterson et al  
Among older women, 
those with sleep 
disordered breathing, 
compared with those 
without SDB, were 
associated with an 
increased risk of 
developing cognitive 
impairment 
Shiota, Japan, 2013 () Experimental 
Not 
Applicable 
In vivo, 15 male triple 
transgenic AD mice were 
exposed to either Chronic 
Intermittent Hypoxia (CIH) or 
normoxia (5% O2 and 21% 
O2 every 10 min, 8 h/day for 4 
weeks). In vitro, human 
neuroblastoma SH-SY5Y cells 
stably expressing wild-type 
amyloid-β protein precursor 
were exposed to either IH (8 
cycles of 1% O2 for 10 min 
followed by 21% O2 for 20 
min) or normoxia 
CIH was applied (n = 9) by 
exposing to alternating 5% 
O2 and 21% O2 every 10 
min for 8 h per day during 
daytime for 8 weeks in a 
chamber (370×260×250 
mm, 26 L, Sibata Scientific 
Technology Ltd, Tokyo, 
Japan). Control mice (n = 6) 
were kept under normoxia 
and touched by human 
hands once a day to balance 
out their stress through 
direct human contact. 
Amyloid-β (Aβ) profile, 
cognitive brain function, 
and brain pathology were 
evaluated.  
Results suggest that 
Obstructive Sleep Apnea 
(OSA) would aggravate 
AD. Early detection and 
intervention of OSA in 
AD may help to alleviate 
the progression of the 
disease. 
Kaushal, United States, 2012 
() 
Experimental 
Not 
Applicable 
Adult male human ApoE4-
targeted replacement mice 
[B6.129P2-
Apoetm3(APOE*4)MaeN8] 
(hApoE4) and C57BL/6NTac 
(wild-type, WT) mice, 
HYPOXIA MEASURE                              
O2 concentration was 
continuously measured by 
an O2 analyzer and was 
changed from 1:00 PM until 
7:00 PM by a computerized 
system controlling the gas 
valve outlets. 
SLEEP INTEGRITY 
MEASURE               
Polysomnography 
The increased 
susceptibility and limited 
recovery ability of 
hApoE4 mice to sleep 
apnea suggests that early 
recognition and treatment 
of the latter in AD 
patients may restrict the 
progression and clinical 
manifestations of this 
frequent 
neurodegenerative 
disorder 
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Sun, Canada, China, United 
States, 2006 () 
Experimental 
Not 
Applicable 
APP23 Transgenic mice 
APP23 mice (8 months of 
age, n = 20, 50% female) 
were assigned randomly to 
hypoxia and control groups. 
The hypoxia group was 
treated in a hypoxia 
chamber at 8% O2 for 16 
h/day for 1 month. 
The water maze test. 
Neuritic Plaque Staining 
was done.  
The results demonstrate 
that hypoxia can facilitate 
AD pathogenesis, and 
they provide a molecular 
mechanism to link 
vascular factors to AD 
Li, China, 2009 () Experimental 
Not 
Applicable 
Transgenic mice (The Jackson 
Lab, No. 003378, APPSwe + 
PS1A246E)  
 The mice were treated with 
hypoxia once a day and 
repeated for 60 days. Mice 
were assigned randomly to 
hypoxia and control groups 
(9 months old female, 10 
mice in each group). 
Neuritic plaques staining 
was performed.  
Taken together, the 
results suggest an 
important role of hypoxia 
in modulating the APP 
processing by facilitating 
both β- and ɣ-cleavage 
which may result in a 
significant increase of Aβ 
generation. 
Zhang, China, 2007 () Experimental 
Not 
Applicable 
Mouse neuroblastoma N2a 
cells stably expressing human 
APP695 (N2a-APP) were 
maintained in cell culture 
medium containing 50% DME 
high glucose medium  
Cell culture, Transfection 
and Hypoxic treatment was 
done. 
Immunoblotting and 
Antibodies, Aβ ELISA 
Assay, In Vitro β-
Secretase Activity Assay, 
Pulse-chase experiments, 
Quantitative Real-time 
Polymerase Chain 
Reaction (RT-PCR), HIF-
1α RNA Interference, 
Tissue Isolation from HIF-
1α Conditional Knock-out 
Mice were also carried out 
on the mice models 
The results demonstrate 
an important role for 
hypoxia/HIF-1α in 
modulating the 
amyloidogenic processing 
of APP and provide a 
molecular mechanism for 
increased incidence of 
AD following cerebral 
ischemic and stroke 
injuries 
Kushida, United States, 2012 
() 
Randomized 
Controlled Trial 
N=1,098 
The Apnea Positive Pressure 
Long-term Efficacy Study 
(APPLES) was a 6-month, 
randomized, double-blind, 2-
arm, sham-controlled, 
multicenter trial conducted at 
5 U.S. University, hospital, or 
private practices. 
Diagnosis of Obstructive 
Sleep Apnea (OSA) with an 
apnea-hypopnea index 
(AHI) ≥ 10 and age ≥ 18 
years 
Three neurocognitive 
variables, each 
representing a 
neurocognitive domain: 
Pathfinder Number Test-
Total Time (attention and 
psychomotor function 
[A/P]), Buschke Selective 
Reminding Test-Sum 
Recall (learning and 
memory [L/M]), and 
Sustained Working 
Memory Test-Overall 
Mid-Day Score (executive 
and frontal-lobe function 
[E/F]) 
CPAP treatment 
improved both 
subjectively and 
objectively measured 
sleepiness, especially in 
individuals with severe 
OSA (AHI >30).  
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Ancoli-Israel, United States, 
2008 () 
Randomized 
Controlled Trial 
N=52 
Participants were men and 
women with mild-moderate 
AD and OSA recruited from 
the University of California 
San Diego (UCSD) 
Alzheimer's Disease Research 
Center. 
Diagnosis of Obstructive 
Sleep Apnea (OSA) with an 
apnea-hypopnea index 
(AHI) ≥ 10.CPAP unit 
pressure was set at 8 cm 
H2O pressure while the 
system mask's pressure 
varied from 0.5 cm H2O at 
end-expiration to 0.0 cm 
H2O during inspiration 
NINCS-ARDRA and a CT 
or MRI of the brain 
consistent with AD done 
within 24 months Mini 
Mental Status 
Examination (MMSE) 
score greater than 17. 
OSA may aggravate 
cognitive dysfunction in 
dementia and thus may be 
a reversible cause of 
cognitive loss in AD 
patients.  
 
Table 1.10. Insomnia and Cognitive/Alzheimer's Disease Measures: Descriptive Study Characteristics, and Main Findings 
First Author, 
Country, Year 
Published 
(Reference) 
Study Design  
Sample size 
N 
Study Population Insomnia Assessment Cognitive/AD Measures Assessment Conclusion 
Merlino, Italy, 2010 
() 
Cross-sectional  N=750 
Subjects aged 65 years or 
older, living independently 
or in an institution, who 
resided in the seventh 
district of Udine, Italy were 
recruited. 
Insomnia and other sleep 
abnormalities were 
investigated with a battery 
of standardized questions 
and questionnaires 
 DSM-IV-TR criteria . AD and VaD were 
diagnosed respectively according to 
NINCS-ARDRA and NINDS-AIREN 
criteria . LBD and PDD, frontotemporal 
dementia (FTD) and MCI were diagnosed 
according to specific consensus guidelines 
. 
Insomnia was not associated 
with the presence of cognitive 
decline. As opposed to 
insomnia, excessive daytime 
sleepiness was significantly 
related to dementia. 
Cricco, Iceland, 2001 
() 
Prospective cohort  N=6444 
The four sites of the 
Established Populations 
for Epidemiologic Studies 
of the Elderly (EPESE).  
Follow-up period: 3 years  
Insomnia was defined as 
self-report of trouble falling 
asleep or waking up too 
early most of the time. 
Cognitive decline was defined as two or 
more errors on the Short Portable Mental 
Status Questionnaire (SPMSQ)  at FU3. 
Chronic insomnia 
independently predicts incident 
cognitive decline in older men.  
Jelicic, The 
Netherlands, 2002 () 
Prospective 
Cohort 
N=838 
Maastricht Ageing Study 
(MAAS), a prospective 
cohort study of cognitive 
ageing based in the 
Netherlands.  Follow-up 
period: 3 years  
Self-reported sleep 
measures 
Cognitive performance at follow-up, 
measured with the Mini Mental Status 
Examination (MMSE) 
Subjective sleep complaints 
predict cognitive decline in 
middle aged and older adults 
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Foley, United States, 
2001 () 
Prospective 
Cohort 
N=2346 
Japanese-American men 
age 71 to 93 of The 
Honolulu-Asia Aging 
Study (HAAS) 
Sleep disturbances were 
assessed by questionnaire.  
Dementia was diagnosed according to 
less-restrictive diagnostic criteria 
developed by Cummings et al. for very 
mild dementia and more-restrictive 
diagnostic criteria for mild or more severe 
dementia from the Diagnostic and 
Statistical Manual of Mental Disorders, 
Third Edition, Re-vised (DSM-IIIR).  
Daytime sleepiness in older 
adults may be an early indicator 
of decline in cognitive 
functioning and onset of 
dementia. 
Osorio, United 
States, 2011 () 
Prospective 
Cohort 
N=346 
Brain aging studies at 
New York University’s 
Alzheimer’s Disease 
Research Center.  Follow-
up period: over 7.7 years. 
Insomnia was collected only 
during the normal cognition 
stage and screened using 
items 4, 5, and 6 from the 
Hamilton Depression Rating 
Scale (HAM-D) 
Mini-Mental State examination  
There is a greater risk of 
Alzheimer's disease in adults 
with Insomnia 
       
       
Table 1.11 Restless Less Syndrome (RLS) and Cognitive/Alzheimer's Disease Measures: Descriptive Study Characteristics, and Main 
Findings 
First Author, 
Country, Year 
Published 
(Reference) 
Study Design  
Sample size 
N 
Study Population RLS Assessment Cognitive/AD Measures Assessment Conclusion 
Pearson, United 
States, 2006 () 
Case-control N=31 
Sixteen patients off RLS 
treatment for at least 2 
weeks and 15 age- and 
gender-matched control 
subjects 
RLS patients were required 
to have daily symptoms and 
to have periodic leg 
movements in sleep (PLMS) 
of greater than 20/h on a 
screening nocturnal 
Polysomnogram (PSG). 
Cognitive Tests consisted of the 
following: the Stroop color-word test, 
Trail Making Test (A and B), the Porteus 
Maze Test (Vineland Revision), the 
Colored Progressive Matrices Test, and 
two verbal fluency tests (words beginning 
with a fixed first letter and words in 
categories). 
RLS patients have statistically 
significant specific cognitive 
deficits and show cognitive 
deficits similar to those seen 
with 36 h total sleep 
deprivation. 
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Figure 1.1   Flow Diagram of Systematic Review of Sleep and Alzheimer’s disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies identified through database searching (n = 2341) 
(PubMed=904, Embase=1026, Web of Science=305, Cochrane library=106) 
Studies after duplicates removed  
(n = 1221) 
Studies screened for titles  
(n = 1221) 
Studies excluded  
(n = 180) 
Full-text articles assessed 
for eligibility  
(n = 201) 
Full-text articles excluded, 
with reasons (n = 130) 
- Review article (n = 7) 
- No risk estimate (n = 
17) 
- Sleep not assessed (n = 
18) 
- Relationship not 
studied (n = 53) 
- Not peer reviewed (n = 
10) 
- Alzheimer not 
examined (n = 25) 
Studies included in 
systematic review  
(n = 72) 
Article identified from 
reference search  
(n = 1) 
Studies screened for abstracts 
(n = 1041) 
Studies excluded  
(n = 840) 
Duplicates removed  
(n = 1120) 
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ABSTRACT 
Study Objectives: Mounting evidence implicates disturbed sleep or lack of sleep as one of the risk 
factors for Alzheimer’s disease (AD) but the extent of the risk is uncertain. We conducted a broad 
systematic review and meta-analysis to quantify the effect of sleep problems/disorders on cognitive 
impairment and AD.  
Methods: Original published literature assessing any association of sleep problems or disorders with 
cognitive impairment or AD was identified by searching PubMed, Embase, Web of Science, and the 
Cochrane library. Effect estimates of individual studies were pooled and relative risks (RR) and 95% 
confidence intervals (CI) were calculated using random effects models. We also estimated the population 
attributable risk (PAR).  
Results: Twenty-seven observational studies (n = 69,216 participants) that provided 52 RR estimates 
were included in the meta-analysis. Individuals with sleep problems had a 1.55 (95% CI: 1.25-1.93), 1.65 
(95% CI: 1.45-1.86) and 3.78 (95% CI: 2.27-6.30) times higher risk for AD, cognitive impairment and 
preclinical AD than individuals without sleep problems respectively. The overall meta-analysis revealed 
that individuals with sleep problems had a 1.68 (95% CI: 1.51-1.87) times higher risk for the combined 
outcome of cognitive impairment and/or AD. Approximately 15% of AD in the population may be 
attributed to sleep problems.  
Conclusion: This meta-analysis confirmed the association between sleep and cognitive impairment or 
AD and, for the first time, consolidated the evidence to provide an “average” magnitude of effect. As 
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sleep problems are of a growing concern in the population, these findings are of interest for potential 
prevention of AD.  
Statement of Significance: This study systematically and efficiently integrated existing information from 
various studies, and for the first time, consolidated the evidence of the association between sleep and 
Alzheimer’s disease (AD) and/or cognitive impairment by providing an “average” magnitude of the 
effect. Subgroup meta-analysis of various aspects of sleep problems examined in this analysis each 
significantly increased the risk for AD. The public health relevance of these findings is buttressed by the 
population attributable risk percent, suggesting that approximately 15% of AD may be prevented should 
interventions be implemented to reduce sleep problems and disorders. These novel findings are of 
pertinent interest to further understand the etiology of AD and are likely to be of interest to researchers, 
clinicians’ and public health policy makers. 
 
 
 
 
 
 
 
 
 
 
 
111 
 
INTRODUCTION 
Alzheimer’s disease (AD) is a neurodegenerative disorder afflicting approximately five million 
older Americans, with a projected annual incidence of one million cases in the United States by 2050.1, 2 
AD and other dementias are associated with significant morbidity and mortality, with worldwide costs 
estimated at US$604 billion in 2010.3  Preventive and/or therapeutic measures targeted at delaying or 
curing AD are therefore imperative to mitigate this societal burden.     
 Mounting evidence implicates disturbed sleep or lack of sleep as a risk factor for AD. Demented 
older adults exhibit significant sleep disturbance and unhealthy sleep patterns, including shorter sleep 
duration and fragmented sleep,4-7 altered circadian rest/activity patterns,5 and elevated rates of sleep 
disordered breathing (SDB).8, 9 It is estimated that about 45% of AD patients have sleep disturbances.10, 11 
However, the ultimate etiologic role of sleep in AD pathogenesis remains unknown. Sources of sleep 
disturbances in AD are thought to include degeneration of neural pathways that regulate sleep-wake 
patterns and sleep architecture.10, 12 Sleep disorders also may exacerbate cognitive symptoms through 
impairment of sleep-dependent memory consolidation processes.13, 14  It is possible that circadian rhythms 
and sleep disorders have a causal role in the pathophysiology of AD. If this is true, they could be critical 
to the goal of preventing this disease, because effective interventions exist to improve sleep.15 Narrative 
review articles examining this association16-19 reflect the opinion and consensus among specialists that 
there is growing experimental and epidemiologic evidence for a close reciprocal association of cognitive 
impairment and AD with sleep problems and disorders. However, to date, no review has quantified the 
effect of having sleep problems and disorders on cognitive impairment and AD. In this context, we 
conducted a broad systematic review and meta-analysis to quantify the effect between sleep problems and 
disorders on cognitive impairment and AD. 
METHODS 
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We conducted this review in accordance with the step-by-step guide for systematic reviews and 
meta-analysis by Pai et al.,20 and adhered to the preferred reporting items for systematic reviews and 
meta-analyses (PRISMA) statement by Moher et al.,21 and the Cochrane handbook.22  
Identification of eligible studies 
Electronic search 
A broad search strategy was employed to identify all eligible published articles in scientific 
(medical, psychological and epidemiological) journals up to November 2014. This strategy combined 
terms characterizing clinical AD or AD pathology as the outcome variable, sleep, as the exposure 
variable, and a third set of terms specifying specific study types including cross-sectional, case control, 
cohort (retrospective and prospective), Randomized Clinical Trials (RCTs), literature reviews, systematic 
reviews, and ecological studies. All terms within each set were combined with the Boolean operator OR, 
and the three sets were combined using AND. Articles were identified by searching four bibliographic 
databases on November 21, 2014:  
• Medline (through PubMed; all years 1946 - present) 
• Embase (through www.embase.com by Elsevier B.V. 2011; all years from 1947 - present) 
• Web of ScienceTM (Thomson Reuters 2014; all years from 1900 – present)  
• Cochrane library (i.e., the Cochrane Central Register of Controlled Trials; all years from 1900 - 
present). 
Articles written in other languages other than English were also considered and screened with the help of 
Google translator. The PubMed search (see supplemental Table 2A in appendix) was adapted to 
searching the other databases. 
Searching other sources 
To locate additional relevant studies, the reference lists of articles identified through database 
searches and the bibliographies of narrative review articles were examined. We also hand-searched the 
previous year’s issues (November 2013 to November 2014) of high ranking journals that published more 
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than one relevant identified article during the initial search, for example Sleep Medicine Reviews, 
Neurology, JAMA (journal of American medical association), Sleep Medicine, Sleep, Journal of Sleep 
Research and Journal of Clinical Sleep Medicine. 
Selection criteria 
Type of studies 
Original articles from observational studies (cross-sectional, case-control and 
retrospective/prospective cohort) and randomized controlled trials (RCT) were included in this review.  
Eligible studies for the meta-analysis were required to: i) have reported a primary or secondary data 
analysis using any of the above mentioned study design of any association of sleep problems or disorders 
with cognitive impairment  or AD;  ii) have an explicit measure of cognitive impairment or AD (e.g. 
performance on individual cognitive tests, international classification of disease-9 (ICD -9), diagnostic 
statistical manual-IV text revision (DSM-IV TR)) or objective measures of Alzheimer pathology (e.g., 
positron emission tomography (PET) scan); iii) have an explicit or obvious measure of  sleep problems or 
disorders (e.g., Pittsburgh sleep quality index (PQSI)), Epworth sleepiness scale (ESS)) or objective 
measures (e.g., wrist actigraphy or polysomnography (PSG)); iv) study a comparison group without sleep 
problems or disorders in cohort studies; and v) provide sufficient data to quantify the  measure of 
association of sleep problems or disorders with cognitive impairment or AD. The following studies were 
excluded: i) case series, case reports, narrative reviews, abstracts or editorials, and ii) any RCT that did 
not examine the cognitive effects of treating sleep and its related problems or disorders in AD.  
Sleep problems and/or disorders 
Sleep problems and/or disorders were considered as the risk factor of interest in this systematic 
review. All sleep disorders described in the international classification of sleep disorders (ICSD-2)23 were 
considered. Previous studies24, 25 employed various concepts to define sleep problems in order to fit their 
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study design. Accordingly, for sub-group analysis, we grouped eligible studies in this review measuring 
sleep using parameters such as quality, efficiency and/or disturbance as sleep quality.  
 Alzheimer’s disease/cognitive impairment  
The outcomes of interest in this review were cognitive impairment or AD. AD is the most 
common form of dementia accounting for up to 50-80% of dementia cases.2 Studies that solely looked at 
specific forms of dementia other than AD, e.g., vascular, Lewy body, or frontotemporal dementia, were 
excluded. 
Participants and setting 
Participants of the included studies were middle aged and elderly adults of both sexes with age 
ranging from 40 – 91 years.  Studies were considered from multiple continents and no geographic 
restrictions were imposed.  
Data Extraction          
 An independent assessment of all titles and abstracts of eligible studies identified by the search 
strategy was performed by two authors (OB, OU) using EndNote X6. Potential articles for the study were 
retrieved and examined for possible inclusion by the same two authors. Discordant decisions regarding 
inclusion were resolved by two other authors (YS and YW). Data extraction was performed by two 
authors (OB, OU). Extracted fields included study design, study population, exposure and outcome 
assessment, statistical methods and tests used, covariates, and the main results of the study. Differences in 
the information extracted were resolved by two other authors (YS and YW). Reviewers were not blinded 
to the funding, authors, or institutions. 
Assessment of study quality 
Study quality was assessed using an adaptation from previous systematic reviews26, 27 and the 
modified version of the Newcastle-Ottawa scale (NOS) for quality assessment of the observational 
studies,28, 29 with addition of new items relevant to this review. Parameters used for the quality assessment 
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included well-specified hypothesis, study design type, appropriately described sample, sample size, 
definition of sleep and its related abnormalities, definition of cognitive impairment or AD, statistical 
analytic methods, and inclusion of or approach used to adjust for potential confounders. For each 
assessment category, a star rating system was used with specific maximum number of stars awarded (see 
supplemental table 2). Studies were divided into three categories: low quality (< 50% of the maximum 
number of stars), medium quality (≈ 55-70% of the maximum number of stars), and high quality (70% or 
more of the maximum number of stars). 
Statistical analysis 
This systematic review consisted of both binary and continuous outcomes. Effect sizes from the 
reviewed studies included odds ratios (OR), hazard ratios (HR), Pearson’s correlation coefficient (r), beta 
estimates (β) and standardized mean differences (d). To proceed with the meta-analysis, we converted the 
different indices to a common index: odds ratios (meta-analyses were computed using log (OR) but were 
converted back to odds for presentation) (see Table 2B in supplemental material). Conversions 
included converting from d to the log(OR) (Log(OR) = d
π
√ , where pi is the mathematical constant 
(approximately 3.14159)), converting from r to d (d = d

√ ), and converting from β to OR (exp(β) (see 
Table 2C in supplemental material).30 The question of whether or not it is appropriate to combine effect 
sizes from studies using varying metrics is under debate. We considered the fact that studies included in 
the review and subsequent analyses had to meet certain inclusion and exclusion criteria and were judged 
to be comparable in relevant ways. Since our aim was to compute a summary effect size of the impact of 
sleep problems on AD, we accounted for multiple outcome measures on the same subjects by computing 
the mean of the effect sizes for each study and used the average effect size as the unit of analysis (see 
Table 2D in supplemental material). For example, we pooled the effect estimates in a single study that 
had separate outcome measures using the mini mental state examination (MMSE) and the trail making B 
test (Trails B) on the same subjects.31 This influenced the calculation of the variance of the sum and mean 
effects of the correlated variables (see Table 2D in supplemental material). For our analysis, we worked 
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with a plausible range of correlations ranging from 0.5-1.0 and performed sensitivity analyses to find the 
most appropriate standard error range. Our method could only have overestimated the variance and 
underestimated the precision of our summary effect. Individual studies that examined the effect of sleep 
on AD on different populations were treated as independent.32-38 Re-analyses of reported effect estimates 
was conducted where appropriate in order to maintain consistency of definitions. For example, effect 
estimates for sleep duration of  ≤ 5 h, 6 h, and for <= 6.5 h were pooled to a single estimate for sleep 
duration of <= 6.5 h.32, 38, 39 Furthermore, we converted the risk estimate for better sleep consolidation to a 
risk estimate for poor sleep consolidation.40 Participants in the reviewed studies were between the ages of 
40 -91. Because the prevalence of AD in this population and in the general population is just under 5%,2 
no relevant artificial bias was introduced by pooling effects from cohort studies with effects from case-
control and cross-sectional studies.  Therefore, we will refer to the pooled effect estimates as relative 
risks, understanding that these are estimated in some studies. Effect estimates of all individual studies 
were pooled and relative risks (RR) and 95% confidence intervals (CI) were calculated using random 
effects models. Heterogeneity of results across studies was assessed using chi-square test and quantified 
using I-square statistics.41 Subgroup analyses were conducted to explore potential causes of heterogeneity. 
We anticipated heterogeneity and as such restricted subgroup analyses to situations where four or more 
studies were available per subgroup, because heterogeneity is better assessed with multiple studies.41 
Multivariate meta-regression analysis was also performed to examine the effect of possible influential 
factors (i.e., sex, mean age, sample size and study quality). We assessed for publication bias using a 
funnel plot asymmetry test and trim-and-fill. Additionally, the population attributable risk percent (PAR 
%), which estimates the percentage of the outcome (AD) that would be prevented in the population if the 
exposure (sleep problems or disorders) was eliminated, was calculated. All statistical analysis were 
conducted using metaphor in R42 and SAS® 9.4.43   
RESULTS 
Study Selection 
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Figure 1 shows the study retrieval and selection process for the effects of sleep on cognitive 
impairment and/or AD. Of the 2,341 publications identified initially from the literature search, 27 studies 
were included in the meta-analysis (Figure 1). A total of 1,120 duplicates were removed. The remaining 
1,221 publications were screened for titles resulting in the exclusion of 180 publications. After this 
exclusion, 1,041 publications were screened using published abstracts, resulting in the exclusion of 840 
publications that were either case series/reports, literature reviews, abstracts or editorials. Two hundred 
and one full text articles were assessed for eligibility and  130 publications (105 observational studies and 
25 RCTs) were further excluded because they were either review articles, did not provide any measure of 
association, were not peer reviewed or because sleep and AD were not assessed. One study was included 
from a search of the reference lists of articles identified through database searches. The remaining 72 
studies were selected for the systematic review. For the meta-analysis, 45 publications were further 
excluded because they lacked sufficient information needed for a meta-analysis, were duplicate studies 
presenting similar or exact information from same study population or had an experimental study design, 
leaving 27 studies with 52 effect estimates.   
Study characteristics 
Design and Quality 
Among the 27 studies identified for the meta-analysis, there were eight cross-sectional31, 37, 44-49 
one case-control.50 two retrospective cohort33, 51 and sixteen prospective cohort,32, 34, 36, 38-40, 52-61 (Table 1). 
Of these, 15 were considered to be of high quality, ten were of medium quality and two were of low 
quality. Selection bias related to sampling, measurements of sleep and/or AD solely based on self-report, 
and insufficient adjustment for core confounders were the main limitations.  All of the included articles in 
the meta-analysis were written in English and published in peer-reviewed journals. 
Participants and setting 
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The 27 studies included in the meta-analysis were published between 2001 and 2014 and included 
a total of 69,216 participants from four continents (Table 1). Pooled relative risks included 25 estimates 
from studies conducted in North America, 14 estimates from Europe, one from Australia, and four from 
Asia (Table 2). Twenty-one studies included both sexes, of which three had separate analysis for men and 
women, five were limited to women, and one was limited to men (Table 1). 
Sleep problems/disorders 
Sleep problems were based on a physician diagnosis (e.g. ICD-9 codes and apnea hypopnea index 
(AHI) scores for sleep apnea), or were assessed using self-reported questionnaires or interviews (Table 
1). There was considerable variability in the methods used to define and validate sleep problems. Nine 
studies utilized objective measures (e.g., wrist actigraphy or PSG), while seven studies utilized 
standardized questionnaires such as the PQSI or ESS. Five studies utilized self-constructed questionnaires 
and one study made use of fluorescence immune-assay (FIA) to determine melatonin/hypocretin 
concentrations.50 Most studies reported risk estimates for individual symptoms. Multiple symptoms were 
also assessed in some studies. Sleep parameters assessed included (but were not limited to)  sleep 
duration, sleep quality, daytime sleepiness, sleep latency, sleep efficiency, wake after sleep onset, sleep 
fragmentation, circadian rhythm abnormalities, obstructive sleep apnea, and insomnia. The interval over 
which sleep problems was assessed extended from about a week to a median of 12.5 years.32 
Cognitive impairment and/or Alzheimer’s disease  
There also was significant variability in the methods used to diagnose cognitive impairment or 
AD. Most studies used self-reported diagnoses with information collected to determine whether they 
likely met standardized criteria (e.g. (DSM-IV TR) (Table 2.1). Cognitive function was assessed by 
various global cognitive function and neuropsychological tests. Individuals were regarded as cognitively 
normal with Mini-Mental State Examination (MMSE) scores between 27 and 30, and a Clinical Dementia 
Rating of 0. For "Mild Cognitive Impairment," MMSE scores ranged from 22-27 according to a DSM-III-
119 
 
R definition (ICD-10: 23-28). Studies utilizing objective measures of Alzheimer pathology (e.g., PET 
scan for amyloid load (Aβ)) to examine associations between sleep and preclinical AD were also 
considered because we intended to also describe possible potential mechanisms showing that sleep is 
possibly associated with changes in AD biomarkers predictive of individuals who develop AD in 
subsequent sub-group analyses..                                                                                                                                                                          
Meta-analysis 
Overall meta-analysis based on risk estimates for the effect of sleep on cognitive impairment and 
Alzheimer’s disease  
Sleep problems including short and long sleep duration, poor sleep quality, circadian rhythm 
abnormality, insomnia and obstructive sleep apnea, were associated with a significantly increased relative 
risk (RR) for the combined outcome of cognitive impairment and AD of 1.68 (95% CI: 1.51-1.87) (Fig. 
2.2). The relative risks ranged from 1.0734 to 4.2549  with two low outliers; 0.56,61  and 0.76,32 and five 
high outliers 5.10,50 5.13, and 5.85,59 6.08,33 and 8.17.37 Removing these 7 outliers from the analysis had 
no significant effect on the pooled RR (RR: 1.62, 95% CI: 1.47-1.79). There was signiﬁcant heterogeneity 
among the effect sizes (I-square 64.50%, p < 0.001). The random-effects variance component was .05 
(95% CI: .023-.195).   A prediction interval that considers both sampling error and random-effects 
variance showed relative risk values ranging from 1.05 to 2.50.  Removal of the 7 outliers reduced 
heterogeneity but it remained statistically signiﬁcant (I-square 54.36%, p < 0.001), indicating that these 
outliers were not the sole source of heterogeneity.  
Sub-group meta-analysis based on risk estimates for the effect of sleep on cognitive impairment, Pre-
clinical and ICD9/DSMIV Diagnoses of Alzheimer’s disease  
Separate analyses of the studies in terms of the outcome measures were also conducted. Our 
outcome measures included the use of cognitive tests by studies examining sleep and the risks of 
cognitive impairment; the use of AD biomarkers or abnormal proteins by studies examining sleep and the 
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risk of preclinical AD; and the use of ICD9/DSMIV diagnoses of AD by studies examining the risk of 
sleep and symptomatic AD respectively. Sleep problems including short and long sleep duration, poor 
sleep quality, circadian rhythm abnormality, insomnia and obstructive sleep apnea, were associated with 
significantly increased relative risks of cognitive impairment (RR: 1.64, 95% CI: 1.45-1.87) ), preclinical 
AD (RR: 3.78, 95% CI: 2.27-6.30) and ICD9/DSMIV diagnoses of AD (RR: 1.55, 95% CI: 1.25-1.93) 
respectively (Fig. 2.3) These results highlight potential mechanistic relationships suggesting that sleep is 
not only associated with cognitive impairment, or symptomatic AD but is also associated with changes in 
AD biomarkers predictive of persons that ultimately develop AD. 
Funnel Plot Asymmetry Test and Trim and Fill Analysis Assessment of Publication Bias 
Regarding possible publication bias, a funnel plot asymmetry test was significant (z = 5.5109, p < 
.0001),62 indicating that some form of publication bias exist. Furthermore, a trim-and-fill analysis63 
(which aims both to identify and correct for funnel plot asymmetry arising from publication bias by 
essentially ‘trimming’ or removing the smaller studies causing funnel plot asymmetry, and then using the 
trimmed funnel plot to estimate the true ‘center’ of the funnel, while replacing the omitted studies and 
their missing ‘counterparts’ around the center (filling)) imputed 17 unpublished studies and conﬁrmed 
that in smaller studies, weaker effects were less often published (Fig. 2.4). The trim and fill method does 
not require any assumptions regarding mechanisms leading to bias in publication, rather it provides an 
estimate of the number of missing studies, and calculates an estimated effect ‘adjusted’ for the publication 
bias (based on the filled studies).  
Sub-group meta-analysis based on risk estimates for the effect of different sleep problems and 
disorders on cognitive impairment and Alzheimer’s disease  
Analyzing various sleep problems and disorders (Fig. 2.5), the highest relative risk for AD and/or 
cognitive impairment was noted for obstructive sleep apnea (OSA) (RR: 2.37, 95% CI: 1.82-3.08). The 
relative risk for cognitive impairment and/or AD associated with sleep quantity was 1.86 (95% CI: 1.34-
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2.57), while sleep quality was 1.62 (95% CI: 1.34-1.97). Insomnia (RR: 1.38 95% CI: 1.13-1.67) and 
circadian rhythm abnormalities (RR: 1.38, 95% CI: 1.18-1.61) were associated with the lowest relative 
risks. After excluding the outliers, the relative risk for cognitive impairment or AD associated with OSA, 
sleep quantity and sleep quality remained statistically significant (RR: 2.30, 95% CI: 1.59-2.41;  RR: 
1.72, 95% CI: 1.24-2.61 and RR: 1.51, 95% CI: 1.244-1.81 respectively).  
Subgroup analyses (Table 2.2) investigating various sleep parameters revealed that poor sleep 
efficiency was associated with the highest risk for cognitive impairment or AD, followed by sleep latency 
and wake after sleep onset (WASO). Nighttime problems were associated with the strongest measure of 
effect for cognitive impairment or AD, with smaller effects seen for night- and daytime problems. When 
examined separately, men and women with sleep problems including short and long sleep duration, poor 
sleep quality, circadian rhythm abnormality, insomnia and obstructive sleep apnea, each had similar 
relative risks.  The risk for cognitive impairment or AD due to sleep duration was higher in long sleepers 
(> 8 h/day) when compared to normal sleepers (7 – 8 h/day), than in short sleepers (≤ 7 h/day). Studies 
with ≥ 5 years of follow-up reported higher relative risks due to sleep problems including short and long 
sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia and obstructive sleep apnea, 
than those with < 5 years of follow-up. Studies from North America and Europe reported similar relative 
risks due to sleep problems. Prospective studies showed slightly lower relative risks than non-prospective 
studies, perhaps indicating a problem with temporality. Finally, the estimated risk for cognitive 
impairment or AD due to sleep problems was lower in the high-quality studies than in the low-quality 
studies. 
Sub-group meta-analysis based on risk estimates for the effect of self-report and actigraphic data of 
poor sleep on cognitive impairment and/or Alzheimer’s disease  
Furthermore, we analyzed studies that generated data on total sleep times (measured 
actigraphically) and examined these effects separately in relation to cognition from more generally 
defined poor sleep or self-reported sleep durations (Fig. 2.5).  The relative risk for cognitive impairment 
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or AD associated with self-reported poor sleep was 1.49 (95% CI: 1.26-1.76), while actigraphic report 
was 1.80 (95% CI: 1.56-2.09). These findings somewhat corroborate effects of self-reported sleep 
durations in relation to cognition examined in terms of actigraphic data. 
Exploring Potential Causes of Heterogeneity 
The overall meta-analysis included a wide array of studies including different measures with 
varying neurobiological substrates (breathing control in sleep, circadian rhythmicity, sleep durations, 
perceived sleep depth) as well as varying outcome measures of AD, including ICD9/DSM diagnoses, 
cognitive tests and abnormal proteins; and this could possibly be a potential source of heterogeneity. 
Therefore, we explored this and other potential causes for heterogeneity and conducted several subgroup 
meta-analyses (Figures 2.4-2.6 and Table 2.2) (also see Figures 2A-2C in supplemental material). The 
differences seen across the subgroups failed to account for significant amounts of heterogeneity except for 
the varying outcome measures of AD and sample size. However, tendencies could be observed. As 
sample size increased, the effect size decreased.  This agreed with the funnel plot. The varying outcome 
measures of AD accounted for 12.78% heterogeneity. Several of the other subgroup analyses were close 
to being statistically significant; however, there were only 52 effect sizes in the analysis, so power may 
have been an issue for some sub-analyses.  
Sensitivity Analyses 
Sensitivity analysis incorporating only studies that examined the relationship between sleep and 
cognitive impairment and/or symptomatic AD for the overall meta-analysis yielded a RR of 1.62 (95% 
CI: 1.45-1.80), suggesting that exclusion of studies that examined sleep associations with preclinical AD 
could reduce the overall effect size, however, the change in effect size was not statistically significant. 
Similarly, removing effect estimates of outliers from the analysis had no significant effect on the pooled 
RR (RR: 1.62, 95% CI: 1.47-1.79). Furthermore, exclusion of studies examining sleep associations with 
preclinical AD for the sub-group meta-analysis based on risk estimates for the effect of different sleep 
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problems and disorders on cognitive impairment and Alzheimer’s disease produced similar relative risks 
for the relationships between OSA, sleep quantity, sleep quality, insomnia and cognitive impairment 
and/or AD. 
Sensitivity analyses incorporating the 17 studies imputed by trim-and-fill showed an estimated 
relative risk of 1.42 (95% CI: 1.28-1.58), suggesting that bias could reduce the size of the effect, but is 
unlikely to explain it entirely. It should also be noted that the small sample, large effect size studies were 
mostly based on results of studies in which correlations were converted to odds ratios, so there may be a 
methodological explanation of funnel asymmetry other than bias. Altogether, the results support an 
association between sleep problems and cognitive impairment or AD. Despite possible publication bias 
and evidence of heterogeneity in the effect sizes, the overall association between sleep problems and 
cognitive impairment or AD remained positive in all sensitivity analyses. 
Furthermore, we clearly understand that testing for heterogeneity may not explain the variability 
in the data because its basis may not simply be empirical but more fundamentally conceptual, therefore 
we conducted several sensitivity analyses on both our exposure and outcome. Sensitivity analyses 
examining the effect of omitting one study revealed no effect as the estimated relative risk remained 
stable (See Fig. 2D in supplemental material). Sensitivity analyses were also conducted to see if all of 
the subcategories of exposure can be combined into one exposure. We examined the effect of the 
exposure on cognitive impairment and AD initially combined as presented in the overall meta-analysis 
(Fig. 2.2) and while excluding each subcategory (Sleep Quality, Sleep Quantity, Obstructive Sleep 
Apnea, Circadian Rhythm Abnormalities and Insomnia) from the exposure one at a time. No significant 
change in the effect size was seen. We also conducted separate analyses of studies in terms of the 
outcome measure since different outcome measures of cognitive impairment and AD was used. We 
conducted analyses with the combined outcome of cognitive impairment and AD and examined the 
change in the estimate while excluding each subcategory (cognitive tests, ICD-9/DSM IV and abnormal 
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proteins). No statistically significant difference was observed in the change in effect estimate. (Type I 
error rate (α=0.05)). 
Meta-regression analysis 
A multivariate meta-regression analysis (Table 2.3) was conducted to examine the potential 
inﬂuence of different factors on the natural logarithm of the odds ratio of sleep problems with cognitive 
impairment or AD. None of the studied factors was statistically signiﬁcant except for sample size (p = 
.01), with larger samples showing smaller effects.  
Population attributable risk percent 
The PAR% suggested that approximately 15% of AD may be attributed to sleep problems, using 
a conservative estimate of 30% as the prevalence of sleep problems in the populations of the included 
studies and the pooled relative risk (RR: 1.55). By comparison, the prevalence of sleep problems in AD 
ranges between 25% – 50%.11 
DISCUSSION 
Summary of the main results 
In the present meta-analysis comprising 27 studies, individuals with sleep problems including 
short and long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia and obstructive 
sleep apnea, had a 1.68 times higher risk for the combined outcome of cognitive decline and AD 
compared to individuals without sleep problems.  Individuals with sleep problems including short and 
long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia and obstructive sleep 
apnea, had a 1.55, 1.65 and 3.78 times higher risk for AD, cognitive impairment and preclinical AD than 
individuals without sleep problems respectively. A subgroup meta-analysis of classified sleep disorders 
revealed a relative risk of 2.37 for obstructive sleep apnea, 1.86 for sleep duration problems, 1.62 for 
sleep quality problems, and 1.38 for both insomnia and circadian rhythm abnormalities.  Various aspects 
of sleep problems examined in this analysis each significantly increased the risk for cognitive impairment 
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or AD. Approximately 15% of cognitive impairment or AD may be attributed to sleep problems including 
short and long sleep duration, poor sleep quality, circadian rhythm abnormality, insomnia and obstructive 
sleep apnea.  
Effect of sleep problems on cognitive impairment or Alzheimer’s disease (meta-analysis) 
Altogether, sleep problems including short and long sleep duration, poor sleep quality, circadian 
rhythm abnormality, insomnia and obstructive sleep apnea, signiﬁcantly increased cognitive impairment 
or AD risk. Our findings show a RR increase seemingly inverse to diagnostic confidence (e.g., 1.55, 1.65 
and 3.78 for AD, MCI and preclinical AD). These findings may reflect the use of more objective 
investigative or diagnostic measures to identify individuals with preclinical  AD in our study, however it  
highlights potential mechanistic relationships suggesting that sleep is not only associated with cognitive 
impairment, or symptomatic AD but is also associated with changes in AD biomarkers predictive of 
persons that ultimately develop AD. Although there was heterogeneity in effect sizes, the variables 
included in the meta-analysis failed to explain significant amounts of this variability. OSA appeared to be 
a strong risk factor for AD. This may be explained by the fact that hypoxia plays a vital role and may 
contribute to increases in Aβ production64, 65 thereby facilitating AD pathogenesis.66 Insomnia and 
circadian rhythm abnormalities were each associated with an intermediate risk for cognitive impairment 
or AD. Sleep quantity and quality seemed more important than insomnia and circadian activity rhythm as 
a risk factor for cognitive impairment or AD. This could be because individuals with insomnia and/or 
circadian rhythm abnormalities tend to have poor sleep quantity and quality, and as such the effect seen 
could possibly reflect other underlying sleep problems such that individuals in the sleep quantity or 
quality groups may also have associated insomnia and/or circadian rhythm abnormalities. Both long sleep 
(> 8 h/day) and short sleep duration (< 7 h/day) increased the risk for cognitive impairment or AD when 
compared to normal sleepers (7 – 8 h/day), with a higher risk seen in long sleepers. Although certain 
prospective studies have shown associations between long sleep and cognitive impairment,67, 68 it is highly 
plausible that this association is as a result of a general decline with old age and maybe reflective of other 
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disease conditions such as depression or other neurological disorders. AD patients, like in Parkinson’s 
disease, may also exhibit a more bimodal distribution of sleep patterns (i.e. short or long) possibly 
reflective of some pre-existing genetic predisposition that develops at disease inception. 
Potentially inﬂuencing factors (meta-regression analysis) 
The heterogeneity seen across studies could not be explained by our subgroup meta-analyses, 
except for sample size and the different AD measures. It is likely that much of the heterogeneity can be 
explained by the conceptual differences in exposure and/or outcome assessment. We explored this further 
by conducting several sensitivity analyses on both our exposure and outcome, each initially combined as 
presented in the overall meta-analysis and also with exclusion of each subcategory one at a time. No 
significant change in the effect size was seen. Sensitivity analyses examining the effect of omitting one 
study revealed no effect as the estimated relative risk remained stable. Several of the subgroup analyses 
were close to being statistically significant. However, since there were only 52 effect sizes in the analysis, 
power may have been an issue. Pooled relative risks from sub-group meta-analyses for the effect of sleep 
problems on cognitive impairment or AD revealed consistent moderate to strong relative risks and these 
relationships could possibly contribute to a causal interpretation of the ﬁndings. No RCT was included, 
suggesting that additional work examining the effect of sleep therapy on cognitive impairment or AD 
would be useful.   
Among the factors tested only sample size signiﬁcantly inﬂuenced the effect size between sleep 
problems and AD such that larger sample size studies tended to result in smaller risk estimates for 
cognitive impairment or AD while smaller sample size studies tended to result in larger risk estimates for 
cognitive impairment or AD (Table 3). Overall, the results indicate that the meta-analyzed estimate 
reﬂects an appropriate estimate of the general association. The need for proper multivariate modeling 
approaches is underscored by the fact that the heterogeneity due to adjustment was close to statistical 
signiﬁcance in some instances, although power was limited. 
Study results in comparison with other reviews on the topic 
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The results of this systematic review and meta-analysis are largely consistent with previous 
reviews. Our study is the ﬁrst systematic review and meta-analysis to quantify an “average” magnitude of 
the association between sleep problems and cognitive impairment or AD. Previous narrative review 
articles that have examined this association did so with a focus on different aspects of sleep 
disturbances/disorders16-19. Palma et al.,16 focusing on sleep deprivation, reviewed how sleep loss 
constitutes a risk factor for various neurologic diseases including AD. Slats et al.,18 focusing on the role of 
hypocretin and melatonin, concluded that there is substantial evidence for impairments in both sleep and 
circadian regulating mechanisms resulting from AD pathology, which may be linked to clinical 
symptoms. Peter-Derex et al.,17 performed a thorough clinical review of sleep and AD, observing that 
micro-architectural sleep alterations, nocturnal sleep fragmentation, decreased sleep duration, diurnal 
napping and inversion of the sleep-wake cycle are the main disorders observed in patients with AD. Spira 
et al.,19 concluded that poor sleep is a risk factor for cognitive impairment and AD and that healthy sleep 
appears to play an important role in maintaining brain health with age, and could play a key role in AD 
prevention. Various reviews69, 70 on the effect of OSA on AD agree on a bidirectional relationship 
between these entities.  
Strengths and Limitations of the study 
Our systematic review allows for a systematic, scientific, constructive and yet replicable review 
of the association between sleep and AD with a pre-specified hypothesis and specific inclusion and 
exclusion criteria. We were able to systematically and efficiently integrate existing information from 
various studies enabling us to establish whether the literature is consistent and can be generalized across 
populations, settings, and/or whether findings vary significantly by particular subsets. The meta-analyses 
in particular increased the power and precision of estimates of the risk of cognitive impairment or AD 
from sleep problems. The explicit methods employed in our meta-analysis limit bias and, hopefully, 
improved reliability and accuracy of our conclusions. Lastly, the generalizability of our findings can be 
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established as this review included a diversity of studies across various continents, providing an 
interpretive context not available in any one study.  
Several methodological concerns must be considered when interpreting the findings of this meta-
analysis. First, one potential limitation relates to the possible bias introduced in the paper selection 
process. To minimize this bias, we adhered strictly to the guidelines and recommendations in the 
Cochrane handbook 22 whenever possible. We also ensured that studies were not restricted by language to 
guard against language bias. Second, the possible bias introduced by the individual studies that were 
included is a further limitation. Various study designs were rated low for assigning the grade of 
evidence71. With a scarcity of controlled studies, this analysis relied mostly on observational studies. 
However, the subgroup meta-analysis revealed no significant difference between the prospective and non-
prospective studies, suggesting that our average estimate adequately reflects the general effect. In addition 
to study design, conclusions made from the poor quality studies could introduce possible bias. We 
included high, medium and low-quality studies in the summarization of findings. Our meta-regression 
analysis indicated that study quality might not have influenced the overall conclusion. Third, there was 
considerable variability between the studies in the assessment methods used to verify sleep problems and 
AD or cognitive impairment, revealing moderate heterogeneity that could possibly raise questions about 
the comparability of results across studies. Our research question focused on a broad concept of sleep 
problems based on having any symptoms. Thus, we assumed a common underlying concept by making 
general conclusions regarding sleep problems and cognitive impairment or AD. We based our assumption 
on findings from reviews that consistently found associations of various sleep problems or disorders such 
as sleep deprivation/loss,16, 19 sleep-wake abnormalities,17, 18 or sleep apnea,69, 70 with cognitive 
impairment or AD. Moreover, our sensitivity analyses on the exposure and outcome measures which 
involved examining the effect of sleep problems on cognitive impairment and AD with the exposure or 
outcome measures combined and separated into subcategories did not reveal any statistical significant 
change in the estimate. The persistence of heterogeneity in the subgroup meta-analysis of sleep 
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parameters and various sleep problems and disorders suggests within-study variation, possibly due to lack 
of objective assessment, standardization or success in controlling for psychiatric and somatic co-
morbidities. However, the prediction interval that considered both sampling error and study heterogeneity 
suggested that although the association may vary across studies, it appears to be positive in at least 97.5 
percent of them. Finally, although funnel plot asymmetry was consistent with publication bias, trim-and-
fill results were also positive; suggesting that our overall result might be an overestimate, but that the 
association does not appear to be explained by biased reporting of studies.  
Future directions   
Existing reviews note growing experimental and epidemiologic evidence for close reciprocal 
associations between cognitive impairment and sleep alteration.  However, longer-term longitudinal 
studies are required to better understand whether sleep problems precede the onset of cognitive 
impairment or AD by many years. Future studies need to be able to define causal pathways more 
definitively so we can test whether neurodegeneration is leading to both sleep changes and memory 
changes, or whether aging is contributing to OSA and/or sleep architecture changes that in turn affect 
memory, or whether the effect of aging on sleep architecture predisposes to both apnea and memory 
impairment. More research with objective sleep measures, AD biomarkers, and cognitive measures also 
are needed. To facilitate appropriate comparisons among studies, it would be expedient to have greater 
standardization of sleep and measures of cognitive impairment or AD. Future research is needed to make 
clear the contribution of different genetic, neurodegenerative and environmental factors to sleep 
impairment, as their findings can be promising for the development of new prevention and/or treatment 
opportunities.  
Conclusion  
This meta-analysis confirmed the association between sleep and cognitive impairmentor AD and, 
for the first time, consolidated the evidence by providing an “average” magnitude of the effect (RR=1.55, 
95% CI: 1.25-1.93). The public health relevance of this finding is buttressed by the PAR%, suggesting 
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that approximately 15% of cognitive impairment or AD might be prevented if effective interventions 
could be implemented to reduce sleep disorders.  
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Table 2.1.  Characteristics of included studies. Meta-analysis of sleep, cognitive decline and Alzheimer's disease/cognitive decline 
Authors, year Study design  
(study quality) 
Sample N  
(location) 
Study population, mean age/age 
range in years (follow-up time, 
years) 
Sleep assessment Cognitive/AD 
measures  
Impact of sleep problems/disorders 
on AD 
Benito-León et al.  
201432  
Prospective cohort 
(high) 
3,857  
(Spain)  
Community-dwelling elderly, 65  
(median,12.5) 
Daily total sleep duration 
(self-reported) 
Death 
certificates, 
ICD-9 
Long sleepers (≥ 9h), aHR=1.63 [1.04-
2.56]* Short sleepers (≤ 5h), aHR=0.76 
[0.33-1.74] 
Blackwell et al.  
200631  
Cross sectional 
(high) 
2,242  
(U.S.) 
Community-dwelling women, 83.5 
(N/A) 
Poor sleep (wrist 
actigraphy) 
MMSE, Trails 
B 
aOR=1.48 [1.44–1.52]*ˠ 
Blackwell et al.  
201451  
Prospective cohort  
(high) 
2822 
(U.S.) 
Community-dwelling men, 76, (3.4 ± 
0.5 y) 
Sleep quality (wrist 
actigraphy, PSQI, ESS).  
MMSE, Trails 
B 
aOR=1.44 [1.38, 1.51]*ˠ 
Chang et al.  
201333  
Retrospective cohort 
(high) 
8484  
(Taiwan) 
Sleep apnea patients. 40+ (5) Sleep apnea (ICD-9)  ICD-9   aHR=1.70 [1.26-2.31]*;                        
Females, aHR=2.38 [1.51–3.74]*;               
Males, 50-59 years, aHR=6.08 [3.15-
11.70]*; 2.5 to 5 y of follow-up, 
aHR=2.31 [2.07-2.58]*ˠ 
Cohen-Zion et al.  
200152  
Prospective cohort 
(Low) 
46  
(U.S.) 
Community-dwelling, 80    (2) Wrist actigraphy MMSE EDS, aOR=2.26 [1.21-4.20]*;                              
SA, aOR=4.04 [2.40-6.68]* 
Cricco et al.  
200134  
Prospective cohort 
(high) 
6,444  
(Iceland) 
Community-dwelling elderly, 72 (3)  Insomnia (self-reported)  SPMSQ Male non-depressed, aOR=1.33 [1.25-
1.42]*; Male depressed, aOR=1.89 
[1.60-2.23]*; Female non-depressed, 
aOR=1.07 [1.03-1.11]*;                                      
Female depressed, aOR=1.23 [1.16-
1.31]* 
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Foley et al.  
200153  
Prospective cohort 
(high) 
2,346  
(U.S.) 
Community-dwelling Japanese-
American men, 76.6 (3)  
Sleep disturbance (self-
reported) 
CASI, DSM-
IIIR.  
aOR=1.44 [1.34-1.54]* 
Hahn et al.  
201354 
Prospective cohort  
(high) 
214  
(U.S.) 
Community-dwelling elderly, 83.4  
(9) 
Poor sleep  (CPRS) DSM-IIIR 
NINCDS-
ADRDA  
aOR=1.78 [1.50-2.11]*ˠ 
Jelicic et al.  
200255 
Prospective cohort  
(medium) 
838  
(Netherlands) 
Community-dwelling elderly, 63.3 (3)  Poor sleep (self-reported)  MMSE aOR=1.46 [1.38-1.54]* 
Keage et al.  
201239 
Prospective cohort  
(high) 
2,012 
(Australia, 
U.K.)  
Community-dwelling elderly, 64-94 
(10)                                              
EDS (self-report)  MMSE aOR=2.09 [1.75-2.50]*ˠ 
Lim et al.  
2013a40 
Prospective cohort 
(medium) 
698  
(Canada) 
Community-dwelling elderly, 83.3 (6) Sleep consolidation 
(actigraphy) 
NINCDS-
ADRDA  
aHR=1.49 [1.39-1.60]* 
Lim et al.  
2013b36 
Prospective cohort  
(high) 
737  
(Canada) 
Community-dwelling elderly, 81.6 (6) Sleep fragmentation  
(actigraphy)  
Cognitive 
performance  
aHR =1.22 [1.03-1.44]*;                                        
Male, aHR=1.33 [0.90-1.96]*;                          
Female, aHR=1.29 [0.99-1.69]* 
Merlino et al.  
201044 
Cross-sectional  
(low) 
750  
(Italy) 
Institutionalized and community-
dwelling elderly, 76.7 (NA) 
Insomnia (self-report)  DSM-IV-TR, 
NINCS-
ARDRA, 
NINDS-
AIREN  
cOR=1.76 [1.02–3.11]* 
Nebes et al.  
200945 
Cross-sectional  
(medium)  
157  
(U.S.) 
Community volunteers, 72.2 (NA)  Sleep quality (PSQI)  RBANS 
TONI 
aOR=2.21 [1.88-2.59]* 
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Ooms et al.  
201461 
Randomized controlled  
trial (high) 
26  
(Netherlands) 
Middle-aged men, 49.9 (1 night) Sleep deprivation (PSG) CSF Aβ42, 
Aβ40, P-tau, 
T-tau  
aOR=5.06 [1.48-17.28]* 
Oosterman et al. 
200946 
Cross-sectional  
(medium) 
144  
(Netherlands) 
Cardiology/internal medicine 
outpatients, 69.5 (NA) 
Sleep fragmentation 
(actigraphy) 
Cognitive 
performance  
aOR=1.84 [1.60-2.12]* 
Osorio et al. 
201156 
Prospective cohort  
(high) 
346  
(U.S.) 
Brain aging study participants, 24-96 
(7.7) 
Insomnia (HAM-D) MMSE Insomnia, aOR=2.39 [1.03–5.55]*;                   
Insomnia w/o depression, aOR=3.32 
[1.33–8.28]* 
Osorio et al.  
201437 
Cross-sectional 
(medium) 
95  
(U.S.) 
Brain aging study participants, 67.7 
(NA) 
SDB (AHI ≥ 15). CSF P-tau, T-
tau, Aβ42  
aOR=4.46 [2.35-8.48]* 
Saint Martin et al.  
201247 
Cross-sectional  
(medium) 
272  
(France) 
Community-dwelling elderly, 74.8 
(NA) 
Sleep quality (PSQI) 
 
 
MMSE, 
GBSRT, 
BVRT, Trail 
A & B, 
WAIS-III, 
Stroop test, 
AFCFT  
aOR=1.65 [1.46-1.86]* 
Schmidt et al.  
201349 
Case-control  
(medium) 
66  
(Germany) 
Consecutive AD patients and controls, 
62.9 (NA) 
Melanin-concentrating 
hormone (MCH) and 
hypocretin-1 (HCRT-1, 
CERAD, 
WMS-R, Trail 
B, MRI, CSF 
aOR=5.1 [1.98-13.12]* 
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orexin-A) (fluorescence 
immunoassay (FIA)) 
Aβ42, Aβ40, 
P-tau, T-tau 
Spira et al.  
201348 
Cross-sectional  
(medium) 
70  
(U.S.) 
Normative aging study participants, 
76.4 (NA) 
 WHIIRS β-amyloid  Lower sleep quality, aOR=3.38 [2.05–
5.58]*; Insomnia, aOR=1.87 [1.19–
2.94]* 
Sterniczuk et al.  
201350 
Retrospective cohort 
(medium) 
28,697  
(Canada) 
Community-dwelling middle-aged 
and elderly, 64.6 (4.3) 
Sleep disturbance Index 
(SDI) (self-report)   
AD (self-
reported),  
aOR=1.18 [1.17-1.19]* 
Tranah et al.  
201157 
Prospective cohort  
(high) 
1,282   
(U.S.)  
Community-dwelling women, 82.7 
(4.9) 
CAR (actigraphy). Modified 
MMSE CVLT 
IQCODE, 
dementia 
(self-reported)  
aOR=1.66 [1.55-1.77]* 
Tworoger et al.  
200638 
Prospective cohort  
(medium) 
 1,844   
(U.S.) 
Community-dwelling women, 74.2 (2) Sleep duration (self-
reported) 
Cognitive 
performance  
  ≤ 6 h sleep, aOR=2.35 [1.90-2.91]*; 
Difficulty initiating sleep, aOR=2.21 
[1.84-2.65]*;                                                                                  
≥ 8 h sleep, a0R=1.31 [0.76-2.29] 
Virta et al.  
201358  
Prospective cohort  
(high) 
2,336  
(Finland) 
Elderly twins, 65+ (18-26) Poor sleep (self-reported) Linear 
cognitive 
score (self-
report) 
≤ 7 h sleep, aOR=4.15 [3.12–5.54]*;                     
Hypnotic use, aOR=1.23 [0.73–2.08] 
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Walsh et al.  
201459 
Prospective cohort  
(high) 
287  
(U.S.) 
Community-dwelling women, 82.8 (5) CAR (actigraphy) Modified 
MMSE 
CVLT, Trails 
B 
aOR=3.43 [1.74–6.75]* 
Yaffe et al.  
201160 
Prospective cohort  
(high) 
298  
(U. S.) 
Community-dwelling women, 82.3 
(2.3) 
SDB (AHI ≥ 15).  DSM-IV  Sleep-wake problems, aOR=1.09 
[0.90–1.32]ˠ; SDB  , aOR=1.87 [1.61–
2.18]*ˠ;                              Sleep 
duration, aOR=0.56 [0.46-0.67]*ˠ 
*: significant, ˠ:  multiple outcome measure on same subject, so mean of the outcome computed. Abbreviations; a: adjusted, Aβ40/42: amyloid beta-40/42, AD: Alzheimer's disease,  AFCFT: alphabetic fluency and category fluency 
tasks, AHI ≥ 15: apnea hypopnea index of 15 or more events per hour of sleep, APOE: apolipoprotein epsilon4,  BVRT: Benton visual retention test, c: crude, CAR: circadian activity rhythms, CASI: cognitive abilities screening 
instrument, CERAD: consortium to establish a registry for Alzheimer’s disease, CPRS: comprehensive psychopathological rating scale, CSF: cerebrospinal fluid,  CVLT:  California verbal learning test , DSM-IIIR/IV-TR: 
diagnostic and statistical manual of mental disorders, third edition/fourth edition, text revised, EDS: Excessive daytime sleepiness, ESS: Epworth sleepiness scale, GBSRT: Grober and Buschké selective reminding test, HAM-D: 
Hamilton Depression Rating Scale , HR: hazard ratio,  ICD-9/10: international classification of diseases ninth/tenth edition AD criteria,  IQCODE: informant questionnaire on cognitive decline in the elderly, , MMSE: mini mental 
state examination,  MRI: magnetic resonance imaging, N: number of participants, NA: not applicable, N/A: not available, NINCDS-ADRDA: national institute of neurological and communicative disorders and stroke and the 
Alzheimer's disease and related disorders association, NINDS-AIREN: national institute of neurological disorders and stroke and association internationale pour la recherché et l'enseignement en neurosciences vascular dementia 
criteria, OR: odds ratio,  PSG: polysomnography, PSQI: Pittsburgh sleep quality index,  P-tau: phosphorylated tau, RBANS: repeatable battery for the assessment of neuropsychological status, RR: relative risk, SDB: sleep 
disordered breathing, SPMSQ: short portable mental status questionnaire , TONI: test of nonverbal intelligence, Trails B:  trail making b test, T-tau: total-tau, WAIS-III: Wechsler adult intelligence scale third version, WHIIRS: 
women’s health initiative insomnia rating scale, WMS-R: Wechsler memory scale-revision 
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Table 2.2: Pooled relative risks from sub-group meta-analysis for the effect of sleep on Alzheimer's 
disease/cognitive decline 
Subgroup N Relative risk (95% CI) 
Sleep parameter 
Sleep Efficiency 7 1.98 (1.11, 3.52) 
Sleep Latency 4 1.33 (1.13, 1.57) 
Wake After Sleep Onset 7 1.26 (1.19, 1.33) 
Daytime vs. nighttime sleepiness 
Daytime Sleepiness 7 1.49 (1.17, 1.90) 
Nighttime problems 31 1.7 (1.48, 1.94) 
Night & Daytime problems 6 1.45 (1.17, 1.78) 
Gender 
Female 7 1.56 (1.24, 1.96) 
Male 13 1.49 (1.23, 1.79) 
Both male & female 24 1.74 (1.49, 2.03) 
Sleep duration 
Long sleepers > 8 hrs/day 6 2.05 (1.24, 3.38) 
Short sleepers ≤ 7 hrs/day 6 1.63 (1.13, 2.34) 
Follow-up time 
< 5 years 18 1.4 (1.23, 1.59) 
≥ 5 years 18 1.76 1.46, 2.112 
Classified sleep disorders 
Insomnia 11 1.5 (1.25, 1.80) 
Obstructive Sleep Apnea Syndrome 11 1.96 (1.59, 2.41) 
Circadian-Rhythm Sleep Disorders 8 1.38 (1.09, 1.75) 
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Sleep Depth (Not classified) 18 1.62 (1.38, 1.91) 
Continent 
North America 25 1.53 (1.35, 1.74) 
Europe 14 1.54 (1.27, 1.86) 
Australia 1 2.09 (1.16, 3.78) 
Asia 4 2.23 (1.60, 3.11) 
Temporality 
Prospective studies 36 1.57 (1.41, 1.77) 
Non-prospective studies 8 1.70 (1.44, 2.02) 
Study quality 
High quality 31 1.58 (1.40, 1.79) 
Medium quality 10 1.67 (1.32, 2.10) 
Low quality 3 2.17 (1.38, 3.41) 
Abbreviations N: Number of relative risk estimates, CI: confidence interval 
 
144 
 
Table 2.3: Results of meta-regression analysis examining potential effects of different factors on the natural logarithm of the odds ratio between 
sleep and Alzheimer's disease/cognitive decline 
Meta-regression variables 
Risk for Alzheimer's disease 
Univariable analysis Multivariable analysis 
Coef. p-Value Coef. p-Value 
Proportion of females (in %) -0.0004 0.8647 0.0007 0.7224 
Mean age (in years) -0.0022 0.7898 -0.0147 0.2287  
Sample size (in number of people) -0.000 0.0413 -0.000 0.0175 
Quality rating (in %) 0.1043 0.3046 0.0198 0.8721 
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Figure 2.1: Study retrieval and selection for effects of sleep on Alzheimer’s disease/cognitive decline 
meta-analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Studies identified through database searching (n = 2341) 
(PubMed=904, Embase=1026, Web of Science=305, Cochrane library=106) 
Studies after duplicates removed  
(n = 1221) 
Studies screened for titles  
(n = 1221) 
Studies excluded  
(n = 180) 
Full-text articles assessed for 
eligibility  
(n = 201) 
Full-text articles excluded, with 
reasons (n = 130) 
- Review article (n = 7) 
- No risk estimate (n = 17) 
- Sleep not assessed (n = 18) 
- Relationship not studied (n = 
53) 
- Not peer reviewed (n = 10) 
- Alzheimer not examined (n 
= 25) 
 
Studies included in systematic 
review  
(n = 72) 
Studies included in meta-
analysis  
(n = 27) 
Article identified from reference 
search  
(n = 1) 
Studies screened for abstracts 
(n = 1041) 
Studies excluded  
(n = 840) 
Duplicates removed  
(n = 1120) 
Studies excluded from analysis, with 
reasons (n = 45) 
- Study design (n = 16) 
- Duplicate studies (n = 
12) 
- Insufficient 
information for a meta-
analysis (n = 17) 
 
146 
 
Figure 2.2   Study retrieval and selection for effects of sleep on cognitive decline and/or Alzheimer’s 
disease meta-analysis                     
 
 
Abbreviations: EDS, excessive daytime sleepiness; RR, relative risk; SA, sleep apnea; SDB, sleep disordered breathing; TST, total sleep time; 
WASO, wake after sleep onset; w/D, with depression; w/o D, without depression; w/o, without 
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Figure 2.3:  Forest plot presenting sub-group meta-analysis based on risk estimates for the effect                       
of sleep on Cognitive decline, Pre-clinical and Symptomatic Alzheimer’s disease  
 
Abbreviations: EDS, excessive daytime sleepiness; RR, relative risk; SA, sleep apnea; SDB, sleep disordered breathing; TST, total sleep time; 
WASO, wake after sleep onset; w/D, with depression; w/o D, without depression; w/o, without 
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Figure 2.4*: Trim and fill funnel plot for effects of sleep on Alzheimer’s disease/cognitive decline meta- 
analysis 
 
 
*Filled dots represent published studies. Empty dots represent unpublished and/or imputed studies 
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Figure 2.5 Forest plot presenting sub-group meta-analysis based on risk estimates for the effect                          
of different sleep problems and disorders on cognitive decline and/or Alzheimer’s disease  
  
Abbreviations: EDS, excessive daytime sleepiness; RR, relative risk; SA, sleep apnea; SDB, sleep disordered breathing; TST, total sleep time; 
WASO, wake after sleep onset; w/D, with depression; w/o D, without depression; w/o, without 
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Figure 2.6:  Forest plot presenting sub-group meta-analysis based on risk estimates for the effect                           
of self-report versus actigraphic data of poor sleep on cognitive decline and/or Alzheimer’s disease  
 
 
Abbreviations: EDS, excessive daytime sleepiness; RR, relative risk; SA, sleep apnea; SDB, sleep disordered breathing; TST, total sleep time; 
WASO, wake after sleep onset; w/D, with depression; w/o D, without depression; w/o, without 
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APPENDIX A 
SUPPLEMENTAL TABLES AND FIGURES: SLEEP AND AD META-ANALYSIS 
 
Table 1A: Main findings from included studies and comments regarding computed conversions of the different indices to a common index: odds ratios and regarding 
computing a summary effect size of the impact of sleep problems on AD 
Authors, year, reference 
number, (country) 
Study Main Findings Comments for conversion 
Impact of sleep problems/disorders on 
Alzheimer's disease 
Benito-León et al. 2014,32 
(Spain)  
Long sleepers (≥ 9h)       aHR=1.63 [1.04-2.56]                                            
Short sleepers (≤ 5h)      aHR=0.76 [0.33-1.74] 
No conversions and/or mean computation 
done 
Long sleepers (≥ 9h), aHR=1.63 [1.04-2.56]*                         
Short sleepers (≤ 5h), aHR=0.76 [0.33-1.74] 
Blackwell et al. 2006,31 
(United States) 
Sleep efficiency (MMSE)          aOR=1.61 [1.20–2.16],               
Sleep efficiency (Trails B)         aOR=1.96 [1.43–2.67],                         
Sleep latency (MMSE)              aOR=1.23 [1.13–1.33];                         
Sleep latency (Trails B)             aOR=1.13 [1.04–1.24],                      
WASO (MMSE)                        aOR=1.15 [1.06–1.23];               
Sleep latency (Trails B)              aOR=1.24 [1.15–1.34].                   
Napping (MMSE)                      aOR=1.42 [1.05–1.93];                 
Napping (Trails B)                     aOR=1.74 [1.26–2.40].  
We accounted for multiple outcome 
measures on the same subjects by 
computing the mean of the effect sizes 
for each study and used the average effect 
size as the unit of analysis 
aOR=1.44 [1.07–1.94]*ˠ 
Blackwell et al. 2014,51 
(United States) 
Sleep efficiency (Trails B)         aOR=1.53 [1.07, 2.18];                    
WASO                                       aOR=1.47 [1.09, 1.98];               
LWEP                                        aOR=1.38 [1.02, 1.86].              
3MS:LWEP                               aOR=1.36 [1.09, 1.71]  
We accounted for multiple exposure 
measures on the same subjects by 
computing the mean of the effect sizes 
for each study and used the average effect 
size as the unit of analysis 
aOR=1.48 [1.17, 1.88]*ˠ;  
Chang et al. 2013,33 
Taiwan 
SA                                                aHR=1.70 [1.26-2.31]                   
Females                                         aHR=2.38 [1.51–3.74]                                 
Males 50-59 years                       aHR= 6.08 [1.96-18.90],                         
Females ≥ 70 years                      aHR=3.20 [1.71–6.00].                           
First 2.5 years of follow-up         aHR: =2.04 [1.35-3.07].                       
5 years of follow-up                      aHR=1.70 [1.26-2.31] 
No conversions and/or mean computation 
done for separate populations and 
measures. Follow-up time measures were 
on the same subjects as such we 
computed the mean of the effect sizes and 
used the average effect size as the unit of 
analysis 
aHR=1.70 [1.25-2.31]*;                                                         
Females, aHR=2.38 [1.51–3.74]*;                                                  
Males, 50-59 years, aHR=6.08 [1.96-18.90]*;                                       
2.5 to 5 y of follow-up, aHR=2.31 [1.45-3.69]*ˠ 
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Cohen-Zion et al. 2001,52 
United States 
Increased RDI (t=-2.17, 42 df, r=-0.32, P=.036)                                         
Increased EDS (t=-3.32, 42 df,  r=-0.46, P=.002)                                        
EDS (t39  = -2.45, r=-0.37, P= .019)-Adjusted model 
RDI (t39=- 0.66, r=-0.11, P=.515)-Adjusted model 
Converted from r to d (d = d2r/√(1-r^2 ) ) 
and from d to the log(OR) (Log(OR) = 
dp/√3 and mean computation done for 
separate populations  
SA, aOR=2.26 [0.75-6.80];                                                    
EDS, aOR=4.04 [1.48-11.06]* 
Cricco et al. 2001,34 
Iceland 
Non-depressed men chronic insomnia       aOR=1.49 
[1.03–2.14]                                                                         
Non-depressed men incident insomnia      aOR=1.16 
[0.82–1.65]                                                                         
Depressed men incident insomnia               aOR=1.60 
[0.87-2.95]                                                                        
Depressed men chronic insomnia                aOR=2.18 
[1.30-3.67]                                                                                      
Non-depressed women chronic insomnia  aOR=1.18 
[0.92–1.52]                                                                                 
Non-depressed women incident insomnia aOR=0.95 
[0.71–1.26]                                                                                     
Depressed women incident insomnia          aOR=1.10 
[0.75-1.61]                                                                          
Depressed women chronic insomnia           aOR=1.36 
[1.01-1.84] 
We accounted for multiple exposure 
measures on the same subjects by 
computing the mean of the effect sizes 
for each study and used the average effect 
size as the unit of analysis for each 
population 
Male non-depressed, aOR=1.33 [0.93-1.90]ˠ;                             
Male depressed, aOR=1.89 [1.07-3.34]*ˠ;                                      
Female non-depressed, aOR=1.07 [1.03-1.11]*ˠ;                                                               
Female depressed, aOR=1.23 [0.87-1.73]ˠ;  
Foley et al. 2001,53 United 
States 
Excessive daytime sleepiness DSM-IIIR    aOR=2.19 
[1.37–3.50]                                                                          
Excessive daytime sleepiness                                                  
CASI            aOR=1.44 [1.01–2.08].                                      
Insomnia DSM-IIIR       aOR=0.99 [0.70-1.41]             
Insomnia CASI              aOR=1.14 [0.91-1.43] 
We accounted for multiple exposure 
measures on the same subjects by 
computing the mean of the effect sizes 
for each exposure category and used the 
average effect size as the unit of analysis 
EDS: aOR=1.82 [1.19-2.79]*                                                  
Insomnia: aOR=1.07 [0.81-1.42] 
Hahn et al. 2013,54 United 
States 
Reduced sleep (Dementia)a      aHR=1.75 [1.04-2.93]                           
Reduced sleep (AD)a                aHR=2.01 [1.12-3.61]                 
Reduced sleep (Dementia)b      aHR=1.50 [0.87-2.59]                      
Reduced sleep (AD)b                aHR=1.69 [0.91-3.14]                 
Reduced sleep (Dementia)c      aHR=1.73 [1.02-2.91]                
Reduced sleep (AD)c                aHR=2.02 [1.11-3.65]               
Reduced sleep (Dementia)d      aHR=1.68 [0.98-2.86]                      
Reduced sleep (AD)d                aHR=1.86 [1.00-3.70]  
We accounted for multiple outcome 
measures on the same subjects by 
computing the mean of the effect sizes 
for each study and used the average effect 
size as the unit of analysis 
aOR=1.78 [0.86-3.70]ˠ 
Jelicic et al. 2002,55 The 
Netherlands 
Overall sleep problems continuous scores β=-0.05 (-
0.09,-0.00)                                                                                    
Overall sleep problems dichotomized scores β=-0.38 (-
0.71,-0.05) 
Converted from β to OR  aOR=1.46 [1.05-2.03]* 
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Ju et al. 2013, United 
States 
Sleep efficiency                OR=5.60 [0.97- 32.5] 
No conversions and/or mean computation 
done 
OR=5.60 [0.97- 32.5] 
Keage et al. 2012,39 
Australia, & United 
Kingdom  
Napping (2years)         aOR=0.38 [0.22–0.67].                 
Napping (10years)       aOR=0.48 [0.29–0.78].                    
Sleep duration (<= 6.5 h 10years)   aOR=2.02 [1.17–
3.48]                                                                                             
Sleep duration (>= 9 h 10years) aOR=1.27 [0.64-2.48]                     
Daytime sleepiness (10 years)    aOR=2.43 [1.24–4.75]. 
We accounted for multiple exposure 
measures on the same subjects by 
computing the mean of the effect sizes 
for each exposure category and used the 
average effect size as the unit of analysis 
Sleep Quality: aOR=1.10 [0.58-2.07]ˠ                                          
<= 6.5h sleep: aOR=2.02 [1.17-3.48]*ˠ;                                          
>= 9h sleep: aOR=1.27 [0.65-2.48]ˠ;  
Lim et al. 2013a,40 Canada  Better Sleep consolidation         aHR 0.67 [0.46-0.97]  
We converted the risk estimate for better 
sleep consolidation to a risk estimate for 
poor sleep consolidation 
aHR=1.49 [1.02-2.17]* 
Lim et al. 2013b,36 Canada 
Sleep fragmentation             aHR =1.22 [1.03-1.44]                        
Male                                     aHR=1.33 [0.90-1.96]                             
Female                                  aHR=1.29 [0.99-1.69] 
No conversions and/or mean computation 
done 
aHR =1.22 [1.03-1.44]*;                                                                   
Male, aHR=1.33 [0.90-1.96];                                                    
Female, aHR=1.29 [0.98-1.69] 
Merlino et al. 2010,44 Italy Excessive daytime sleepiness OR=1.76 (1.02–3.11) 
No conversions and/or mean computation 
done 
cOR=1.76 [1.02–3.11]* 
Nebes et al. 2009,45 United 
States 
Sleep latency correlated the RBANS (r = −.241, p = 
.002)          Sleep latency correlated the TONI (r = −.258, 
p = .001).            Sleep efficiency correlated with the 
RBANS (r = .185, p = .020), Sleep efficiency correlated 
with the TONI (r = .197, p = .013), Sleep efficiency 
correlated with the N-Back (r = .211, p = .008).  
Converted from r to d (d = d2r/√(1-r^2 ) ) 
and from d to the log(OR) (Log(OR) = 
dp/√3 and computed the mean of the 
effect sizes for each study and used the 
average effect size as the unit of analysis 
aOR=2.21 [1.26-3.87]* 
Oosterman et al. 2009,46 
Netherlands 
Fragmentation of the sleep-wake rhythm (Mental: r =-
0.16, Memory: - 0.19, andExecutive: - 0.16 respectively)  
Converted from r to d (d = d2r/√(1-r^2 ) ) 
and from d to the log(OR) (Log(OR) = 
dp/√3 and computed the mean of the 
effect sizes for each study and used the 
average effect size as the unit of analysis 
aOR=1.84 [1.09-3.11]* 
Osorio et al. 2011,56 
United States 
Insomnia                                        aOR=2.39 [1.03–5.55].       
Insomnia without depression        aOR=3.32 [1.33–8.28].  
No conversions and/or mean computation 
done 
Insomnia, aOR=2.39 [1.03–5.55]*;                                          
Insomnia w/o depression, aOR=3.32 [1.33–
8.28]* 
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Osorio et al. 2014,37 
United States 
In ApoE3+ subjects, significant differences were found 
between sleep groups for p-tau (F[df2] = 4.3, p =0.017), 
and t-tau (F[df2] = 3.3, p = 0.043). Additionally, among 
ApoE3+ subjects, the apnea and/or hypopnea with 4% 
O2-desaturation index was positively correlated with p-
tau (r = 0.30, p = 0.023), t-tau (r = 0.31, p = 0.021), and 
Aβ-42 (r = 0.31, p = 0.021). In ApoE2+ subjects, the 
apnea and/or hypopnea with 4% O2-desaturation index 
was correlated with lower levels of CSF Aβ-42 
(r = −0.71, p = 0.004), similarly to ApoE4+ subjects 
where there was also a trend toward lower CSF Aβ-42 
levels. 
Converted from r to d (d = d2r/√(1-r^2 ) ) 
and from d to the log(OR) (Log(OR) = 
dp/√3 and computed the mean of the 
effect sizes for each study population and 
used the average effect size as the unit of 
analysis 
ApoE3+ subjects: aOR=3.20 [1.18-8.66]*                                      
ApoE2+ subjects: aOR= 8.17 [1.96-34.07]*  
Saint Martin et al. 2012,47 
France 
PSQI correlated with the MMSE (r = -0.14, p = .03)                                     
Sleep Quality correlated with Delayed free recall (r = -
0.14, p < .05)   
Converted from r to d (d = d2r/√(1-r^2 ) ) 
and from d to the log(OR) (Log(OR) = 
dp/√3 and computed the mean of the 
effect sizes for each study and used the 
average effect size as the unit of analysis 
aOR=1.65 [1.02-2.68]* 
Schmidt et al. 2013,49 
Germany 
A significant main effect of diagnosis (F(1,62) = 8.490, 
p<0.01) on MCH levels was found between AD (93.76 ± 
13.47 pg/mL) and HS (84.65 ± 11.40 pg/mL). MCH 
correlated with T-tau (r = 0.47; p<0.01) and P-tau (r = 
0.404; p,0.05) in the AD but not in the HS. CSF-MCH 
correlated negatively with MMSE scores in the AD (r = -
0.362, p<0.05) and was increased in more severely 
affected patients (MMSE ≤ 20) compared to HS 
(p<0.001) and Behavioral and Psychological Symptoms 
of Dementia (BPSD) positive patients compared to HS 
(p<0.05). In CSF-HCRT- 1, a significant main effect of 
sex (F(1,31) = 4.400, p<0.05) with elevated levels in 
females (90.93 ± 17.37 pg/mL vs. 82.73 ± 15.39 pg/mL) 
was found whereas diagnosis and the sex*diagnosis 
interaction were not significant. 
Converted from r to d (d = d2r/√(1-r^2 ) ) 
and from d to the log(OR) (Log(OR) = 
dp/√3 and computed the mean of the 
effect sizes for each study and used the 
average effect size as the unit of analysis 
aOR=5.1 [1.31-19.89]* 
Spira et al. 2013,48 United 
States 
Shorter sleep duration                                                                         
Mean cortical DVR (B = 0.08 [95% CI, 0.03-0.14]; r 
=.38; P = .005) Mean precuneus DVR (B = 0.11 [0.03-
0.18]; r =.36; P = .007).         Lower sleep quality                                                                        
Mean cortical DVR (B = 0.04 [95% CI, -0.01-0.09]; r 
=.19; P = .13) Mean Precuneus DVR (B = 0.08 [0.01-
0.15]; r=.29; P = .03). WHIIRS, Women’s Health 
Initiative Insomnia Rating Scale           Mean cortical 
DVR (B = 0.01 [95% CI, -0.004-0.02]; r =.16; P=.23) 
Mean Precuneus DVR(B = 0.01 [95% CI, -0.004-0.02] 
r=.18; P=.16). 
Converted from β to OR Converted from 
r to d (d = d2r/√(1-r^2 ) ) and from d to 
the log(OR) (Log(OR) = dp/√3 and 
accounted for multiple exposure 
measures on the same subjects by 
computing the mean of the effect sizes 
for each study and used the average effect 
size as the unit of analysis 
Sleep duration, aOR= 4.25 [1.52-11.88]*ˠ;                               
Lower sleep quality, aOR=2.51 [0.96–6.56]ˠ;                               
Insomnia, aOR=1.87 [0.73–4.80]ˠ  
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Sterniczuk et al. 2013,50 
Canada 
SDI           aOR=1.23 [1.11-1.36]                                                               
SDI           aOR=1.12 [1.00-1.25] 
We accounted for multiple outcome 
measures on the same subjects by 
computing the mean of the effect sizes 
for each study and used the average effect 
size as the unit of analysis 
aOR=1.18 [1.06-1.31]*ˠ;  
Tranah et al. 2011,57 
United States 
Decreased activity rhythms      aOR=1.57 [1.09–2.25]                     
Rhythm robustness                   aOR=1.57 [1.10–2.26]                             
Peak Activity timing                 aOR=1.83 [1.29–2.61]  
We accounted for multiple outcome 
measures on the same subjects by 
computing the mean of the effect sizes 
for each study and used the average effect 
size as the unit of analysis 
aOR=1.66 [1.16-1.31]*ˠ;  
Tworoger et al 2006,38 
United States 
<=5hrs of sleep aOR=2.19 (1.10-4.39)                                                            
6hrs of sleep aOR=1.01 (0.61-1.67)                                                            
8hrs of sleep aOR=1.16 (0.74-1.82)                                                          
>=9hrs of sleep aOR=1.46 (0.77-2.76)                                                   
TICS aOR=2.51 (1.38, 4.54) Women who regularly had 
difficulty falling or staying asleep                                                         
TICS (aOR: 1.85, 95% CI: 1.04, 3.30) global score 
(aOR: 2.57, 95% CI: 1.39, 4.74) TICS (Telephone 
Interview of Cognitive Status)                     
We accounted for multiple exposure 
measures on the same subjects by 
computing the mean of the effect sizes 
for each exposure category and used the 
average effect size as the unit of analysis 
≤ 6 h sleep, aOR=1.68 [0.92-3.08]ˠ;                                          
Difficulty initiating sleep, aOR=2.21 [1.22-
4.01]*ˠ;                                                                                   
≥ 8 h sleep, a0R=1.30 [0.71-2.39]ˠ;  
Virta et al 2013,58 Finland,   
Sleep Length (N=2328)                                                                     
Sleep Length (< 7 h/day) (β = -0.84 (-1.51,-0.17), P = 
0.014                                                                                          
Sleep Length (< 7 h/day) (β = -0.79 (-1.44,-0.14), P = 
0.019 and Sleep Length (> 8 h/day) (β = -1.66 (-2.37,-
0.95) P < 0.001                                                                         
Sleep Length (> 8 h/day) (β = -1.61 (-2.33,-0.91) P < 
0.001.                                                                                      
Poor sleep quality (β = -1.00 (-1.77,-0.23) P = 0.011.                 
Poor sleep quality (β = -0.89 (-1.69,-0.09) P = 0.028                    
The use of hypnotics ≥ 60 days per year (β = -1.92 (-
3.11,-0.73), P = 0.002). The use of hypnotics ≥ 60 days 
per year (β = -1.58 (-2.75,-0.41), P = 0.008).                                                                           
Model 1 adjusted for age, sex, education, ApoE status, 
and follow-up.                                                                                                       
Model 2 adjusted for life satisfaction, obesity, 
hypertension, physical inactivity, heavy drinking, and 
binge drinking in addition to the factors adjusted for in 
Model 1 
We accounted for multiple exposure 
measures on the same subjects by 
computing the mean of the effect sizes 
for each exposure category and used the 
average effect size as the unit of analysis 
≤ 7 h sleep, aOR=2.26 [1.17–4.38]*ˠ;                                                    
>=8 h sleep, aOR=5.13 [2.51-10.49]*ˠ;                                                                
Sleep quality, aOR=3.72 [2.45-5.65]*ˠ;                                                              
Hypnotic use, aOR=5.85 [1.80–19.03]*ˠ  
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Walsh et al 2014,59 United 
States  
Women lowest vs. highest quartile                                                   
CAR amplitude (group difference (d) = 30.42 sec, d = -
1.01 words respectively, P < 0.05).                                                                                          
Categorical fluency mesor (d = -0.86 words, P < 0.05). 
Women Categorical fluency later acrophase categorical 
fluency (d = -0.69 words, P < 0.05).                                                                 
Controlling for baseline Mini-Mental State Examination 
and sleep factors had negligible effects on the results. 
Converted from d to the log(OR)  aOR=3.43 [1.08–10.85]* 
Yaffe et al. 2011,60 United 
States 
SDB (Women)      aOR=1.85 [1.11-3.08].                              
AHI (≥15 events/hour)    aOR=1.71 [1.04 − 2.83]        
>7% of sleep time in apnea/hypopnea    aOR=2.04 [1.10 
− 3.78] respectively).                                                                                            
Sleep Fragmentation   Mild     aOR=0.54 [0.29-0.98]        
Sleep Fragmentation   High     aOR=0.58 [0.32-1.07]             
WASO       Mild                       aOR=1.17 [0.63-2.19]      
WASO       High                       aOR=1.79 [0.97-3.29]           
Sleep Duration  Mild                 aOR=0.58 [0.31-1.09]          
Sleep Duration  High                aOR=0.83 [0.46-1.51]  
We accounted for multiple exposure 
measures on the same subjects by 
computing the mean of the effect sizes 
for each exposure category and used the 
average effect size as the unit of analysis 
Sleep Fragmentation, aOR=0.56 [0.31-1.02]ˠ 
WASO, aOR=1.48 [0.80–2.74]ˠ;                                                                      
SDB  , aOR=1.87 [1.08–23.23]*ˠ;                                                           
TST, aOR=0.71 [0.37-1.35]ˠ  
*: significant, ˠ:  multiple exposure/outcome measure on same subject, so mean of the outcome computed. Abbreviations; a: adjusted, AD: Alzheimer's disease,  APOE: apolipoprotein epsilon4,  c: crude, 
CAR: circadian activity rhythms, CASI: cognitive abilities screening instrument, MMSE: mini mental state examination,  OR: odds ratio,  PSG: polysomnography, PSQI: Pittsburgh sleep quality index, 
RR: relative risk, SDB: sleep disordered breathing, Trails B:  trail making b test, TST: total sleep time, WASO: wake after sleep onset,  
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Table 2A: Formula used for converting among effect sizes and for calculating the variance of the 
effect sizes 
Converting Among Effect 
Sizes* 
Formula Variance Formula** 
Converting from d to the log 
odds ratio 
Log(OR) = d
π
√ , where pi is 
the mathematical constant 
(approximately 3.14159) 
The variance of 
Log(OR) would then be 
 
	
() =  	 π

3  
Converting from r to d d = d

√ The variance of d computed in this way (converted from r) 
is 
 
	 =  4	(1 −   ) 
Converting from d to r r = 

√ , where a is a 
correction factor for cases 
where n1 ≠ n2, 
 
a = 
( )
      
The correction factor (a) 
depends on the ratio of n1 to 
n2, rather than the absolute 
values of these numbers. 
Therefore, if n1 and n2 are 
not known precisely, use n1= 
n2, which will yield a=4. 
The variance of r computed in 
this way (converted from d) is 
 
	 =  
 	( + ) 
Converting from the log odds 
ratio to d 
d = Log(OR)* √
π
 	 = 	
() ∗ √
π
 
converting from β to OR exp(β) N/A 
 
*Effect sizes from the reviewed studies included odds ratios (OR), hazard ratios (HR), Pearson’s correlation coefficient (r), beta 
estimates (β) and standardized mean differences (d). To proceed with the meta-analysis, we converted the different indices to a 
common index: odds ratios (meta-analyses were computed using Log(OR) but were converted back to OR for presentation).               
** Reference #30 in manuscript: Borenstein Michael HLV, Higgins J. P. T., Rothstein H.R. Introduction to Meta-Analysis. : John 
Wiley & Sons, Ltd.; © 2009 
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Table 3A: Formula used for computing the variance of a composite or a difference  
Computing the variance of a composite or 
a difference* 
Formula** 
The variance of the sum of two correlated 
variables 
If we know that the variance of Y1 is V1 and 
the variance of Y2 is V2, then 
Var (! +  !) =  	 +  	 + 2#	#	  
Where r is the correlation coefficient that 
describes the extent to which Y1 and Y2 co-
vary. If Y1 and Y2 are inextricably linked (so 
that a change in one determines completely 
the change in the other), then r =1, and the 
variance of the sum is roughly twice the sum 
of the variances. At the other extreme, if Y1 
and Y2 are unrelated, then r=0 and the 
variance is just the sum of the individual 
variances. 
 
The variance of the mean of two correlated 
variables 
Var $  (! +  !)% =  &'

 Var (! +  !) =
 (  )	 +  	 + 2#	#	 * 
The variance of the mean of several correlated 
variables 
var& +  ∑ !-+-. '= & +'
 
var)∑ !-+-. *= 
& +'
 /∑ 	-+-. + ∑ /-0 1	- #	02- 30 2 
The variance of the difference between two 
correlated variables 
If we know that the variance of Y1 is V1 and 
the variance of Y2 is V2, then 
Var (! −  !) =  	 +  	 − 2#	#	  
 
 
*Since our aim was to compute a summary effect size of the impact of sleep problems on cognitive decline and Alzheimer’s 
disease, we accounted for multiple exposure or outcome measures on the same subjects by computing the mean of the effect sizes 
for each study and used the average effect size as the unit of analysis. This influenced the calculation of the variance of the sum 
and mean effects of the correlated variables. For our analysis, we worked with a plausible range of correlations ranging from 0.5-
1.0 and performed sensitivity analyses to find the most appropriate standard error range.                                                                             
** Reference #30 in manuscript: Borenstein Michael HLV, Higgins J. P. T., Rothstein H.R. Introduction to Meta-Analysis. : John 
Wiley & Sons, Ltd.; © 2009 
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Figure 1A Forest plot presenting sub-group meta-analysis based on continent in which study                           
was published for the effect of sleep problems and disorders on cognitive decline and/or Alzheimer’s 
disease                        
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Figure 2A:  Forest plot presenting sub-group meta-analysis based on day versus night time                      
sleepiness for the effect of sleep problems and disorders on cognitive decline and/or Alzheimer’s disease 
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Figure 3A   Forest plot presenting sub-group meta-analysis based on study temporality for the                         
effect of sleep problems and disorders on cognitive decline and/or Alzheimer Disease                     
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Figure 4A   Forest plot presenting meta-analysis risk estimates based on omitting one study for                          
the effect of sleep problems and disorders on cognitive decline and/or Alzheimer Disease 
 
 
 
 
 
 
 
163 
 
 
 
 
SECTION 3 
OBSTRUCTIVE SLEEP APNEA IS ASSOCIATED WITH LONGITUDINAL INCREASES IN BRAIN 
FLORBETAPIR PET IMAGING, CSF TAU, PTAU, AND DECREASE IN CSF AΒ42 BURDEN, IN 
ELDERLY COGNITIVE NORMAL AND MCI INDIVIDUALS. 
 
KEY POINTS 
Question: Does Obstructive Sleep Apnea (OSA) affect longitudinal changes in brain amyloid deposition 
and cerebrospinal fluid (CSF) Aβ42, t-tau and p-tau181 in cognitive normal (NL), mild cognitive 
impairment (MCI) and Alzheimer’s Disease (AD) older adults. 
Findings: OSA accelerates increases in brain amyloid deposition, CSF TAU and PTAU and decreases in 
CSF biomarkers burden, over time, both in elderly NL and MCI individuals. 
Meaning: Clinical interventions aimed at OSA, such as treatment with CPAP or dental appliances, in NL 
and MCI patients, could possibly slow the progression of cognitive impairment to AD. 
ABSTRACT 
Importance: Recent studies demonstrate that OSA is associated with AD biomarkers. To evaluate 
evidence for a causal association between OSA and AD, demonstrating AD-specific neuropathology 
changes resulting from increased disease burden in OSA patients is vital. 
Objective: To determine the effect of OSA on longitudinal changes in brain amyloid deposition and CSF 
Aβ42, t-tau and p-tau181 in NL, MCI and AD older adults. 
Design: Longitudinal study. Mean follow up time was 2.52 ±0.51 years.      
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Setting: Data used for this study were obtained from the Alzheimer’s disease Neuroimaging Initiative 
(ADNI) database (adni.loni.usc.edu) on December 7, 2016.  
Participants: 516 NL, 798 MCI and 325 AD subjects. 
Exposure: Participant self-reported physician diagnosis of OSA.  
Main Outcomes and Measures: Rate of change in brain Aβ42, CSF TAU, PTAU, and CSF Aβ42 
burden over time. Multi-level mixed effects linear regression models with randomly varying intercepts 
and slopes were constructed to test whether the rate of change in biomarker data differed between subjects 
with and without OSA.  The final models were adjusted for age, sex, BMI, CPAP use, APOE e4 status, 
and history of chronic medical conditions. 
Results: The self-reported prevalence of OSA in the 3 study cohorts was as follows: NL (6%), MCI 
(13%), AD (7%). Across all groups, mean ages of OSA+ and OSA- were 72.3 ±7.1 and 73.9 ±7.3 
respectively. Females were 49% in the NL group, 40% in the MCI group, and 37% in the AD group. In 
NL and MCI groups, the annual rate of AD biomarker burden change over time, indicated that OSA+ 
subjects experienced faster increase in brain Aβ-42 (B = - .06, 95% CI, -.09, -.04 for both), CSF TAU (B 
= -2.89, 95% CI, -3.51 to -2.29 and B = -1.89, 95% CI, -2.91, -.87, respectively), CSF PTAU (B = -1.21, 
95% CI, -1.71, -.74 and, B = -1.48, 95% CI, -2.05, -.94, respectively), and a faster decrease in CSF Aβ-42 
(B = 3.93, 95% CI, 3.56, 4.31 and B = 2.69, 95% CI, 2.02, 3.36, respectively); compared to OSA- 
subjects, over the follow-up period. 
Conclusion and Relevance: OSA appears to accelerate increases in brain amyloid deposition, CSF TAU 
and PTAU and decreases in CSF biomarkers burden, over time, both in elderly Cognitive Normal and 
MCI individuals. Clinical interventions aimed at OSA, such as treatment with CPAP or dental appliances, 
in cognitive normal and MCI patients, could possibly slow the progression of cognitive impairment to AD 
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INTRODUCTION 
Obstructive Sleep Apnea (OSA) and Alzheimer’s disease (AD) are both common chronic disease 
conditions in older adults. OSA affects between 19% and 57% of individuals aged over 65.1-4 By 2050, 
the incidence of AD in the U.S is expected to approximate a million people each year, with a total 
estimated prevalence of 11 to 16 million people.5 Both OSA and AD cause significant morbidity and 
mortality to those afflicted,6-8 and have very high socio-economic burden worldwide.5,8-16 It is therefore 
pertinent that preventive and/or treatment efforts targeting both disease conditions are consolidated to 
create a better quality of life in older adults. 
OSA is characterized by intermittent partial or complete breathing cessation during sleep, 
occurring from narrowing of various upper airway sites.1 OSA related hypoxemia and sleep fragmentation 
have been implicated as possible links between OSA and AD, with recent studies demonstrating 
associations between OSA and AD biomarkers in cognitive normal (NL) and MCI older adults.17-21 
Clearly distinguishing whether OSA individuals with normal cognition or MCI are at heightened risk to 
develop AD is critical to our ultimate mission of preventing AD.     
AD biomarkers serve as in-vivo indicators of particular AD pathologies.22-24 They can be used in 
the clinical setting to predict future clinical course of AD. 25,26 PET amyloid imaging of significant Aβ 
load and significant levels of cerebrospinal fluid (CSF) Aβ42 are robust predictors of the development of 
AD in at risk populations’ i.e. cognitive normal to amnestic mild cognitive impairment (aMCI) and MCI 
to AD.25,26  Aβ deposition commences many years prior to AD symptoms’ onset27,28 while MRI brain 
imaging show abnormalities later in the disease trajectory.29 This suggests a time-dependent risk of 
developing AD from amnestic MCI. Significant increases of CSF P-tau have been demonstrated in AD 
patients compared with controls.30 P-tau in CSF is a measurable core marker of AD.31 Since cross-
sectional studies demonstrate that OSA is associated with AD biomarkers, we further examined OSA’s 
effect on longitudinal changes of these biomarkers, especially since they have been shown to predict time-
to-progression from MCI to AD.32 Demonstrating associations between OSA and AD-specific 
166 
 
neuropathology changes, progression or worsening consolidates the evidence for a potential causal 
relationship between OSA and AD.  
METHODS 
Data used in the preparation of this article were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a 
public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of 
ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography 
(PET), other biological markers, and clinical and neuropsychological assessment can be combined to 
measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD).  Thus 
far, ADNI has recruited over 2,000 adults aged 55 to 90 years, consisting of cognitively normal (NL) 
older individuals, people with early or late MCI, and people with early AD-dementia. Follow-up is at 6 
month intervals with duration ranging from 2 to 3 years as specified in the protocols for ADNI-1, ADNI-
2, and ADNI-GO. 
Study Participants 
Participant data used for this study were based on medical history from baseline and follow-up 
visits obtained from downloaded ADNI data on December 7, 2016. Study participants included 1,639 
subjects (516 Cognitive Normal (NL), 798 MCI and 325 AD). Subjects missing important study covariates 
were excluded in each of the study groups. Subjects having co-morbid sleep disorders, body mass index 
(BMI) change greater than 5 between any follow-up visits, were further excluded, since disturbed sleep, 
and BMI are known independent risk factor for cognitive decline and AD, and being overweight is 
associated with SDB and AD.33 Other exclusions included subjects who indicated they have had previous 
OSA surgery, and those who had a reversible diagnosis (i.e. they had an MCI or AD diagnosis at any time 
point but an NL diagnosis or MCI diagnosis at their last visit, thereby allowing us to control for unspecified 
diagnoses.  
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OSA diagnosis 
Presence or absence of OSA was self-reported (variable name: MHDESC). Patients with reported 
“sleep apnea” or “OSA” were labeled OSA+ and the remaining participants were considered OSA−.  To 
ensure that patients were allocated into the correct groups, three physicians (R.O, S.A and O.B.) reviewed 
medical history descriptions in the ADNI download, for OSA+ and OSA-. 
NL, MCI and AD Diagnosis 
ADNI criteria for subject classification is described elsewhere.34 In summary, NL subjects had no 
memory complaints while MCI and AD subjects had memory complaints. NL and MCI scored between 
24 – 30 on the Mini-Mental State Examination (MMSE) while AD subjects scored between 20 – 26. NL, 
MCI and AD subjects had a Clinical Dementia Rating (CDR) score of zero, 0.5 with a mandatory 
requirement of the memory box score being 0.5 or greater, and 0.5 or 1, respectively. In addition, MCI 
subjects had to have largely intact general cognition and functional performance, and could not qualify for 
dementia diagnosis.35 The diagnosis of AD was made using established clinical criteria.36 Patient 
diagnosis was recorded at 6-month intervals for 24 months. Subjects were classified as converters if they 
converted to AD between 12 months and 24 months and as stable if they did not convert by 24 months. 
Florbetapir-PET Imaging Acquisition and Interpretation  
ADNI Florbetapir summary data are updated regularly, and uploaded to LONI by the University 
of California at Berkeley group.37,38 More information on the methods can be found at:  
https://adni.loni.usc.edu/wp-content/uploads/2010/05/ADNI2_PET_Tech_Manual_0142011.pdf, 
http://adni.loni.usc.edu/updated-florbetapir-av-45-pet-analysis-results/.  
Cerebrospinal Fluid Methods (CSF) 
CSF bio-specimen data collection are explained in detail at http://adni.loni.usc.edu/data-
samples/biospecimen-data/ and (http://www.adni-info.org/index.php). 
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Covariates/potential confounders 
Covariates/potential confounders in our study include age, sex, educational status, smoking 
status, body mass index (BMI), APOE4 status, hypertension, diabetes and history of cardiovascular 
disease.  
Data analysis  
Given that ADNI data is unbalanced with unequal numbers of measurement for each study 
participant, we used multi-level mixed effects linear regression models with normal errors39-41 for our 
longitudinal analyses to examine the relationship between OSA and CSF P-tau, and Aβ-42 volumes, as 
they provide a flexible and valuable tool for analyzing such unbalanced longitudinal data. Our method 
allowed for incorporation of all the available information in the data, and possibly reduced or even 
eliminated any bias resulting from an analysis confined to the complete cases.42  
Specifically, to determine the specific type of modeling, we examined profile plots for the 
biomarker data levels over time, by OSA status (=1 if OSA, =0 if non-OSA) using both the original data 
and within-subject residuals. We also examined trajectory plots obtained by subtracting the baseline 
measurement from the original measurements (i.e. dij = Yij − Yi1), and examined plots of mean and 
variance of the biomarker data at each time point by OSA status. Further, using the slopes as summary 
statistics, we conducted different formal tests to compare the two OSA statuses. Based on the above, our 
assumption was that the rate of change of biomarker data is approximately linear over time, so we 
proposed a parametric model with time as a continuous variable. Using PROC MIXED in SAS software; 
we fit the models with randomly varying intercepts and slopes and allowed them to depend on exposure 
group (i.e., OSA status). Based on the findings from above, we fit a random coefficients model for the 
relationship between OSA status and time using unstructured covariance model. For finding a 
parsimonious covariance structure, we fit as many different covariance models and conducted a likelihood 
ratio test of each nested model using information criteria for non-nested models. Finally, using the 
preferred covariance structure obtained above, we used PROC MIXED to construct a test of whether the 
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rate of change in biomarker data differed between the two OSA groups. The final models were adjusted 
for age, sex, BMI, CPAP use, APOE e4 status, and history of chronic medical conditions. 
These analyses allowed us to examine whether there was significant variation between OSA and 
non-OSA subjects in mean AD biomarker level at baseline (intercept), as well as whether significant 
variation in the change in AD biomarker level over time (slope) occurred. Furthermore, the covariance 
between the baseline AD biomarker level (intercept) and AD biomarker change over time indicated 
whether OSA+ or OSA- subjects had experienced a faster increase or decrease in AD biomarker level 
over time (significant slope). It also allowed for assessment of significant differences in the rate of change 
in AD biomarker level between OSA+ and OSA- patient groups over time. Statistical analyses was 
performed using SAS software (version 9.4; SAS Institute Inc., Cary, NC). For sensitivity analyses, we 
attempted using the dichotomized brain Aβ level outcome (Aβ+ vs. Aβ-) and examined the rate of change 
in AD biomarker level in these populations (SDB+/ Aβ+ vs. SDB-/ Aβ+; SDB+/ Aβ- vs. SDB-/ Aβ-; and 
SDB+/ Aβ+ vs. SDB+/ Aβ-; SDB-/ Aβ - vs. SDB-/ Aβ+). However, power issues limited our analyses; 
moreover, convergence issues did not permit any estimation with these categorical variables.  
RESULTS 
Demographic and Clinical Characteristics 
Table 3.1 shows the demographic and clinical characteristics of study participants. Overall, the 
mean ages of OSA+ and OSA- were 72.3 ±7.1 and 73.9 ±7.3 respectively. Forty-nine percent were female 
in the NL group, while in the MCI and AD groups, females consisted of 40% and 37% of the participants 
respectively. In the NL group, 6% were OSA+, while 13% of the MCI group and 7% of the AD group 
were OSA+. Participants differed markedly in APOE4 status with 28%, 51% and 66% being APOE 
positive in the NL, MCI and AD groups respectively. Participants were similar in age, educational status, 
BMI, and chronic medical conditions across groups (i.e. NL, MCI and AD), however, within group 
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differences (i.e. OSA+ vs. OSA-) existed on these characteristics. Mean follow up time for all participants 
was 2.52 ±0.51 years. 
Baseline AD Biomarker levels by clinical group and OSA status  
Table 3.1 and Figure 3.1 show baseline CSF Aβ-42, TAU, PTAU and Brain Florbetapir PET 
imaging levels by NL, MCI and AD group and OSA status without controlling for confounders. There 
were significant differences in CSF Aβ-42 levels for both MCI (P =0.04), and AD (P <0.01) groups 
respectively, with OSA+ participants having significantly higher levels at baseline. No significant 
difference was seen in NL group by OSA status. Significant difference in TAU levels was seen for the 
MCI patients (P =0.02), with OSA+ individuals having significantly lower levels. No significant 
difference was seen in both the NL and AD groups. For PTAU levels, no significant difference was seen 
across all groups. For Brain Florbetapir PET imaging levels, at baseline, there was significant differences 
between OSA groups for both NL and MCI participants (P =0.02 for all), with OSA+ participants having 
significantly lower brain Florbetapir levels. No difference was seen in AD group. For the MCI group, the 
inclusion of an interaction term OSA*APOE4 was also significant (P =0.01). 
Rate of Change in AD Biomarker by OSA status 
Table 3.2 reports the covariance parameter estimates and between subject (i.e. OSA+ vs. OSA-) 
variation in AD biomarker levels over time.  
Brain Aβ-42 levels 
In NL participants, there was significant variation by OSA status in the annual change in brain 
Florbetapir PET volumes over time (slope) (mean SUVR; B = 0.06, p < .0001). The covariance between 
the baseline brain Florbetapir level and the annual brain Florbetapir volume change over time was -.06, 
indicating that OSA+ subjects experienced faster increase in brain Aβ-42 deposition over time (p < .0001) 
when compared to OSA- subjects. In MCI participants, there was also significant variation by OSA status 
in the annual change in brain Florbetapir volumes over time (slope) (mean SUVR; B = 0.08, p < .0001). 
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The covariance between the baseline brain Aβ-42 level and the annual brain Aβ-42 volume change over 
time was -.006, indicating that OSA+ subjects experienced faster increase in brain Aβ-42 deposition over 
time (p < .0001) when compared to OSA- subjects. For the MCI group, the inclusion of an interaction 
term OSA*APOE4 was also significant (P =0.01) with APOE4+/OSA+ individuals showing a faster 
increase in brain Aβ-42 compared to APOE4-/OSA- patients. No significant variation in the change in 
brain Florbetapir PET volumes by OSA status over time was seen for the AD group. 
CSF Aβ-42, TAU and PTAU levels  
For the NL and MCI groups, there was significant variation in the annual change in CSF Aβ-42 
by OSA status (mean SUVR; B = -2.708, mean SUVR; B = -2.264, p < .0001 for all respectively) over 
time.  Significant differences in the annual change in TAU and PTAU levels over time (slope) were also 
seen in both groups. Covariance parameters between the baseline CSF Aβ-42, TAU and PTAU volume 
change over time indicated that OSA+ subjects experienced a faster decrease in CSF Aβ-42 and increases 
in TAU and PTAU volumes over time (p < .0001 for all) compared to OSA- participants, in both the CN 
and MCI groups (Table 3.2). No significant variations in the change in CSF Aβ-42, TAU and PTAU over 
time was seen for the AD group. 
DISCUSSION 
Major findings from this study include the following:  
i. At baseline, OSA+ patients had significantly higher CSF Aβ-42 in the MCI group; and lower 
brain Florbetapir PET in NL and MCI groups; and lower TAU levels in the MCI group, 
compared to OSA- patients.  
ii. Longitudinally, there was significant differences in the annual rate of change in brain Florbetapir 
PET, CSF Aβ-42, TAU and PTAU levels over the follow up period for the NL and MCI group 
iii. OSA+ subjects experienced significantly faster increase in brain Aβ-42, TAU and PTAU levels 
and a faster decrease in CSF Aβ-42 over the follow-up period in both the NL and MCI groups. 
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iv. For the MCI group, APOE4+/OSA+ individuals showed a faster increase in brain Aβ-42 
compared to APOE4-/OSA- patients 
Baseline AD Biomarker levels by clinical group and OSA status  
At baseline, the data showed that OSA+ patients had significantly higher CSF Aβ-42 and lower 
brain Aβ-42 in NL and MCI groups, and lower TAU levels in the MCI group, compared to OSA- patients. 
Theoretically, this may be attributed to slow wave sleep (SWS) occurring during non-rapid eye movement 
(NREM) sleep, a known Aβ modulator.43-45 Sleep is involved in the clearance of Aβ,45 and fragmented 
SWS limits brain Aβ clearance, thereby leaving higher levels that reflect in the CSF.46,47  At cross-section, 
disrupted SWS has been shown to be associated with higher CSF Aβ-42 in middle-aged48,49 and older 
adults.50 It is also important to note that CSF tau protein pathology and CSF Aβ-42 burden may not be 
specific to AD in these participants.51 The effect of normal aging in NL subjects on CSF turnover and 
brain Aβ-42 clearance is still not fully understood.52,53 Furthermore, cross-sectional data show little 
evidence for an association between age and CSF Aβ-42.54,55 It is also noteworthy that the functional 
significance of high CSF Aβ42 levels is not fully known. 
Rate of Change in AD Biomarker by OSA status 
The major objective of this study was to examine the effect of OSA on longitudinal changes in 
brain amyloid deposition, and AD CSF biomarkers.  There were significant differences in the annual rate 
of change in brain Florbetapir PET, CSF Aβ-42, TAU and PTAU levels over the follow-up period for the 
NL and MCI group, with OSA+ subjects experiencing significantly faster increase in brain Florbetapir 
PET, TAU and PTAU levels and a faster decrease in CSF Aβ-42. The direction of these longitudinal 
changes are in cognizance with emanating evidence-linking disturbed sleep, OSA with AD pathogenesis. 
Self-reported sleep duration and quality has been shown to be associated with higher brain Aβ-42 
burden.19 MCI individuals with higher apnea-hypopnea index and oxygen desaturation index 
demonstrated higher brain Aβ-42 burden globally and regionally in the precuneus.20 A recent study by 
Yun et al56 examined whether OSA increased brain amyloid burden relative to controls in middle-aged 
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participants from the Korean Genome and Epidemiology Study. After adjusting for potential confounders, 
OSA patients had a higher brain amyloid burden in the right posterior cingulate gyrus and right temporal 
cortex, relative to controls, suggesting that OSA may have been responsible for these findings. Bu et al.17 
examined whether hypoxia indices in OSA was associated with serum amyloid (Aβ40, Aβ42), total tau 
and phosphorylated tau 181 (P-tau 181) comparing their levels with controls. Results from this study 
demonstrated significantly higher levels of serum Aβ40, Aβ42, total Aβ and P-tau 181 in OSA patients 
compared to control. Hypoxia indices including apnea-hypopnea index, the oxygen desaturation index, 
and the mean and lowest oxyhemoglobin saturations correlated positively with Aβ40, Aβ42, and total Aβ 
in OSA patients, suggesting that hypoxia possibly effects AD pathogenesis. In a population of MCI 
individuals, Liguori et al57 compared CSF β-amyloid42, tau proteins, and lactate levels in OSA versus 
CPAP treated OSA and controls. Findings from the study demonstrated lower CSF β-amyloid42, higher 
lactate levels and t-tau/ Aβ42 ratio compared to controls and CPAP treated OSA patients. Controls and 
CPAP treated OSA MCI patients had similar AD biomarker levels. These findings suggest that OSA may 
effect early AD biomarker changes that may be susceptible to CPAP treatment.  
In our study, among MCI patients, APOE4+/OSA+ individuals showed a faster increase in brain 
Aβ-42 compared to APOE4-/OSA- patients, suggesting that the APOE4 allele may be a moderator of the 
association between OSA and AD. In a population of cognitive normal (NL) older adults, Osorio et al18 
demonstrated an association between intermittent hypoxia and increases in CSF T-Tau, P-Tau and Aβ42 
in ApoE3+, suggesting that hypoxia may be responsible for changes in the AD biomarkers in this 
population. In ApoE4+ subjects, OSA severity tended towards lower CSF Aβ42 levels. There was no 
difference in the rate of biomarker change in the AD group by OSA status. This may be because in AD 
patients, risk profile is possibly linear with brain atrophy until it reaches a threshold thereby exhibiting a 
ceiling effect at higher levels of brain Aβ.32 OSA’s effect as it relates to AD biomarker changes may 
therefore be attenuated or have reached its maximum. 
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Strengths and Limitations 
Our study possesses several strengths including a well-defined cohort, and objective assessment 
of CSF P-Tau, Hippocampal atrophy and β-amyloid burden, which allowed for a high degree of certainty 
regarding measurement of our outcome.58 Furthermore, our statistical analytic methods were robust with 
respect to unbalanced number of observations per subject over time. However, we were limited by our 
measurement of OSA since this was self-reported. It is known that self-reported sleep measures can be 
impacted by diminished cognition59 and in certain situations might not be correlated with objective 
measurements using polysomnography or wrist actigraphy.60 Moreover any positive findings from our 
study will need to be replicated using objective measures of sleep function. The ADNI racial demographic 
is largely white; as such this limits the generalizability of our findings to other racial populations.  
CONCLUSIONS 
OSA appears to accelerate increases in brain amyloid deposition, CSF TAU and PTAU and 
decreases in CSF biomarkers burden, over time, both in elderly Cognitive Normal and MCI individuals. 
Sleep fragmentation and/or intermittent hypoxia from OSA are likely candidate mechanisms. Thus, 
clinical interventions aimed at OSA, such as treatment with CPAP or dental appliances, in cognitive 
normal and MCI patients, could possibly mitigate or slow the progression of cognitive impairment to AD. 
Further research examining mechanisms underlying these observed effects are needed. 
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Table 3.1: Descriptive Characteristics of Participants by Obstructive Sleep Apnea Status at 
Baseline 
 
Cognitive Normal 
Characteristics All OSA- OSA+ 
Number of participants (%) 516 (100) 487 (94) 29 (6) 
Female gender, number (%) 253 (49) 241 (49) 9 (32) 
Age, years, median (interquartile range) 74 (71, 78) 71 (70, 78) 71 (70, 76) 
APOE positive, number (%) 145 (28) 140 (29)  5 (17) 
Education, years, median (interquartile range) 16 (14, 18) 16 (14, 18) 16 (15, 18) 
BMI (kg/m2) 27.2 ± 4.8  27.1 ± 4.7 29.8 ± 5.9  
Hypertension, number (%) 251 (49) 235 (48) 16 (55) 
Diabetes, number (%) 45 (9) 40 (8) 5 (17) 
Thyroid Disease, number (%) 112 (22) 109 (22) 3 (10) 
Respiratory Disease, number (%) 123 (24) 100 (21) 23 (79) 
CSF-ABETA pg/ml median (interquartile range) 
210 (155, 
241) 
209 (155, 
241) 
226 (199, 259) 
TAU pg/ml median (interquartile range) 59 (45, 84) 59 (45 83) 56 (48, 84) 
PTAU pg/ml median (interquartile range) 27 (20, 40) 27 (20, 42) 27 (20, 32) 
Aβ, median (interquartile range) 1.1 (1.0, 1.2) 1.1 (1.0, 1.2) 1.0 (1.0, 1.0) 
Mild Cognitive Impairment 
Characteristics All OSA- OSA+ 
Number of participants (%) 798 (100) 695 (87) 103 (13) 
Female gender, number (%) 319 (40) 297 (43) 25 (25) 
Age, years, median (interquartile range) 74 (68, 79) 71 (70, 78) 71 (70, 76) 
APOE positive, number (%) 410 (51) 368 (53)  42 (41) 
Education, years, median (interquartile range) 16 (14, 18) 16 (14, 18) 16 (14, 18) 
BMI (kg/m2) 26.9 ± 4.6  26.5 ± 4.4 29.4 ± 5.3  
Hypertension, number (%) 395 (49) 337 (48) 58 (56) 
Diabetes, number (%) 75 (9) 57 (8) 18 (17) 
Thyroid Disease, number (%) 156 (20) 133 (19) 23 (22) 
Respiratory Disease, number (%) 195 (24) 133 (19) 62 (60) 
CSF-ABETA pg/ml median (interquartile range) 
153 (130, 
209) 
150 (128, 
206) 
169 (139, 214) 
TAU pg/ml median (interquartile range) 80 (54, 116) 81 (54, 122) 67 (51, 97) 
PTAU pg/ml median (interquartile range) 36 (23, 51) 37 (23, 52) 32 (21, 44) 
Aβ, median (interquartile range) 1.2 (1.0, 1.4) 1.2 (1.0, 1.4) 1.1 (1.0, 1.3) 
Alzheimer's Disease 
Characteristics All OSA- OSA+ 
Number of participants (%) 325 (100) 303 (93) 22 (7) 
Female gender, number (%) 119 (37) 113 (37) 6 (27) 
Age, years, median (interquartile range) 76 (71, 80) 76 (71, 80) 71 (64, 76) 
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APOE positive, number (%) 216 (66) 198 (65)  18 (82) 
Education, years, median (interquartile range) 16 (14, 18) 16 (14, 18) 16 (14, 18) 
BMI (kg/m2) 25.9 ± 4.6  25.6 ± 4.3 29.0 ± 6.8  
Hypertension, number (%) 165 (51) 149 (49) 16 (73) 
Diabetes, number (%) 32 (10) 30 (10) 2 (9) 
Thyroid Disease, number (%) 65 (20) 61 (20)  4 (18) 
Respiratory Disease, number (%) 67 (21) 52 (17) 15 (68) 
CSF-ABETA pg/ml median (interquartile range) 
132 (116, 
151) 
115 (96, 
182) 
115 (79, 151) 
TAU pg/ml median (interquartile range) 80 (54, 116) 67 (51, 97) 81 (54, 122) 
PTAU pg/ml median (interquartile range) 42 (33, 61) 41 (33, 61) 54 (35, 66) 
Aβ, median (interquartile range) 1.4 (1.3, 1.5) 1.4 (1.3, 1.5) 1.4 (1.3, 1.6) 
Abbreviation: Aβ: amyloid beta, APOE: Apolipoprotein epsilon, BMI: body mass index, CSF: cerebrospinal fluid, TAU: tau 
protein, PTAU: phosphorylated tau 
 
Table 3.2    Covariance Parameter estimates and Between Subject variation in AD Biomarker 
Deposition 
 
Parameters Estimate 95% CI P-value 
OSA+ vs. OSA-  (Cognitive Normal Patients) 
β-Amyloid Burden over time (slope) 0.06 .02, .11 <.0001 
β-Amyloid Burden over time (covariance) -0.06 -.09, -.04 <.0001 
CSF Aβ-42 volume over time (slope) -2.71 -3.11, -2.35 <.0001 
CSF Aβ-42 volume over time (covariance) 3.93 3.56 - 4.31 <.0001 
CSF TAU volume over time (slope) 3.68 3.31 - 4.07 <.0001 
CSF TAU volume over time (covariance) -2.89 -3.51, -2.29 <.0001 
CSF PTAU volume over time (slope) 1.22 1.02 - 1.42 <.0001 
CSF PTAU volume over time (covariance) -1.21 -1.71, - .74 <.0001 
OSA+ vs. OSA- (Mild Cognitive Impairment Patients) 
β-Amyloid Burden over time (slope) 0.08 .05, .12 <.0001 
β-Amyloid Burden over time (covariance) -0.06 -.09, -.04 <.0001 
CSF Aβ-42 volume over time (slope) -2.62 -3.23, -2.03 <.0001 
CSF Aβ-42 volume over time (covariance) 2.69 2.02, 3.36 <.0001 
CSF TAU volume over time (slope) 2.21 1.58, 2.86 <.0001 
CSF TAU volume over time (covariance) -1.89 -2.91, -.87 <.0001 
CSF PTAU volume over time (slope) 1.74 1.22, 2.27 <.0001 
CSF PTAU volume over time (covariance) -1.48 -2.05, -.94 <.0001 
OSA+ vs. OSA- (Alzheimer's disease Patients) 
β-Amyloid Burden over time (slope) 0.07 -1.19, 1.33 0.33 
β-Amyloid Burden over time (covariance) -0.29 -2.07, 1.49 0.31 
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CSF Aβ-42 volume over time (slope) -1.11 -3,31, 1.09 0.53 
CSF Aβ-42 volume over time (covariance) -1.14 -3.38, 1.63  0.56 
CSF TAU volume over time (slope) 0.26 -1.02, 1,28 0.47 
CSF TAU volume over time (covariance) -0.15 -1.94, 1.64 0.47 
CSF PTAU volume over time (slope) 0.94 0.23, 1.65 0.11 
CSF PTAU volume over time (covariance) -0.16 -1.66, 1.34 0.11 
Abbreviation: Aβ: amyloid beta, APOE: Apolipoprotein epsilon, BMI: body mass index, CSF: cerebrospinal fluid, TAU: tau 
protein, PTAU: phosphorylated tau 
Models were adjusted for age, sex, BMI, CPAP use, APOE e4 status, and history of chronic medical 
conditions. 
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Figure 3.1: Baseline Alzheimer Disease Biomarker burden and Brain 
Aβ-42 levels in Cognitive Normal subjects by OSA status  
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Figure 3.2: Baseline Alzheimer Disease Biomarker burden and Brain 
Aβ-42 levels in Mild Cognitive Impairment subjects by OSA status  
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Figure 3.3: Baseline Alzheimer Disease Biomarker burden and Brain 
Aβ-42 levels in Alzheimer disease subjects by OSA status  
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SECTION 4 
Obstructive Sleep Apnea: A Distinct Physiological Phenotypic Risk Factor in older adults with Cognitive 
decline and Alzheimer’s disease 
ABSTRACT 
Introduction: Studies suggest that Obstructive Sleep Apnea (OSA) in the elderly may result in varying 
functional outcomes relative to OSA in the middle-aged. Therefore, understanding and appreciating the 
heterogeneity of OSA and its outcomes in distinct age groups especially at it relates to cognition, 
subsequent cognitive decline and Alzheimer disease (AD), is critical in mitigating the deleterious effects 
of OSA.  
Methods: In this review, we integrated over 3 decades of research examining OSA and cognition; OSA 
and subsequent cognitive decline; and OSA and AD, with particular focus in appreciating the 
heterogeneity of OSA and its outcomes in distinct age groups. A systematic literature search of 
bibliographic databases including PubMed/Medline, Embase, Psych INFO and Cochrane library for 
clinical trials, was conducted to identify all eligible studies (published from their onset up until August 
31, 2017) that examined associations between OSA and cognitive function, OSA and subsequent 
cognitive decline, and OSA and AD 
Results: Thirty-four studies examining the association between OSA and cognition, 7 studies examining 
the association between OSA and subsequent cognitive decline, and 15 studies examining the association 
of OSA and AD or AD pathology were identified by the literature search after applying specific inclusion 
and exclusion criteria. The data suggests that OSA is associated with greater cognitive deficits in middle-
188 
 
age adults than in older adults and the elderly; greater risk of subsequent cognitive decline in middle-aged 
adults than in older adults and elderly; and in older adults with MCI rather than in healthy older adults, 
OSA may be the critical correlate of cognition. 
Conclusion: OSA may be age-dependent in older adults (60 – 70 years old) and the elderly (70 years and 
above) and is associated with neurodegenerative diseases particularly, cognitive decline and AD. In the 
middle-aged (30 – 60 years old), the data suggests that OSA may be age-related and presents with a 
distinct phenotype, with cardiovascular, and possibly metabolic effects. Intermittent hypoxia and sleep 
fragmentation are two main processes by which OSA induces neurodegenerative changes. 
 
INTRODUCTION 
Cognitive decline in older adults and Alzheimer’s disease (AD) both have debilitating effects on 
individuals affected, with significant socioeconomic implications.1-4 It is well known that advanced age is 
the most notable risk factor for cognitive decline and AD. With projected substantial increase in the 
ageing population, it is pertinent that efforts directed at comprehending risk factors of cognitive decline 
and AD be consolidated. There is increasing evidence in recent years linking cognitive decline and AD to 
various sleep problems and disorders.5-8 Notably, the link between cognitive impairment and Obstructive 
Sleep Apnea (OSA) is well-established,9-12 and recent evidence suggest that a longitudinal risk between 
OSA, cognitive decline and AD exist.13-15 It is therefore vital to clearly understand the distinct and unique 
relationship OSA has with cognitive decline and AD in the elderly as this will help inform prevention and 
treatment strategies of both OSA and AD. 
 
Age-related and Age-dependent OSA co-morbidities  
Obstructive sleep apnea (OSA) is characterized by intermittent hypoxemia, sleep fragmentation 
and intrathoracic pressure changes.16,17 OSA is an issue of public health significance, because it is highly 
prevalent,18-21 results in serious morbidity and significant mortality, 22-26 and has a high socio-economic 
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impact.27,28  Studies suggest that OSA in the elderly may result in varying functional outcomes relative to 
OSA in the middle-aged. Therefore, understanding and appreciating the heterogeneity of OSA and its 
outcomes in distinct age groups is critical in mitigating the deleterious effects of OSA.  
Bliwise et al.29 in their study using the Bay Area Sleep Cohort described two peak incidences of 
OSA, one being age-dependent and the other being age-related. The concept describes OSA as an age-
dependent condition in the elderly, relative to OSA being an age-related condition in the middle-aged. 
OSA affects 3–7% of the middle-aged population and becomes more prevalent with increasing age.20,30-37 
In middle-aged individuals, Bliwise noted that OSA is thought to show an age-related occurrence 
conferring a specific period of susceptibility,38,39 in association with disparate morbidities. Age-related 
diseases and disorders are not particularly related to the process of aging, occurring at a distinctive 
age/age-group and then lessening in frequency with increasing age (e.g. multiple sclerosis and 
amyotrophic lateral sclerosis).29   
Conversely, in the elderly, the prevalence of OSA ranges from 30-80%,32,40-46 contingent on the 
definition of OSA. The significance of these high rates in the elderly is ambiguous; while certain studies 
suggest reduced mortality with increasing age,47 others suggest otherwise.48 However, the pathogenesis of 
OSA somewhat appears to involve normal aging with exponential increases in mortality and morbidity 
with advancing age.49,50 This physiologic susceptibility with increased incidence with chronological age 
suggests that OSA is age-dependent in the elderly. Mechanisms underlying how aging increases the risk 
of OSA are not completely understood. The effects of advancing age are generally considered to function 
with other physiologic systems experiencing aging.51,52  Notable factors in OSA pathogenesis during 
aging include an extremely collapsible airway, limited upper airway dilator muscle activity, diminished 
respiratory arousal threshold, and a precarious ventilatory control system.35,53,54 Furthermore, age-
dependent changes in lung function as reported in cross-sectional studies,55-57 are associated with 
increments in OSA frequency.   
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Much focus on OSA’s age-dependence in the elderly has been in cardiovascular outcomes 
relative to cognitive outcomes. However, the various co-morbidities associated with increasing age in 
OSA increases susceptibility to cognitive decline.58,59 Cardiovascular outcomes of OSA such as 
hypertension, coronary heart disease, and congestive heart failure; 25,60,61 stroke; 62-64 multiple 
inflammatory and metabolic effects including diabetes; 65-68 are associated with increased severity of 
OSA, and may be more likely to occur in young and middle-aged (30 – 70 years), rather than older 
populations.69-73 In young and middle-aged adults, substantive evidence exists establishing relationships 
between OSA and cognitive function, including areas such as memory, motor, vigilance and executive 
functions.74-76 Studies examining cardiovascular outcomes of OSA in the elderly show varying findings. 
Some studies77-79 report increased mortality and incidence of stroke in older adults while other 
studies47,48,80 report decreased mortality with age in OSA patients compared to the general population. In 
the elderly, multiple studies demonstrate associations between OSA and cognitive decline.15,81-83 We 
demonstrated that in the elderly, OSA patients had an earlier age of cognitive decline to MCI and to AD 
than non-OSA controls,84 and showed that individuals with OSA were more than two times more likely to 
have AD compared to non-OSA individuals in a recent meta-analysis.5 A meta-analysis of cross-sectional 
studies also concluded OSA-AD associations, such that AD patients were at an increased risk of 
presenting with OSA than cognitively normal individuals.85 Of particular concern is that longitudinal 
studies also provide evidence of an association between OSA and cognitive decline. A 5-year prospective 
study of older women (mean ±SD age: 82.3 ±3.2 years) found elevated oxygen desaturation index (≥15 
events/ hr) to be associated with increased risk of developing mild cognitive impairment (MCI) or 
dementia.15 In general, the literature regarding OSA, cognitive function, cognitive decline and AD have a 
relationship with advancing age, suggesting that age may be an effect modifier of these association and 
that OSA may present as a distinct physiologic phenotypic risk factor in older adults with cognitive 
decline and AD. 
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Review Objective 
Recent narrative reviews on OSA, Cognitive Decline and AD described the cognitive profiles 
found in association with OSA in children and adults (young, middle-aged and elderly adults);9,86 
explored mechanisms, neurobiology and treatment for geriatric psychiatry audience; and discussed 
probable explanatory mechanisms linking OSA, depression and cognitive dysfunction. 87-89 Other 
narrative discussions focused on the probable explanatory mechanisms linking OSA to dementia.82 
Previous systematic and meta-reviews focused on how OSA affects specific neurocognitive domains, 
producing inconsistent74,90 and sometimes non-conclusive findings.12,91 The only meta-review focusing on 
older adults reported a small association between OSA and cognitive dysfunction and suggested that some 
individuals may be more at risk of adverse cognitive effects.92 
In this review, we integrate over 3 decades of research examining OSA and cognition; OSA and 
subsequent cognitive decline; and OSA and AD; with particular focus in appreciating the heterogeneity of 
OSA and its outcomes in distinct age groups. We note that the data suggests that OSA may be age-
dependent in older adults (60 – 70 years old) and the elderly (70 years and above) and is associated with 
neurodegenerative diseases particularly, cognitive decline and AD. In the middle-aged (30 – 60 years 
old), the data suggests that OSA may be age-related and presents with a distinct phenotype, with 
cardiovascular, and possibly metabolic effects. We also explore and describe possible mechanisms linking 
OSA as a precipitator of AD pathogenesis especially in the elderly, by systematically reviewing clinical 
and epidemiological evidence of such an association. Where findings are discrepant, we focus on 
methodological differences among studies. 
METHODS 
Search strategy 
 
A systematic literature search of bibliographic databases including PubMed/Medline, Embase, 
Psych INFO and Cochrane library for clinical trials, was conducted to identify all eligible studies 
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(published from their onset up until August 31, 2017) that examined associations between OSA and 
cognitive function, OSA and subsequent cognitive decline, and OSA and AD. Our search strategy utilized 
the combination of terms characterizing cognitive function, cognitive impairment, AD or AD pathology 
as the dependent variables, OSA as the independent variable and a third set of terms specifying specific 
study types including clinical and epidemiological studies. For the dependent variables, search terms 
included cognition, cognitive function, executive function, neuropsychological function, cognitive 
decline, mild cognitive impairment, Alzheimer’s disease, AD biomarkers and amyloid beta. For the 
independent variable, search terms included sleep apnea; sleep disordered breathing and obstructive sleep 
apnea. All terms were combined with the Boolean Logic operator OR, within each set, and the three sets 
were combined using AND. Furthermore, we performed a manual search of references of included 
articles to identify relevant references not identified by the automated search. Indexing and management 
of the references was done using EndNote X7 (Thompson Reuters, New York, NY). This review was 
conducted adhering to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) 
statement by Moher et al.93 
 
Selection criteria 
Eligible studies for this review had to meet the following selection criteria: 1) be original research 
investigations examining associations between OSA and cognition, OSA and cognitive decline, and OSA 
and AD; 2) conducted in humans; 3) include both healthy controls and OSA patients and conducted 
between group comparisons. Studies without controls that conducted within group comparisons based on 
OSA severity were also considered; 4) conducted in adults (young, middle-aged and older); 5) studies 
examining cognition or cognitive decline as an outcome must have utilized objective neuropsychological 
cognitive tests; 6) studies examining AD or AD pathology as an outcome must have utilized objective 
measures; and 7) diagnosis of OSA must have been based on polysomnography. Excluded studies include 
case reports, case series, narrative or systematic reviews, abstracts or editorials. Studies conducted in 
OSA patients that did not include relevant cognitive parameters (i.e. executive, motor, verbal, attention, 
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memory) and those that examined the effects of CPAP but did not include an examination of OSA vs. 
control at baseline, were also excluded. 
 
Reviewing Procedure and Data Extraction 
Bibliographic data base searches were conducted first in May 2017.  Another search was 
conducted in August 2017 to identify manuscripts published between May and August 2017. Independent 
examination of all titles and abstracts of identified eligible studies by the search strategy was performed 
by two authors (OB and XX) using EndNote X7. Selected articles at this stage were further assessed by 
retrieving and reading the manuscript’s full text. Identified articles for the review were assessed for 
possible inclusion by the same two authors. Where there were discordant decisions regarding inclusion, a 
resolution was reached by two other authors (XX and XX). Two authors (OB and XX) performed data 
extraction for each reference. Extracted fields included authors, year of publication, study design, study 
population, age, exposure and outcome assessment, statistical analytic methods used, covariates, and the 
main findings of the study. Two other authors (XX and XX) resolved discrepancy in the information 
extracted. Reviewers were not blinded to the funding, authors, or institutions. Figure 1 shows a summary 
of the study selection and retrieval process. 
 
Assessment of Study Quality 
We assessed the quality of included studies in this review using an adaptation from the modified 
version of the Newcastle-Ottawa scale (NOS) for quality assessment of the observational studies,94 with 
addition of new items relevant to this review. Following adaptations from previous reviews, parameters 
used for the quality assessment included well-specified hypothesis, study design type, appropriately 
described sample, sample size, assessment and definition of OSA, cognitive impairment or AD, statistical 
analytic methods used, and approach used to adjust for potential confounders. We utilized a star rating 
system with increasing number representing increasing quality. Tables 1-3. 
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RESULTS 
OSA and Cognition (Cross-sectional studies) 
Main findings 
Table 4.1 summarizes the findings from 34 studies that examined the association of OSA and 
cognitive function at a single time point. Most studies that were conducted in the middle-aged adults 
consistently linked OSA and deficits in attention,95-99 memory,100-102 executive function,99,103,104 motor 
function,99 reaction time,105 psychomotor vigilance106 and information processing speed.107 Explanations 
and plausible mechanisms responsible for these findings in the middle-aged include daytime sleepiness or 
drowsiness from fragmented sleep because of frequent apneic episodes,108-110 and hypoxia.111,112 
Specifically, deficits of attention and memory may be due to fragmented sleep and excessive daytime 
sleepiness,102,113 while motor function, executive function, reaction time and vigilance may be related to 
the severity of hypoxemia.114-116 For example, studies where middle-aged adults with OSA who 
complained of excessive daytime somnolence were compared to healthy controls, consistently showed 
scores in memory and attention that were lower than normal.99,100,102 Furthermore, correlation analysis 
revealed that daytime somnolence correlated with attention while nocturnal hypoxemia correlated with 
executive function and visual-constructive abilities.99 
Studies in the middle-aged that examined the effect of CPAP treatment on cognitive impairment 
after both a short and long-term treatment period revealed conflicting results. Studies included in our 
review administered CPAP and assessed for its effect after 3-months,96,97 6 months117 and 12 months.98 
After 3-months of CPAP treatment, Canessa et al.96 observed significant improvements involving 
memory, attention, and executive functioning in OSA patients, while Saunamaki et al.117 did not show 
improvements in OSA patients’ visuospatial organizational skills or their mental set-shifting performance, 
after a 6 months CPAP treatment. Variations in methods of assessing cognitive decline, and the possible 
presence of confounding variables, such as rapid eye movement (REM) and slow-wave sleep (SWS) 
occurring after first night of CPAP use could be responsible for the discrepant findings.  
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Castronova et al.96 employed imaging techniques using diffused tensor imaging (DTI) to examine 
changes in white matter integrity and cognition following CPAP treatment in severe OSA patients. Pre-
treatment OSA patients showed impairments in most cognitive areas, and diffuse reduction of white 
matter integrity. Limited changes of white matter were seen after 3 months of CPAP. However, the 
authors report an almost complete reversal of white matter abnormalities over the course of 12 months 
CPAP treatment. In addition, significant improvements involving memory, attention, and executive-
functioning paralleled white matter changes after treatment. Other studies using imaging techniques 
showed regions of diminished grey matter volume in the left hippocampus, frontal structures of the brain 
and within more lateral temporal areas in patients with OSA after CPAP treatment.97,118,119 These findings 
suggest that cognitive impairment seen in middle-aged patients with moderate to severe OSA is 
associated with damage to brain tissue in areas involved in several cognitive tasks. In addition, nocturnal 
intermittent hypoxia and fragmented sleep could be culprits in cognitive and brain structural deficits in 
OSA.  
Studies that restricted their populations to older adults or whose mean age occurred in that range 
(i.e., ages 61 – 70) generally show weaker results with cognition where associations were identified. 
Otherwise the plurality of findings in studies where potential confounders were accounted for were null 
findings. First, consider evidence for hypoxia indices and executive, memory and attention. Boland et 
al.120 in their study examined the effect of Respiratory Disturbance Index (RDI) values on attention, 
executive function and memory in 1700 subjects free of clinically diagnosed SDB who underwent at-
home polysomnography (PSG) as part of the Sleep Heart Health Study (SHHS). This study controlled for 
age, education, occupation, field center, diabetes, hypertension, body-mass index, use of CNS 
medications, and alcohol drinking status, and found no association between the RDI and any of the three 
cognitive function measures assessed. Foley et al.121 assessed the association between sleep-disordered 
breathing and cognitive functioning in an elderly cohort of Japanese-American men and found no 
association between sleep-disordered breathing and memory function, concentration, and attention.  
Phillips et al.122 and Sforza et al.123 also had null findings between AHI findings and global cognition, 
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attention, executive function, memory, language and motor functions. Dlugaj et al.124 examined the 
association between Mild Cognitive Impairment (MCI) and MCI sub-types and SDB severity and found 
no association. Except for Sforza and Dlugaj, the other studies made use of a healthy population and this 
may have contributed to this finding. 
On the contrary, other studies conducted in older adults showed associations between OSA and 
delayed verbal memory,125,126 non-verbal IQ memory delayed recall,127 executive function, and 
attention128,129 and decreased vigilance.130 As earlier specified most of these studies were only able to 
demonstrate relatively weak associations. For example, Yesavage et al.,129 Terpening et al.,131 and Berry 
et al.,127 demonstrated effects between hypoxia measures and cognitive measures that were minimally 
significant. Perhaps OSA in older adults with MCI rather than in healthy older adults is the critical 
correlate of cognition in older adults.  Kim et al.132 specifically examined the effect of SDB in older adults 
with MCI on language test performance. Individuals with MCI have an increased risk of developing AD. 
Although the study found no differences between MCI and control groups on AHI and hypoxia measures, 
higher AHI was associated with language test performance among individuals with MCI. These findings 
possibly reflect frontal-subcortical pathology in patients with MCI suggesting that susceptibility to a 
specific brain damage associated with OSA could increase the risk for AD. 
Examination of studies conducted in the elderly (i.e. ages > 70 years) are also contradictory; 
however, more recent studies tend to show associations between hypoxemia and executive function or 
global cognition. Blackwell et al130 examined SDB and cognition in elderly men and adjusted for age, 
race, education, BMI, lifestyle, comorbidities and medication use. Findings from the study showed 
significant associations between SDB and cognition. Spira et al.133 conducted a similar study in elderly 
women and determined whether the apolipoprotein E (APOE) e4 allele modifies the association. Results 
showed that increased AHI was associated with decreased cognition and APOE4 increased this risk by 
five times.  
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OSA and Cognitive Decline (Longitudinal studies) 
Main findings 
Table 4.2 summarizes the only seven prospective epidemiological studies that have attempted to 
answer this critical question. Six of the studies were in older adults and the elderly while one study 
included a mixture of middle-aged, older adults and the elderly.  
In older adults and elderly, OSA at baseline may be a weak predictor of cognitive decline. Only 
two studies that included older adults and the elderly reported significant cognitive associations with OSA 
that were mostly modest. Blackwell et al. conducted a population-based study in a setting that included 
six centers in the United States. They included community-dwelling older men without cognitive 
impairment at baseline, and followed them for approximately 3 years. Results from the study showed a 
modest association between nocturnal hypoxemia and subsequent decline in cognition. Martin et al 
utilized a subset of individuals enrolled in the PROgnostic indicator OF cardiovascular and 
cerebrovascular events, study (PROOF). They assessed whether cognitive function changes occurred in 
untreated elderly SBD patients and without dementia. After an 8-year follow-up, SDB showed a 
minimally significant association with decline in the attentional domain and this was more evident in the 
patients with an AHI > 30. There were no significant changes in the executive and memory functions over 
the follow-up period. In this study chronic hypoxemia accounted for between 4–7% of variance in the 
decline in attention. In contrast, Cohen-Zion et al in their study utilizing community-dwelling elderly 
individuals with high risk for SDB found no association of hypoxia indices with cognitive decline after 
controlling for oximetry, sleep and subjective report. However, a significant association existed between 
increases in daytime sleepiness and declining cognitive function. In addition, Lutsey et al utilizing a 
subset of individuals from The Atherosclerosis Risk in Communities (ARIC) study, who participated in 
the Sleep Heart Health Study (SHHS), examined the effect of OSA and cognitive decline over a 15-year 
follow-up. Overall, this study found no evidence that OSA severity, degree of nocturnal hypoxemia, sleep 
fragmentation, or habitual sleep duration were associated with subsequent cognitive decline. The 
relationship between midlife OSA and later life cognition was also null. 
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Studies examining the relationship between OSA and Dementia outcomes tend to be more 
consistent in their findings. Yaffe et al in their prospective study of SDB and cognition in elderly women 
without dementia at baseline who were a substudy of the Study of Osteoporotic Fractures (SOF) followed 
for approximately 5 years, found that elderly women had an 85% increased risk of developing 
MCI/Dementia. In another study, Yaffe and her colleagues conducted a retrospective cohort study using 
medical record data, and examined the relationship between a diagnosis of sleep disturbance and 
dementia in elderly veterans. Sleep disturbance was significantly associated with an increased risk of 
dementia and specifically, OSA demonstrated significant associations with increased risk of AD, Vascular 
dementia and other dementias combined (frontotemporal dementia, senile dementia, or dementia not 
otherwise specified). Furthermore, Chang et al in their retrospective matched-control cohort study that 
utilized data from Taiwan’s Health Insurance Database estimated dementia risk in OSA versus non-OSA 
patients in individuals 40 years and older, followed for 5 years. Results from the study showed a 70% 
increased risk of developing dementia among OSA compared to non-OSA individuals. This study also 
demonstrated gender-dependent, age-dependent and time-dependent associations of OSA and dementia. 
OSA females were more like to develop dementia; OSA males aged 50-59 (middle-aged) had an 
increased risk for developing dementia, while OSA females aged ≥ 70 years (elderly) had a greater risk of 
developing dementia, and OSA patients were more likely to develop dementia in the first 2.5 years of 
follow-up. 
Summary, critique and future research directions 
In middle-aged adults, cross-sectional studies mostly demonstrate that OSA is often associated 
with cognitive decline. Longitudinal studies demonstrating that OSA can precede cognitive decline in 
middle-aged adults are rare, however, the one study that examined this relationship, suggests so. 
Nocturnal intermittent hypoxia and fragmented sleep could be culprits in cognitive and brain structural 
deficits in middle-aged OSA patients. Studies utilizing brain-imaging techniques suggest that cognitive 
impairment seen in middle-aged patients with moderate to severe OSA is associated with damage to brain 
tissue in areas involved in several cognitive tasks including grey matter volume in the left hippocampus, 
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frontal structures of the brain and lateral temporal areas. CPAP treatment seems to be beneficial however 
over a long-term as one study reported an almost complete reversal of white matter abnormalities over the 
course of 12 months CPAP treatment.  
In older adults and elderly, cross-sectional studies have not consistently demonstrated OSA-
Cognition associations and studies that identified such only revealed relatively weak associations. This 
distinction and pattern in OSA-Cognition associations in middle-aged, older adults and elderly provides 
the foundation for envisioning age-related modification of OSA-cognition relationships. Most of the 
studies that examined this relationship in healthy community older adults revealed null associations. On 
the contrary, studies examining this association in older adult OSA patients with MCI consistently 
showed significant associations of OSA with cognition, suggesting that perhaps OSA in older adults with 
MCI rather than in healthy older adults is the critical correlate of cognition in older adults. Longitudinal 
studies in older adults and elderly, suggest that OSA at baseline may be a weak predictor of cognitive 
decline. However, longitudinal studies examining the relationship between OSA and Dementia outcomes 
produced consistent significant findings. This evidence that OSA can possibly precede MCI/AD and that 
perhaps OSA in older adults with MCI rather than in healthy older adults is the critical correlate of 
cognitive decline in older adults, may indicate that the presence and deposition of the AD biomarker, beta 
amyloid, may be a moderator in these relationships. We consider this theme in the remaining sections.  
Methodological differences existed among studies reviewed and can be rightly viewed as 
limitations in the field of OSA and AD research. Issues related to the single assessment of OSA in 
longitudinal studies, absent or incomplete CPAP intervention information during follow-up, and the 
possibility that the etiological timeframe relevant for the association between OSA and AD could be 
outside the examined period, variability in ways in which cognition was assessed, and issues relating to 
selection bias, are all opportunities for future improvements. Many studies utilized clinic patients. It is 
clear that the likelihood of clinic attendance in such participants is associated with disturbed sleep. 
Therefore, when analyses are conducted on only such participants, biased results are likely the outcome. 
In addition, not all studies accounted for the possible role of depression and its symptoms, which may be 
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important mediator or confounder of the association between disturbed sleep and cognition.134,135 
Therefore, new research in the field should endeavor to separate causality relating to OSA, depression and 
cognition. 
Despite methodological strengths such as use of PSG sleep measures, and certain long follow-
ups, these were not all present in all studies, therefore limiting the strength of causal inferences that can 
be made. Lastly, future studies should examine whether these associations are causal, focusing on the 
mechanisms responsible for the somewhat different OSA effects seen at different ages or in different 
populations.  
 
OSA and Alzheimer’s disease (Cross-sectional studies) 
Main findings 
Studies examining any association between OSA and a diagnosis of AD were conducted in older 
adults and the elderly since most AD diagnoses occur after age 65 (Tables 4.3 and 4.4). The scarcity of 
epidemiological studies examining OSA and AD co-morbid associations was noteworthy. The five 
studies included were conducted some 2 to 3 decades ago and had varying findings (Table 4.3). Two 
studies136,137 demonstrated a significant association for OSA in AD patients relative to controls while 
three of the studies had null associations. However, a recent meta-analysis of these studies concluded that 
the aggregate odds ratio for OSA in AD vs. healthy control was 5.05 and homogeneous.85  Given the 
cross-sectional nature of these analyses, the data cannot be interpreted as suggesting direction of causality 
or temporality between OSA and AD. However, it does suggest the possibility of a reciprocal relationship 
between these two disorders. OSA possibly facilitates progressive central nervous alterations and 
excessive daytime sleepiness in patients and this further increases the risk of cognitive decline or AD 
progression in older adults.86  
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OSA and AD Pathology  
Main findings 
Cross-sectional studies 
Observational studies of OSA and AD pathology are vital in establishing links between OSA and 
AD. If the relationship between OSA and AD is causal then demonstrating AD-specific neuropathology 
resulting from increased disease burden in OSA patients can be vital. Cross-sectional studies examining 
this association were conducted mostly in older adults and the elderly. We identified two studies 
conducted in middle-aged participants (Table 4.4). A recent study by Yun et al138 examined whether OSA 
increased brain amyloid burden relative to controls in middle-aged participants from the Korean Genome 
and Epidemiology Study. After adjusting for potential confounders, OSA patients had a higher brain 
amyloid burden in the right posterior cingulate gyrus and right temporal cortex, relative to controls, 
suggesting that OSA may have been responsible for these findings. In this study, examination of regional 
differences in cortical thickness were not significant. Bu et al.139 examined whether hypoxia indices in 
OSA was associated with serum amyloid (Aβ40, Aβ42), total tau and phosphorylated tau 181 (P-tau 181) 
comparing their levels with controls. Results from this study demonstrated significantly higher levels of 
serum Aβ40, Aβ42, total Aβ and P-tau 181 in OSA patients compared to control. Hypoxia indices 
including apnea-hypopnea index, the oxygen desaturation index, and the mean and lowest oxyhemoglobin 
saturations correlated positively with Aβ40, Aβ42, and total Aβ in OSA patients, suggesting that hypoxia 
possibly effects AD pathogenesis. 
In older adults, all cross-sectional studies examined demonstrated associations between OSA and 
AD pathology (Table 3). Osorio et al140 examined whether an association existed between SDB severity, 
cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers, and the APOE alleles in cognitively 
normal older adults. Findings from the study demonstrated an association between SDB and CSF 
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AD- biomarkers. They also found an association between intermittent hypoxia and increases in CSF T-
Tau, P-Tau and Aβ42 in ApoE3+, suggesting that hypoxia may be responsible for changes in the AD 
biomarkers in this population of cognitive normal older adults. In ApoE4+ subjects, the study did not 
detect significant SDB group differences for Aβ42, T-Tau or P-Tau, though SDB severity tended towards 
lower CSF Aβ42 levels. However, participants were at varying stages of preclinical disease amongst the 
ApoE4+ subjects. A recent study by Liguori et al141 compared CSF β-amyloid42, tau proteins, and lactate 
levels in OSA versus CPAP treated OSA and controls. All participants had MCI. Findings from the study 
demonstrated lower CSF β-amyloid42, higher lactate levels and t-tau/ Aβ42 ratio compared to controls 
and CPAP treated OSA patients. Controls and CPAP treated OSA MCI patients had similar AD 
biomarker levels. These findings suggest that OSA may effect early AD biomarker changes that may be 
susceptible to CPAP treatment. Furthermore, in the elderly MCI patients, Spira et al showed that greater 
SDB severity was associated with greater brain amyloid burden 
 
Prospective/Longitudinal studies 
Lutsey et al142 examined whether diagnosed OSA in the middle-aged was associated with adverse 
morphological brain changes 15 years later. They utilized participants from the Atherosclerosis Risk in 
Communities Study (ARIC). After accounting for body mass index in a series of multivariate models, 
OSA at mid-life was not associated with cerebral markers of dementia or White Matter Hyper intensity 
brain volume or regional brain volume changes. This study’s strength is its length of follow-up, since 
dementia is known to have a long preclinical duration and middle-aged individuals may represent the 
etiological relevant phase, similar to other dementia risk factors including diabetes,143-145 hypertension,146-
149 and smoking.145,150 Also, use of community based participants rather than small sample sized clinic 
participants is also a plus. However, various methodological concerns could have been responsible for 
their findings. Selection bias issues could have occurred from loss to follow-up as a third of participants 
did not attend follow-up for neurocognitive assessments. The study had relatively few diagnosed severe 
OSA patients, necessitating lumping of moderate and severe OSA patients together, which could have 
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attenuated any association that could potentially have occurred in severe OSA patients.  The study also 
did not account for CPAP use or treatment of OSA during the follow-up period. In contrast, Osorio et al14 
using Alzheimer’s Disease Neuroimaging Initiative (ADNI) data examined whether SDB was associated 
with an earlier onset age at MCI or AD. The study also determined whether CPAP treatment delayed MCI 
or AD onset. Findings showed that in all population subsets examined, SDB patients had an earlier onset 
age to MCI or AD-dementia. CPAP use also delayed the age of MCI onset. This study utilized a well-
defined longitudinal cohort; however, study limitations include the self-reported SDB and CPAP status. 
 
Randomized Controlled Trials 
The most effective treatment for OSA is continuous positive airway pressure (CPAP). With 
CPAP treatment, OSA patients without dementia show an increase in slow wave sleep (SWS) and rapid 
eye movement (REM) sleep.151-154 However, what is the effect of CPAP on sleep parameters and 
cognition in AD patients with OSA? All four RCTs identified in this review included elderly participants 
(mean age > 70) and reported significant improvements in deep sleep,155 mood,156 cognition,156,157 and 
daytime sleepiness158 in OSA patients with AD (Table 4.4). For example, in a randomized placebo-
controlled trial, Cooke et al examined the effect of CPAP on sleep parameters in AD patients with OSA. 
The researchers administered 3 weeks of CPAP treatment and compared the outcome with 3 weeks 
placebo CPAP in patients with AD and OSA. Results from the study showed significant improvements in 
SWS after one night with the improved effect extending for three weeks. Chong et al also examined the 
effect of CPAP treatment on daytime sleepiness and found a significant reduction in patients with mild-
moderate AD with SDB after CPAP treatment. Examining the effects of CPAP on cognition in AD 
patients, Ancoli-Israel et al157 compared CPAP treatment for three weeks versus placebo CPAP for three 
weeks and found significant cognitive improvements. In addition, post-hoc analyses showed 
improvements in episodic verbal learning and memory, executive functioning such as cognitive 
flexibility, and mental processing speed.  
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A limitation identified in these RCTs include the issue of power to detect meaningful changes 
across treatment arms. Some studies were underpowered and as such could not make definitive statements 
specific to improvements within certain cognitive constructs. Other limitations include examination of 
sleep parameters post-hoc while the study was powered for changes in cognition, inability to make causal 
inferences due to non-random group assignment (continued use versus discontinuation of CPAP), limited 
validation of ESS in elderly patients with AD, and issues with generalizability. Despite these limitations, 
there is sufficient evidence to conclude that CPAP treatment may be effective in improving cognition in 
OSA patients with AD. 
Summary, critique and future research directions 
In older adults and the elderly, cross-sectional studies suggest the possibility of a reciprocal relationship 
between OSA and AD. The aggregate odds ratio in older adults, for OSA in AD vs. healthy control was 
5.05 and homogeneous as demonstrated in a recent meta-analysis. OSA patients have an increased risk of 
cognitive decline as shown in the above in the OSA and Cognition section, and cognitive decline 
increases the risk for AD. Methodological concerns relating to these studies include the fact that 
participants were mostly probable AD, because of the clinical and cognitive presentations of the enrolled 
patients and the lack of reported neuroimaging or biomarkers data. Participants were also significantly 
more educated which could have been responsible for the null findings seen in some studies. Higher 
educational level and cognitive reserve are known protective risk factors for OSA induced cognitive 
decline.86,159 Other studies failed to control for demographic and other possible confounders of the 
association between OSA and AD. For example, Smallwood et al.160 failed to account for gender 
differences in their sample. Women were significantly higher in their sample, which could have been 
responsible for their null findings since studies suggest that OSA is more prevalent in men and increases 
with age.161 
In middle-aged, older adults and elderly individuals, cross-sectional data consistently suggests 
that there is an association between OSA and preclinical-AD in the cognitively normal. Studies 
consistently demonstrated OSA associations with AD biomarkers including higher levels of serum Aβ40, 
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Aβ42, total Aβ and P-tau 181 in OSA patients compared to control, with APOE possibly acting as an 
effect modifier. Although determination of the causal relationships and directionality of these associations 
is limited in these studies, it is possible that OSA increases the risk for preclinical AD or vice versa.  
Prospective studies examining whether OSA accelerates amyloid deposition and effects regional 
brain morphological changes that contribute to the development or progression of Alzheimer’s disease are 
sparse in all age groups. The two prospective studies examined had contradictory findings. Both studies 
also had their strengths and weaknesses (see section on OSA and AD Pathology/Prospective studies). 
Therefore, future research is needed in the field to address the temporal nature of OSA-AD relationship 
and the possible mechanisms underlying the relationship.  
Evidence from RCTs provide an insight into the possibility of causal associations between OSA 
and AD and are somewhat compelling. All RCTs were conducted in the elderly, and showed that CPAP 
treatment not only improved sleep parameters in AD patients with OSA, such as improved SWS, and 
excessive daytime sleepiness, it also increased cognitive function including areas such as episodic verbal 
learning and memory, executive functioning such as cognitive flexibility, and mental processing speed. 
Such compelling is the evidence such that effects were seen with a single night of CPAP treatment. These 
findings clearly provides evidence that AD patients (particularly mild to moderate AD) with OSA can 
benefit from CPAP treatment. It is also important to note that studies have shown that management of AD 
with donepezil improved various hypoxia and sleep duration measures, suggesting that the cholinesterase 
inhibitor improves subjective measures of OSA independently, 162,163 therefore highlighting the potential 
reciprocal relationship between sleep and AD. 
Future RCTs need to include dose-response studies stratified not only to the mild, moderate, and 
severe categories of OSA, but also to include categories addressing duration of disease, extent of 
intermittent hypoxemia extent, fragmented sleep severity, and presence of comorbidities. Issues with 
design and sample size of double-blinded, placebo controlled clinical trials addressing the effect of CPAP 
exist and need to be improved. Furthermore, as Pan et al164 noted in their review, non-inferiority trials 
utilizing sleep apnea dental devices or other non-PAP therapeutics will also be beneficial. 
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DISCUSSION 
Altogether, over three decades of research has investigated OSA-cognition, OSA-cognitive decline 
and OSA-AD associations in the middle-aged, older adults and elderly. The data suggests the following: 
- OSA is associated with greater cognitive deficits in middle-age adults than in older adults and the 
elderly;  
- OSA is associated with greater risk of subsequent cognitive decline in middle-aged adults than in 
older adults and elderly;  
- OSA in older adults with MCI rather than in healthy older adults may be the critical correlate of 
cognition in older adults, therefore suggesting that presence or absence of amyloid burden might 
act as a moderator in these relationships. This could be responsible for findings showing 
increased amyloid deposition in older MCI patients with higher AHI but not in cognitive normal 
controls165 
- There is a link between OSA and AD biomarkers of neurodegeneration (e.g. Aβ40, Aβ42, total 
Aβ and P-tau 181) and subsequent cognitive decline, in the middle-aged, older-adults and even in 
elderly cognitive normal individuals.  
We believe that this distinct pattern observed in OSA-Cognition and OSA-AD biomarker associations in 
middle-aged, older adults and elderly provides the foundation for envisioning age-related modification of 
OSA-cognition relationships. 
A pertinent question arises from the findings: why are OSA-cognitive associations particularly 
pronounced in the middle-aged and less so in older adults or the elderly? Several studies suggest that the 
link between sleep and cognition weakens with increasing age because the aging brain is unable to 
adequately and efficiently facilitate specific sleep supported cognitive processes.166-171 If this is true, then 
it could have been responsible for the null or weaker results with cognition where associations were 
identified in older adults and the elderly in this review. It also implies that improving duration and quality 
of sleep in older adults and the elderly may not improve cognitive dysfunction because of diminished 
neural plasticity, increased neuronal loss and atrophy, neuroendocrine changes, and nocturnal hypoxia 
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that occurs as one ages.172 These neurobiological changes seen in older adults and the elderly may also 
compromise memory consolidation processes despite possible preservation of slow wave sleep amplitude 
and density. Scullin and Bliwise in their review make the case that functional weakening of the brain in 
their support of sleep-specific cognitive processes as we age, that hippocampal—neocortical 
consolidation will not occur regardless of slow wave sleep quantity, if the hippocampus, neocortex, or 
hippocampal—neocortical connections are greatly impaired in aging.170,173 
Another pertinent question from the above is what mechanisms underlie the subsequent cognitive 
decline in the middle-aged, even when no OSA-cognition associations are seen in older adults and the 
elderly? Scullin and Bliwise highlight the possibility of disturbed sleep causing changes in sleep 
modulated cognitive functions across the lifespan such that there is weakening of and/or compensation 
attempts incited at sleep-cognition links. They note that studies demonstrate increases in insulin, cortisol, 
blood pressure, proinflammatory cytokines and sympathetic tones, during acute or chronic sleep 
restriction states,174,175 all of which possibly hasten cognitive aging.176 In addition, experimental studies 
show that restriction of sleep in young animals can increase beta amyloid burden,177,178 and cause protein 
misfolding,179 therefore compromising consolidation of memory.180,181 The prolonged accumulation over 
time of beta amyloid and protein misfolding in the young and middle-aged further results in irreversible 
neurodegeneration,182 thereby suggesting that sleep disturbances could possibly underlie subsequent 
cognitive decline, even when no sleep-cognition associations are expressed in older adults and the 
elderly.172 
In middle-aged OSA individuals with cognitive deficits and particularly in OSA elderly AD 
patients, randomized placebo controlled clinical trials provide promising findings of improvement of 
cognitive deficits that range from attention and vigilance to memory and executive function. Although 
CPAP improved hypoxia and other sleep measures relative to pre-CPAP indices, treated OSA patients 
demonstrate comparable level of performance in certain areas such as working memory storage functions, 
but still show deficits in other areas such as working memory.157,183 Furthermore, intricate 
neuropsychological measures of attention, psychomotor speed and executive function tend to improve 
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only minimally since intermittent hypoxia upregulates death of neurons and hypertrophy of astrocytes in 
the hippocampus and parietal cortex.184-186 The literature suggests that deprived sleep negatively affects 
the prefrontal cortex (PFC) which largely controls executive function.187,188 Maillet and Rajah189 in their 
review found that task performance matched between age groups yielded negative associations between 
regional PFC and activity in older adults, however, the reverse was the case between volume and right 
lateral PFC, when older adults performed worse than younger adults did. In addition, several studies 
showed that in healthy older adults, PFC activity is positively related to grey matter volume in the medial 
temporal lobe, but the reverse was observed in MCI and AD patients. In older adults, prefrontal sleep 
spindles that facilitates hippocampal episodic learning are markedly reduced, and the increase in disturbed 
sleep further compromises cognition.190,191 Therefore, OSA worsens metabolic injury192 that is particularly 
resplendent in middle-aged, and exacerbates neuronal injury and facilitates memory and cognitive 
impairment,193-197 that is particularly resplendent in older adults and the elderly. 
Recent exciting trends in the literature point to a link between OSA and AD biomarkers of 
neurodegeneration and subsequent cognitive decline, in the middle-aged, older-adults and even in elderly 
cognitive normal individuals. This finding across our entire examined age spectrum poses a thought 
provoking question as to why this is so. The data suggests that intermittent hypoxia and sleep 
fragmentation are two main processes by which OSA induces neurodegenerative changes. Chronic 
intermittent hypoxia, hypercapnia and hypertension in OSA can induce neuronal damage, including 
axons,198 white matter,199 and reduced Diffusion tensor imaging based mean diffusivity in multiple brain 
regions.200 Multiple studies also show grey matter loss in OSA patients compared to controls.119,201,202 As 
a result of the pathophysiological effect of hypoxia precipitating hypertension,203-206 hypoperfusion,207-209 
impaired glucose metabolism,210-212 and adverse cardiovascular,213,214 and metabolic consequences,215,216 
beta amyloid deposition,217-220 and tau hyperphosphyrylation,212,221-224 ultimately these effects lead to 
cognitive decline and progress to AD. In addition, inflammation,210,221-224 and oxidative stress,225,226 
upregulate neurocognitive impairment in OSA and sustained OSA-cognitive dysfunction overlay with 
that seen in AD-associated cognitive decline.82  
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CONCLUSION 
OSA may be age-dependent in older adults (60 – 70 years old) and the elderly (70 years and 
above) and is associated with neurodegenerative diseases particularly, cognitive decline and AD. In the 
middle-aged (30 – 60 years old), the data suggests that OSA may be age-related and presents with a 
distinct phenotype, with cardiovascular, and possibly metabolic effects. Intermittent hypoxia and sleep 
fragmentation are two main processes by which OSA induces neurodegenerative changes. 
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Table 4.1: Literature Search Terms for the Systematic Review of Obstructive Sleep Apnea, Cognition and 
Alzheimer’s disease                  
                    
 
Obstructive Sleep Apnea 
Related 
Cognition and Alzheimer's 
Disease Related 
Alzheimer's disease 
pathology related 
Sleep apnea Alzheimer's disease Dementia Amyloid beta  
OR Obstructive Sleep Apnea OR Cognitive Decline OR Amyloid beta 
deposition/generation 
OR Obstructive Sleep Apnea 
Syndrome 
OR Cognitive Impairment OR Alzheimer's disease 
pathogenesis 
OR Sleep Disordered Breathing OR Mild Cognitive Impairment 
(MeSH) 
OR Amyloid Precursor 
Protein 
OR OSA OR MCI OR Amyloid cascade 
hypothesis 
OR OSAH OR aMCI OR Inflammation 
OR Obstructive Sleep Apnea 
Hypopnea Syndrome 
OR Cognition OR P-Tau 
OR Respiratory Disturbance 
Index 
OR Alzheimer (MeSH) OR Phosphorylated Tau 
OR Apnea Hypopnea Index OR Cognitive function OR Hippocampal atrophy 
OR Hypoxia OR Neuropsychological 
function 
OR Apolipoprotein E  
OR Sleep Apnea Syndromes OR Executive function OR APOE4 
OR Sleep Apnea, Obstructive 
 
OR CSF-Tau 
OR Sleep Apnea, Central 
 
OR CSF-PTau 
OR Anoxia 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
234 
 
Table 4.2: Descriptive Study Characteristics and Main Findings: Obstructive Sleep Apnea, Cognition, Cognitive Decline and Alzheimer’s disease 
(Cross-sectional studies) 
 
Authors, 
Year 
Published 
Study Design, 
Setting (Study 
Quality) 
Subjects 
Cognitive Domains 
Adjusted 
Variables 
Major Findings Controls OSA+ 
Gender SDB Severity 
N Age N Age 
Middle Aged (30-60) 
Alchantis et 
al., 2008 
Cross-sectional, 
sleep clinic 
41 49 (33-63) 58 
49 (32-
65) 
N/A 
AHI: range 
31-137 
OSAS; 
Range=1-7 
NC 
Reaction time 
Age, AHI, 
SaO2min/mean, 
T90, BMI 
OSA individual’s ≥ 50 
had decreased reaction 
times. This effect was 
not seen in those <50. 
Bawden et 
al., 2011 
Cross-sectional 20 27.6 (8.7) 17 
41.4 
(13.0) 
N/A 
AHI: 5-
15/>15-30/ 
>30 
Global function, 
attention, memory, 
executive function 
Age, education 
OSA individuals had 
significantly impaired 
cognitive performance 
Canessa et 
al., 2011 
Controlled clinical 
trial 
15 
42.15 
(6.64) 
17 44 (7.63) All men AHI: ≥ 30 
Memory, executive 
functions, attention, 
constructional 
abilities, abstract 
reasoning, vigilance, 
ESS 
Age, education 
▪ At baseline OSA 
assoc. with 
↓neurocognitive 
function 
 ▪OSA group had 
improved 
neurocognitive 
function after 3 months 
of CPAP 
 ▪OSA assoc. with 
structural deficits 
Castronovo et 
al., 2009 
Controlled clinical 
trial 
14 
42.15 
(6.64) 
14 
43.93 
(7.78) 
All men AHI > 30 
Working memory, 
Brain activation 
(fMRI) 
Age, education 
▪OSA associated with 
over recruitment of 
brain regions in 
working-memory task  
▪Decreases in 
activation after 
treatment 
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Castronovo et 
al., 2014 
Prospective clinical 
study 
15 
42.15 
(6.64) 
13 
43.23 
(7.63) 
All men AHI ≥  30 
Global function, 
memory, attention, 
vigilance, abstract 
reasoning, visuo-
spatial, verbal 
Age, education 
▪After 12 months of 
CPAP treatment, 
almost a complete 
reversal of white 
matter abnormalities 
was seen ▪Significant 
improvements in 
neuropsychological 
function 
Ferini-
Strambi et al., 
2003 
Case-control, sleep 
clinic 
23 55.8 (5.4) 23 56.6 (6.1) 40M6F 
AHI: 
Controls: <5, 
OSA: ≥5-40 
Processing speed, 
language, executive 
function, motor 
learning 
Age, education 
▪ 15 days of CPAP 
treatment returned 
visuospatial and motor 
skills to normal ▪CPAP 
did not improve 
executive function/ 
constructional abilities 
Hrubos-
Strom et al., 
2012 
Cross-sectional, 
community 
N/A N/A 290 
48.2 
(11.2) 
162M 
129F 
AHI:<15/ ≥15 
Memory, Executive 
function 
Age, sex, 
education 
▪Average oxygen 
saturation was the 
indicator of obstructive 
sleep apnea severity 
most strongly assoc. 
with cognitive function 
Kim et al., 
2007 
Cross-sectional, 
community 
N/A N/A 611 
Range: 
35-74 
346 M 
265 W 
AHI: 
median=2.8; 
range=0-121 
Vigilance 
BMI, 
caffeine/alcohol 
consumption, 
smoking status, 
stimulants before 
testing 
▪SDB related with 
diminished vigilant 
attention performance 
Kloepfer et 
al., 2009 
Cross-sectional 20 47.4(5.6) 15 46.4 (5.9) 
22M 
13F 
Clinical 
diagnosis: 
AHI >5 and 
questionnaire 
Memory, global Age, sex, IQ 
▪Moderate OSA assoc. 
with impairment of 
procedural and verbal 
declarative memory 
Mathieu et 
al., 2008 
Cross-sectional, 
sleep clinic 
Younger: 
12 
 Older: 
18 
Younger: 
38.9 (2.2) 
Older: 
62.5 (1.8) 
Younger: 
14 
Older: 
14 
Younger: 
37.7 (2.0) 
Older: 
62.3 (2.0) 
26 M  
2 W 
AHI: 51(4) 
OSAS 
younger; 
43(4) OSAS 
older 
Attention, Executive 
Function, Memory 
Age, education 
▪No Group-by-Age 
interaction for 
cognitive performance. 
▪Main effects for both 
Group and Age 
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Naegele et 
al., 1995 
Cross-sectional 17 49 (3) 17 49 (3) All men RDI > 10 
Attentional capacity, 
memory efficiency, 
long-term memory, 
frontal lobe function 
Age, education, 
verbal IQ 
▪Memory deficits were 
associated with the 
number of apneas and 
hypopneas per hour of 
sleep ▪Typical frontal-
lobe related 
abnormalities were 
associated with levels 
of nocturnal 
hypoxemia 
Naegele et 
al., 2006 
Cross-sectional 95 47.4 95 48 144M46F RDI  ≥ 10 Memory Age, education 
▪OSA associated with 
impaired episodic 
memory, overall 
procedural memory 
performance, specific 
working memory 
capabilities ▪No 
impairment of 
maintenance, 
recognition, or 
forgetfulness 
Nikodemova 
et al., 2013 
Cross-sectional, 
community 
AHI <5 AHI 5-14 
AHI ≥ 
15 
Total 
1,081 M 
F 
AHI: <5/5-
14/≥ 15 
Memory, Executive 
function 
Age, sex, 
education, BMI 
▪No significant 
association between 
SDB and cognitive 
performance in 
APOE4- ▪AHI ≥15, 
APOE4+ associated 
with ↓cognitive 
function 
n: 1,148 
age: 52.1 
(9.9) 
n: 399  
age: 56.4 
(9.6) 
n: 298 
age: 56.6 
n:  1,845 
age: 53.9 
(10.1) 
age range: 
30-81  
Quan et al., 
2006 
Cross-sectional, 
community 
74 57.4(9.2) 67 59.4 (9.2) 
84M 
57F 
AHI: ≤5 
Attention and 
vigilance, processing 
speed, executive 
function, motor 
learning, visuospatial 
ability, memory 
Age, sex, 
education 
▪No significant impact 
of OSAH and 
neuropsychological 
function ▪↑hypoxemia 
associated with ↓motor 
and processing speed 
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Salorio et al., 
2002 
Cross sectional 24 44.2(8.5) 28 44.0 (7.9) 
34M 
18F 
Hypoxic 
episodes: 5-
20/21-35/>35 
episodes per 
hour 
Long-term Learning 
and Memory, 
Executive control 
Sex, education, IQ 
▪OSA individuals 
exhibited poorer recall, 
less efficient semantic 
clustering, poorer use 
of semantic cues 
▪Other than letter 
fluency, deficits were 
not observed in general 
executive control 
Saunamaki, 
Himanen, et 
al., 2009 
Controlled clinical 
trial 
15 
44 
Range: 
30-63 
15 
50 
Range: 
37-59 
All men AHI:≤5/> 10 WAIS-R Age, education 
▪OSAS associated with 
mild visually based 
cognitive dysfunction 
and reduced amount of 
sleep in the right 
hemisphere even after 
CPAP 
Saunamaki et 
al., 2010 
Controlled clinical 
trial 
17 
44Range: 
30-63 
20 
50 Range: 
37-65 
All men AHI:≤5/> 10 
WAIS-R; Short term 
memory, working 
memory, verbal 
fluency, visuomotor 
tracking, visuospatial 
organization 
Age, education, 
IQ 
▪OSAS showed poorer 
performance on 
executive tests ▪OSAS 
did not show any 
improvement on 
executive or 
visuospatial function 
even after long-term 
CPAP treatment 
Saunamaki, 
Jehkonen et 
al., 2009 
Controlled clinical 
trial 
20 
43 
Range: 
29-63 
40 
47 
Range: 
28-65 
All men AHI:≤5/> 10 
WAIS-R; Verbally-
based cognitive 
abilities, visually-
based cognitive 
abilities, 
Age, education 
▪OSAS had lower set-
shifting and 
analysis/synthesis 
performance than 
controls ▪Based on 
normative data, most 
had normal, while 
others had more 
serious deficits 
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Sharma et al., 
2010 
Cross-sectional 25 45.6 (6.2) 50 43 (7.5) 
63M 
12F 
AHI > 30 
 Alertness, working 
memory, response 
inhibition, problem 
solving, executive 
function 
Age, sex, 
education 
▪OSA subjects had 
significantly impaired 
performance on tests 
on alertness, working 
memory, response 
inhibition, problem 
solving, executive 
function ▪Significance 
disappeared after 
adjusting for delayed 
information processing 
Older Adults (61-70) 
Aloia et al., 
2003 
Cross-sectional, 
clinic 
Noncompliant Compliant 
N/A 
RDI: 51(20) 
OSAS 
compliant; 
46(22) OSAS 
noncompliant 
Attention, Executive 
Function, 
Construction, Motor 
Speed, Memory, 
Language 
Age, education, 
sleep apnea 
severity 
▪↑RDI related to↓ 
verbal delayed recall 
memory 
▪↑sleep fragmentation 
and hypoxemia 
associated with↓ verbal 
delayed recall memory  
▪Cognitive benefits 
with CPAP compliance 
6 64.8 (2.6) 6  64.8 (6.4) 
Berry et al., 
1990 
Cross-sectional, 
sleep clinic 
12 68.4 (2.2) 8 68.6(4.8) Men only 
AHI: 28(12) 
OSAS; 
3(3)NC 
Global, IQ, Memory   
▪OSAS: ↓nonverbal IQ 
and nonverbal memory 
delayed recall 
Boland et al., 
2002 
Cross-sectional, 
community 
N/A N/A 1700 
62 (range 
52-75) 
837M923W 
RDI median 
range: .4-23 
Attention, Executive 
Function, Memory 
age, education, 
occupation, field 
center, diabetes, 
hypertension, 
body-mass index, 
CNS meds, 
alcohol use 
▪No relationships 
Dlugaj et al., 
2014 
Cross- sectional, 
population-based 
AHI <15 AHI 15-29 
AHI ≥ 
30 
Total 
919M 
874F 
AHI; <15/15-
29/ ≥ 30 
Memory, executive 
function 
Age, sex, 
education 
▪SDB not associated 
with MCI or MCI 
subtypes (amnestic and 
non-amnestic) 
n: 1323 
age: 
62.94 
(7.23) 
n: 327 
age: 65.79 
(7.41) 
n: 143 
age: 
62.17 
(7.31) 
n: 1793 
age: 63.79  
(7.45) 
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Foley et al., 
2003 
Cross-sectional, 
community 
N/A N/A 718 
Range: 
79-97 
Men only 
71% had 
AHI≥5; 19% 
had AHI ≥ 30 
Global, Attention, 
Executive Function, 
Construction, 
Memory, Language 
Age, education, 
marital status 
▪No relationships 
Ju et al., 2012 
Case-control, sleep 
clinic 
21 68.7 (5.5) 42 68(4.4) 
37M 
26F 
AHI: Controls 
:< 15. OSA: 
<15.3* 
General 
cognitive/intellectual 
ability, executive 
function 
Age, sex, 
education, BMI 
▪Significant findings 
with delayed recall and 
executive function 
Kim et al., 
2011 
Cross-sectional, 
clinic 
N/A N/A 30 67.4 (3.8) 
42M 
18W 
AHI: 13(12) 
MCI;15(14) 
NC 
Executive function, 
Language, Memory, 
Visuospatial 
construction 
  
▪↑AHI associated with 
language with MCI 
Lutsey et al., 
2016 
Cross-sectional 521 60.7 (5.1) 445 62(4.9) 
435M 
531W 
AHI (<5/5- 
14.9/15-
29.9/≥30) 
Global 
Age, sex, field 
center, education, 
alcohol intake, 
smoking, physical 
activity, APOE4, 
BMI, CRP, CVD 
comorbidities 
▪OSA category and 
additional indices of 
sleep were not 
associated with change 
in any cognitive test 
Phillips et al., 
1992 
Cross-sectional, 
community 
N/A N/A 92 64.2 (8.6) 
44M 
48W 
AHI: 3(4) 
Global, IQ, Attention, 
Executive Function, 
Memory, Language, 
Motor 
None 
▪No relationship 
between AHI and 
cognition 
Sforza et al., 
2010 
Cross-sectional, 
community 
382 
Combined 
exposure 
and 
controls: 
68(1.8) 
445 
Combined 
exposure 
and 
controls: 
68(1.8) 
343M 
484W 
AHI: 20(15); 
53% had 
AHI≥15 
Global, Attention, 
Executive Function, 
Memory, Language 
gender, BMI, 
diabetic status, 
hypertension, 
education level, 
anxiety and 
depression scores, 
ESS, blood 
pressure, self-
reported sleep 
time 
▪No relationships 
Terpening et 
al., 2015 
Case-
control(convenience 
sample), 
community 
N/A N/A 40 63.5 (8.9) 19M21F   Processing speed   ▪Findings significant** 
Yesavage et 
al., 1985 
Cross-sectional, 
sleep clinic 
N/A N/A 41 69.5 (6.5) Men only 
RDI: 26(30); 
73% had 
RDI>5 
Attention, Executive 
Function, Memory 
Age, depression, 
education, typical 
sleepiness/fatigue 
▪RDI associated with 
attention and executive 
function 
Elderly (>70) 
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Blackwell et 
al., 2011 
Cross-sectional, 
population-based 
N/A N/A 2,909 76 (6) Only men 
AHI: <5/5-
14/≥ 30 
Global, Executive 
Function 
Age, race, clinic, 
BMI, IADL, CVD 
comorbidities, 
antidepressant 
use, 
benzodiazepine 
use, depressive 
symptoms, 
education, alcohol 
use, smoking, 
physical activity, 
self-reported 
health 
▪↓ time in REM, ↑ time 
in Stage 1 sleep,  and 
↑nocturnal hypoxemia 
are associated with 
poorer cognition 
Hayward et 
al., 1992 
Cross-sectional, 
community 
N/A N/A 96 78 (3.9) 
21 M 
75 W 
RDI: 6(6) 
Attention, Executive 
Function, Memory, 
Language, Motor 
Age, education 
▪RDI not associated 
with memory, verbal, 
or motor factors 
▪RDI associated with 
cerebral efficiency 
factor  
Spira et al., 
2008 
Cross-sectional, 
community 
391 82.7 (3.3) 57 83.6 (4.3) 
Women 
only 
AHI:  <30/≥ 
30 
Global, Executive 
Function 
Age, Education, 
SSRI (BMI and 
functional 
impairment were 
found to not have 
a significant 
impact on results) 
▪↑AHI&↑hypoxemia& 
↑central apnea 
associated with 
cognition 
▪APOE4+ associated 
with 5x risk of 
cognitive impairment 
Abbreviations: a, adjusted; Aβ40/42, amyloid beta-40/42; AD, Alzheimer’s disease; AFCFT, alphabetic fluency and category fluency tasks; AHI ≥ 15, apnea hypopnea index of 15 or more events per 
hour of sleep; APOE, apolipoprotein epsilon4; BVRT, Benton visual retention test; c, crude; CAR, circadian activity rhythms; CASI, cognitive abilities screening instrument; CERAD, consortium to 
establish a registry for Alzheimer’s disease; CPRS, comprehensive psychopathological rating scale; CSF, cerebrospinal fluid; CVLT, California verbal learning test; DSM-IIIR/IV-TR, diagnostic and 
statistical manual of mental disorders; third edition/fourth edition, text revised; EDS, Excessive daytime sleepiness; ESS, Epworth sleepiness scale; GBSRT, Grober and Buschke selective reminding 
test; HAM-D, Hamilton Depression Rating Scale; HR, hazard ratio; ICD-9/10, international classification of diseases ninth/tenth edition AD criteria; IQCODE, informant questionnaire on cognitive 
decline in the elderly; MMSE, mini mental state examination; MRI, magnetic resonance imaging; N, number of participants; NA, not applicable; N/A, not available; NINCDS-ADRDA, national institute 
of neurological and communicative disorders and stroke and the Alzheimer’s disease and related disorders association; NINDS-AIREN, national institute of neurological disorders and stroke and 
association internationale pour la recherche et l’enseignement en neurosciences vascular dementia criteria; OR, odds ratio; PSG, polysomnography; PSQI, Pittsburgh sleep quality index; P-tau, 
phosphorylated tau; RBANS, repeatable battery for the assessment of neuropsychological status; RR, relative risk; SDB, sleep disordered breathing; SPMSQ, short portable mental status questionnaire; 
TONI, test of nonverbal intelligence; Trails B, trail making b test; TST, total sleep time; T-tau, total-tau; WAIS-III, Wechsler adult intelligence scale third version; WASO, wake after sleep onset; 
WHIIRS, women’s health initiative insomnia rating scale; WMS-R, Wechsler memory scale-revision; w/o, without. 
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Table 4.3: Descriptive Study Characteristics and Main Findings: Obstructive Sleep Apnea, Cognition, Cognitive Decline and Alzheimer’s disease 
(Longitudinal studies – older adults mainly) 
        
 
Authors, 
Year 
Published 
Study 
design, 
setting 
(study 
quality) 
Subjects 
Cognitive 
Domains 
Adjusted Variables Major Findings Controls OSA+ 
Gender 
SDB 
Severity N Age N Age 
Blackwell et 
al., 2015 
Longitudinal, 
community 
based 
1,504 
75.8 
(5.3) 
1,132 
76.4 
(5.2) 
Men 
only 
ODI: <15, 
≥15 
AHI: <15,  
≥15) 
Global 
Age, site, race, BMI, 
education, depressive 
symptoms, CVD 
comorbidities, Parkinson's 
disease, IADL, 
benzodiazepine use, 
antidepressant use, self-
reported health, physical 
activity, alcohol intake, 
smoking 
▪No significant association 
between AHI and cognitive 
decline in older community-
dwelling men 
▪Modest association of 
nocturnal hypoxemia with 
global cognitive decline 
Chang et al., 
2013 
Longitudinal, 
community 
based 
7,070 
55.5 
(4.78) 
1,414 
55.5 
(4.93) 
M: 
5,034 
F: 
3,450 
Not 
specified; 
clinical 
diagnosis 
(according to 
the 
guidelines of 
the AASM) 
Dementia 
diagnosis 
Age, sex, CVD 
comorbidities, urbanization 
level, income 
▪ Hazard ratio of dementia is 
1.44 times greater for patients 
with SA than for the 
comparison group 
▪SA is an age, time, and gender 
dependent risk factor for 
dementia 
Cohen-Zion 
et al., 2001 
Longitudinal, 
Community 
N/A N/A 46 80(3) 
7M 
39 W 
RDI: 10(9) Global Age, education 
▪↑EDS associated with global 
cognitive decline over 3 years 
follow-up ▪Hypoxemia and RDI 
not associated with cognition 
Lutsey et al., 
2016 
Longitudinal 521 
60.7 
(5.1) 
445 62(4.9) 
435M 
531W 
AHI: <5/5- 
14.9/ 15-
29.9/ ≥30 
Global 
Age, sex, field center, 
education, alcohol intake, 
smoking, physical activity, 
APOE4, BMI, CRP, CVD 
comorbidities 
▪OSA category and additional 
indices of sleep were not 
associated with change in any 
cognitive test 
N/A N/A 599 67.0 (1) Global 
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Martin et al., 
2015 
Longitudinal, 
population 
based 
224M 
335W 
AHI: <15/ 
15-30/ >30) 
Age, sex, education, follow-
up length, BMI, ESS, CVD 
comorbidities, anxiety, 
depression 
▪Abnormal breathing events 
associated slightly with decline 
in attentional domain  
▪No association with changes in 
executive and  memory function 
Yaffe et al., 
2011 
Longitudinal, 
Community 
193 82.1(3.2) 105 82.6(3.1) 
Women 
only 
AHI:  ≥15 
Global, 
Attention, 
Executive 
Function, 
Memory 
Age, race, BMI, education, 
smoking, diabetes, 
hypertension, antidepressant 
use, benzodiazepine use, 
non-diazepam anxiolytics use 
▪SDB: ↑hypoxemia had ↑risk of 
developing MCI or dementia 
over 5 year follow-up▪Sleep 
fragmentation and duration not 
associated with cognition 
Yaffe et al., 
2015 
Longitudinal ###### 68.5 13,480 66.9 
Men 
Only 
Not 
specified; 
clinical 
diagnosis 
Dementia 
(classified using 
International 
Classification of 
Disease, Ninth 
Revision codes) 
Age, CVD comorbidities, 
obesity, depression, income, 
education 
▪Those with a sleep disturbance 
had a 27% increased risk for 
dementia (HR: 1.27) 
Abbreviations: a, adjusted; Aβ40/42, amyloid beta-40/42; AD, Alzheimer’s disease; AFCFT, alphabetic fluency and category fluency tasks; AHI ≥ 15, apnea hypopnea index of 15 or more events per 
hour of sleep; APOE, apolipoprotein epsilon4; BVRT, Benton visual retention test; c, crude; CAR, circadian activity rhythms; CASI, cognitive abilities screening instrument; CERAD, consortium to 
establish a registry for Alzheimer’s disease; CPRS, comprehensive psychopathological rating scale; CSF, cerebrospinal fluid; CVLT, California verbal learning test; DSM-IIIR/IV-TR, diagnostic and 
statistical manual of mental disorders; third edition/fourth edition, text revised; EDS, Excessive daytime sleepiness; ESS, Epworth sleepiness scale; GBSRT, Grober and Buschke selective reminding 
test; HAM-D, Hamilton Depression Rating Scale; HR, hazard ratio; ICD-9/10, international classification of diseases ninth/tenth edition AD criteria; IQCODE, informant questionnaire on cognitive 
decline in the elderly; MMSE, mini mental state examination; MRI, magnetic resonance imaging; N, number of participants; NA, not applicable; N/A, not available; NINCDS-ADRDA, national institute 
of neurological and communicative disorders and stroke and the Alzheimer’s disease and related disorders association; NINDS-AIREN, national institute of neurological disorders and stroke and 
association internationale pour la recherche et l’enseignement en neurosciences vascular dementia criteria; OR, odds ratio; PSG, polysomnography; PSQI, Pittsburgh sleep quality index; P-tau, 
phosphorylated tau; RBANS, repeatable battery for the assessment of neuropsychological status; RR, relative risk; SDB, sleep disordered breathing; SPMSQ, short portable mental status questionnaire; 
TONI, test of nonverbal intelligence; Trails B, trail making b test; TST, total sleep time; T-tau, total-tau; WAIS-III, Wechsler adult intelligence scale third version; WASO, wake after sleep onset; 
WHIIRS, women’s health initiative insomnia rating scale; WMS-R, Wechsler memory scale-revision; w/o, without. 
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Table 4.4    Descriptive Study Characteristics and Main Findings: Obstructive Sleep Apnea, and Alzheimer’s disease/AD Pathology            
                    
 
Authors, Year 
Published 
Study 
Design 
Subjects 
OSA 
assessment 
Alzheimer's disease 
assessment 
Adjusted Variables Major findings 
N 
Age 
(Mean ± 
SD) 
Gender 
OSA and AD 
Hoch et al., 
1986 
Cross-
sectional 
80 71.5 (8.1) 
33 M 
57 F 
AHI DSM-III None Significant association 
Hoch et al., 
1989 
Cross-
sectional 
27 74.5 (5.1) 
7 M 
20 F 
AHI 
NICNDS-ADRDA, 
DSM-III 
N/A 
No association between OSA 
and dementia 
Reynolds et 
al., 1985 
Cross-
sectional 
61 69.7 (6.8) 
19 M 
42 F 
AI, AHI 
DSM 3, Hamilton 
rating, Folstein 
score, and a 
modified Hachinski 
Ischemia score 
Gender 
Significant association between 
sleep apnea and dementia in 
women 
Reynolds et 
al.,1987 
Cross-
sectional 
30 73.3 (9.1) 
3 M 
12 F 
24 Chanel 
polygraphs 
DSM 3, Hamilton 
rating, Folstein 
score, and a 
modified Hachinski 
Ischemia score 
N/A 
No association between OSA 
and dementia 
Smallwood et 
al., 1983 
Cross-
sectional 
55 
Range: 23-
81 years 
45 M 
10 F 
AHI 
DSM 3, neurological 
examination 
Age, sex 
 
No relationship between 
dementia and apnea severity 
OSA and AD pathology 
Bu et al., 2015 
Cross-
sectional 
94 
43.62 
(9.78) 
67M 
27F 
AHI, ODI, 
MSaO2, 
LSaO2 
Amyloid beta levels Age, sex 
Significant association between 
hypoxia and amyloid levels 
Ligouri et al., 
2017 
Cross-
sectional 
50 
66.96 
(7.98) 
33M 
17F 
AHI 
CSI classified by 
subjective memory 
decline, cognitive 
performance 
Age, education 
Significant association between 
OSA and CSF AD biomarkers 
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Lutsey et al., 
2017 
Prospective 312 61.7 (5.0) 
145M 
167F 
AHI, SHHS 
Sleep Habits 
Questionnaire 
Neurocognitive 
exam, brain MRI 
age, sex, field center, 
education, physical 
activity, ethanol intake, 
smoking status,  leusire 
time physical activity, 
and APOE e4 risk 
allele, BMI 
No relationship between mid-
life OSA and dementia 
Osorio et al., 
2014 
Cross-
sectional 
95 67.6 37M58F AHI 
Neuropsychological 
test battery 
Age, BMI, CSF internal 
batch, time interval 
between sleep study and 
lumbar puncture,ApoE4 
status 
Significant association between 
SDB and AD CSF biomarkers 
Osorio et al., 
2015 
Prospective 2,285     Self reported 
Self-report; 
diagnosis by 
clinician 
APOE e4 status, sex, 
education, BMI, 
depression, 
cardiovascular disease, 
hypertension, diabetes, 
and age 
Significant association between 
SDB and earlier age at 
cognitive decline 
Yun et al., 
2017 
Cross-
sectional 
38 56.7 (4.0) 
M: 18 
F: 20 
AHI 
Neuropsychological 
test battery 
Age, sex, education, 
APOE genotype, status 
of sleep duration, 
hypertension, diabetes, 
BMI, exercise, 
depressive mood, 
smoking, and alcohol 
drinking 
Significant association between 
OSA and amyloid deposition 
Random Control Trials 
Ancoli-Israel 
et al., 2008 
RCT 52 78.2 (7.2) 
39M 
13F 
Rechtschaffen 
and Kales 
criteria 
Nueropsychological 
test battery 
None 
CPAP improved some 
cognitive functioning 
Chong et al., 
2006 
RCT 39 78.0 (7.04) 
29M 
10F 
RDI 
NINCDS-ADRDA 
criteria 
None 
CPAP reduces sleepiness in 
those with AD and OSA 
Cooke et al., 
2009a 
RCT 52 77.8 (7.3) 
39M 
13F 
Rechtschaffen 
and Kales 
criteria 
NINCDS-ADRDA 
criteria, MMSE 
None 
After one night of tCPAP use: 
deeper sleep, affects for three 
weeks 
Cooke et al., 
2009b 
RCT 10 75.7 (5.9) 
7M 
3F 
AHI, PSQI, 
ESS, FOSQ 
Neuropsychological 
test battery 
None 
Sustained CPAP use associated 
with less cognitive decline  
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Spira et al., 
2014 
RCT 13 71.6 (7.8) 
7M 
6F 
AHI, ODI 
Neuropsychological 
tests, GDS, CDR 
None 
SDB severity associated with 
amyloid deposition 
Abbreviations: a, adjusted; Aβ40/42, amyloid beta-40/42; AD, Alzheimer’s disease; AFCFT, alphabetic fluency and category fluency tasks; AHI ≥ 15, apnea hypopnea index of 15 or more events per 
hour of sleep; APOE, apolipoprotein epsilon4; BVRT, Benton visual retention test; c, crude; CAR, circadian activity rhythms; CASI, cognitive abilities screening instrument; CERAD, consortium to 
establish a registry for Alzheimer’s disease; CPRS, comprehensive psychopathological rating scale; CSF, cerebrospinal fluid; CVLT, California verbal learning test; DSM-IIIR/IV-TR, diagnostic and 
statistical manual of mental disorders; third edition/fourth edition, text revised; EDS, Excessive daytime sleepiness; ESS, Epworth sleepiness scale; GBSRT, Grober and Buschke selective reminding 
test; HAM-D, Hamilton Depression Rating Scale; HR, hazard ratio; ICD-9/10, international classification of diseases ninth/tenth edition AD criteria; IQCODE, informant questionnaire on cognitive 
decline in the elderly; MMSE, mini mental state examination; MRI, magnetic resonance imaging; N, number of participants; NA, not applicable; N/A, not available; NINCDS-ADRDA, national institute 
of neurological and communicative disorders and stroke and the Alzheimer’s disease and related disorders association; NINDS-AIREN, national institute of neurological disorders and stroke and 
association internationale pour la recherche et l’enseignement en neurosciences vascular dementia criteria; OR, odds ratio; PSG, polysomnography; PSQI, Pittsburgh sleep quality index; P-tau, 
phosphorylated tau; RBANS, repeatable battery for the assessment of neuropsychological status; RR, relative risk; SDB, sleep disordered breathing; SPMSQ, short portable mental status questionnaire; 
TONI, test of nonverbal intelligence; Trails B, trail making b test; TST, total sleep time; T-tau, total-tau; WAIS-III, Wechsler adult intelligence scale third version; WASO, wake after sleep onset; 
WHIIRS, women’s health initiative insomnia rating scale; WMS-R, Wechsler memory scale-revision; w/o, without. 
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Figure 4.1: Study retrieval and selection for Obstructive Sleep Apnea, Cognitive Decline and/or  
                   Alzheimer’s disease Review 
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APPENDIX C 
IRB LETTER 
 
 
 
10/20/2017 
 
Omonigho Bubu, MD, MPH 
Epidemiology and Biostatistics 
4202 East Fowler Ave. 
Tampa, FL 33612 
 
RE: Not Human Subjects Research Determination  
IRB#: Pro00032613  
Title: Obstructive Sleep Apnea and the risk of Alzheimer’s disease 
 
Dear Dr. Bubu: 
 
The Institutional Review Board (IRB) has reviewed your application. The activities presented in 
the application involve methods of program evaluation, quality improvement, and/or needs 
analysis. While potentially informative to others outside of the university community, study 
results would not appear to contribute to generalizable knowledge. As such, the activities do not 
meet the definition of human subject research under USF IRB policy, and USF IRB approval and 
oversight are therefore not required. 
 
While not requiring USF IRB approval and oversight, your study activities should be conducted 
in a manner that is consistent with the ethical principles of your profession. If the scope of your 
project changes in the future, please contact the IRB for further guidance. 
 
If you will be obtaining consent to conduct your study activities, please remove any references to 
"research" and do not include the assigned Protocol Number or USF IRB contact information. 
 
If your study activities involve collection or use of health information, please note that there may 
be requirements under the HIPAA Privacy Rule that apply. For further information, please 
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contact a HIPAA Program administrator at (813) 974-5638. 
 
Sincerely, 
 
 
 
 
 
 
E. Verena Jorgensen, M.D., Chairperson 
USF Institutional Review Board 
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